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Clostridium difficile infection (CDI) is the most common cause of nosocomial diarrhoea worldwide.  
Current treatment options have varied levels of success and there is no licensed vaccine. Most 
vaccines investigated to date use the C. difficile toxins, as these induce a protective immune 
response. However, this is only against the symptoms of CDI, therefore there is a need for antigens 
capable of preventing colonisation and transmission.  
The results of a C. difficile specific pan-protein array, screened against blood samples from CDI 
patients and healthy controls, was analysed and a shortlist of proteins identified where the IgG 
antibody response was significantly higher in the control group. Three of these were expressed and 
purified in E. coli, and tested against patient samples in an ELISA. For two of the three proteins, there 
was a higher IgG response in the healthy control group (albeit not significant) confirming the array 
results.  
Inactivation of three immunogenic proteins from the array in C. difficile R20291 revealed the 
putative permease CDR20291_0342, was not involved in efflux of the antimicrobials tested. 
Inactivation of the putative pilin protein, CDR20291_3343, did not influence surface motility, but 
motility was almost abolished in a flagella mutant. The putative cobalt transporter CDR20291_0330, 
was proposed to contribute to a putative vitamin B12 synthesis pathway, which is required for 
ethanolamine utilisation. Neither R20291Δ0330 or R20291 utilised ethanolamine in the conditions 
tested but it was found that inactivation of one component of the two-component regulatory 
system in C. difficile 630Δerm abolished ethanolamine utilisation.  
Finally, mechanisms of synthesising C. difficile glycoconjugates using bioconjugation were 
investigated, using a carrier protein and portion of the R20291 flagella glycan. A short acceptor 
peptide was designed and found to be glycosylated at all sites with a glycan from Campylobacter 
jejuni but it was not possible to detect glycosylation with the flagella glycan from C. difficile.  
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1.1. An introduction to Clostridium difficile  
In 1974, Tedesco and colleagues found 21% of patients receiving clindamycin experienced diarrhoea, 
with almost half of these also presenting with inflammatory lesions along the colonic mucosa, 
known as pseudomembranous colitis (PMC) [1]. Three years later, the causative agent Clostridium 
difficile was implicated [2-4]. First identified in infants in 1935, the strict anaerobe C. difficile is a 
Gram-positive spore forming organism from the Firmicutes phylum of bacteria [5]. More recently, 
the Clostridium genus was restricted to Clostridium butyricum and its related species. As C. difficile is 
phylogenetically distant from this species, it was reassigned into the Clostridioides genus [6]. It is 
found in 4-15% of healthy adults but can cause serious disease when established as a dominant 
member of the gut microbiome, following disturbance to the protective gut microbiome [7]. The 
symptoms of C. difficile infection (CDI) are primarily associated with the action of Toxins A and B, 
which the pathogen releases into the gut, resulting in breakdown of the epithelial cell barrier [8-10]. 
CDI is a major cause of nosocomial diarrhoea but can have more severe outcomes, including PMC, 
toxic megacolon and fatalities [11, 12].  
 C. difficile and the intestinal microbiota  
The microbiota of the intestinal tract is one of the most influential microbiomes in the human body, 
ranging from roles in intestinal illness such as inflammatory bowel disease through to development 
of the immune system [13-16]. Microbiome composition displays high inter-person variability, 
influenced by diet, environment and health status, but is relatively stable within individuals 
throughout adulthood [17-19]. Difficulties arise following community disturbance and loss in 
diversity, a process accelerated with advanced age, particularly in institutionalised settings [20, 21] 
and as a result of exposure to broad-spectrum antibiotics [22-24].  
A robust gut microbiome is crucial for protection against CDI. The microbiome can complete with C. 
difficile for space, nutrients and access to the epithelial cell lining and produces antimicrobial 
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peptides (AMPs), which may be toxic to C. difficile [25]. Specific species within this microbiome are 
particularly important in providing protection from CDI. Louie et al. found include Bacteroides and 
Prevotella species are important in the maintenance of a healthy microbiome as patients with lower 
counts of these were more likely to experience recurrence of CDI [26].   
Additionally, microbiome-mediated bile salt metabolism is also important, as certain bile salts can 
inhibit outgrowth of C. difficile. Primary bile salts such as glyco- and tauro- cholate and 
chenodeoxycholate are released into the gut by the gall bladder, for the digestion of dietary fats. 
They are then metabolised by the gut microbiome to release taurine and glycine, leaving behind the 
unconjugated cholate and chenodeoxycholate. Specific members of the gut microbiome can then 
further process these into secondary bile salts, deoxycholate and lithocholate [27]. Bile salts 
promote germination of C. difficile spores but interestingly secondary bile salts such as deoxycholate 
prevent their outgrowth [28, 29]. Therefore, secondary bile salts and the bacteria harbouring the 
enzymes to produce them are an important means of preventing C. difficile colonisation (although 
colonisation doesn’t automatically equate to CDI (1.1.2.1)). Buffie et al. identified Clostridium 
scindens as a member of the gut microbiome that harbours the 7α-dehydroxylating enzymes 
required for the production of secondary bile salts. Administration of this species to mice resulted in 
resolution of CDI [30]. Furthermore, Mullish et al. recently reported bile salt hydrolases, which 
mediate deconjugation of glycine and taurine from primary bile salts, are found in lower proportions 
in those with CDI [31].  
The increased understanding of the relationship between bile salts and particular species of the 
microbiome and C. difficile is now being investigated for its suitability as a treatment for CDI, with 
delivery of the whole microbiome via faecal transplants already in practice (1.4.4, 1.4.5).  
 C. difficile metabolism  
Defined minimal media is a valuable tool for bacterial study as it enables precise manipulation of the 
growth environment. Early work by Karasawa et al. identified the growth requirements for C. 
20 
 
difficile, including a combination of amino acids, salts, trace salts, vitamins and glucose as a carbon 
source [32]. This study also found, for the strains of C. difficile they investigated, proline, cysteine, 
isoleucine, leucine, valine and tryptophan were all essential for growth [32]. Many of these amino 
acids can be used in Stickland fermentation, a primary energy source for C. difficile involving the 
oxidation and reduction of amino acids [33]. Minimal media has been used to elucidate the 
nutritional relationship between toxin production and the metabolism of substrates in the host gut, 
such as glucose, sorbitol and ethanolamine [34][35, 36]. Theriot et al. used minimal media to 
demonstrate the range of carbohydrates C. difficile can utilise as a carbon source, including fructose, 
mannitol and sorbitol, which all increase in abundance following antibiotic ablation of the gut 
microbiome(i.e. a CDI susceptible state), in the mouse model [37]. Finally, in a recent study, Collins 
et al. used minimal media to support their finding that dietary trehalose in humans is associated 
with the emergence of hypervirulent strains of C. difficile [38].  
 C. difficile infection 
 Outcomes of infection and asymptomatic carriage 
C. difficile’s presence in the gut can result in a range of outcomes, from asymptomatic colonisation 
through to severe disease and fatalities. Although definitions vary, asymptomatic colonisation 
typically refers to patients who are positive for C. difficile (i.e. by faecal culture) but are negative for 
the detection of free Toxin A and B in stool and do not display clinical signs of CDI [7]. Current 
estimates indicate 4-15% of adults are asymptomatically colonised [7]. Rates of colonisation in 
infants under two years old tend to be higher than in adults, reaching over 50% in some studies [39-
41]. However, reports of actual CDI in this cohort are rare, which has been suggested to be a result 
of immaturity of the infant mucosa, rendering it resistant to Toxins A and B [39, 42-44].  
Colonisation with C. difficile is associated with increased risk of CDI [45]. In a recent review, Crobach 
et al. found the risk of developing CDI was increased in those colonised with toxigenic C. difficile [7]. 
Importantly, patients colonised with C. difficile are also a source of nosocomial transmission. High 
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levels of spores have been identified on the skin of these individuals which are then shed into the 
environment [46-50]. Lawley et al. found treating immunocompetent mice colonised with C. difficile 
with clindamycin resulted in disruption of the microbiome, C. difficile outgrowth and anincrease in 
sporulation. This increase in the presence of spores in the mouse faeces was termed a “super 
shedder” state and resulted in increased transmission to other animals [51]. As many hospitalised 
patients are on antibiotics, this study offers a plausible role for asymptomatically colonised patients 
in the transmission of CDI.  
Although CDI can result in self-limiting diarrhoea, it can also develop into a severe infection leading 
to PMC and toxic megacolon [12, 52]. Furthermore, there are reports of systemic and extra-
intestinal outcomes of CDI, including multiple organ dysfunction syndrome, liver abscesses and 
sepsis [53-55]. Of the total 13, 286 people diagnosed with CDI in England in 2017/18, 15.2% died 
within 30 days of onset [56]. Recurrence of infection is another well-established aspect of CDI and 
can be differentiated into relapse, i.e. infection with the same strain or re-infection, with a new 
isolate [57, 58]. Estimates put recurrence of CDI at 15-30% following primary infection but following 
two recurrent episodes, 45-65% will experience another case of CDI [59-61]. Multiple risk factors 
have been associated with recurrence of CDI, which often overlap with those for the acquisition of 
primary CDI, including antibiotic exposure and advanced age [62, 63].    
 Risk factors 
Antibiotic use is a major risk factor for CDI, as this depletes the microbiome, resulting in loss of 
colonisation resistance. Although the majority of antibiotics can disturb the microbiome to some 
extent, clindamycin, cephalosporins and fluoroquinolones are particularly associated with 
development of CDI [64, 65]. The predisposition of those receiving clindamycin treatment to CDI has 
been known since the 1970s [1, 3, 66] but the importance of fluoroquinolones only came to light in 
the early 2000s, when a hypervirulent ribotype 027 strain emerged in Canada which was highly 
fluoroquinolone resistant [67-69]. Restriction of fluoroquinolone use resulted in a substantial 
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decrease in fluoroquinolone resistant infections [70]. Proton pump inhibitors (PPI) are used to 
reduce gastric acid production and have been implicated in increasing susceptibility to CDI, by 
reducing stomach acid. However, this association is controversial, as spores are the major route of C. 
difficile transmission and these are unaffected by stomach acid[71-73]. A systematic review and 
meta-analysis conducted by Kwok et al. found a probable association between PPI use and CDI, but a 
similar study in the same year found low quality evidence for this [71, 74].  
Another predominant risk factor is advanced age (>65 years old). In the UK, the highest rates of CDI 
are found in people over 85 years of age [75-78]. Elderly people are more likely to experience the 
common risk factors of CDI, including hospitalisation, presence of co-morbidities and antibiotic use 
[79-83]. Furthermore, the diversity of the microbiome decreases with age, which could reduce 
colonisation resistance [17, 20, 21, 84, 85]. Waning of the humoral immune response with age is 
often mentioned as a risk of CDI due to the importance of antibodies in protection from infection, 
but there is a lack of evidence to fully support this (1.4.1) [86-88]. Kyne et al. found patients with 
higher IgG responses to Toxin A had reduced recurrence of infection, but IgG titres were not affected 
by age [89, 90]. Those with co-morbidities are also at an increased risk of CDI, both due to the fact 
they are likely immunocompromised and often require stays in hospital, which increases exposure to 
C. difficile [80, 83]. Illnesses, such as inflammatory bowel disease and surgery of the gastrointestinal 
tract are particularly associated with the development of CDI [76, 91-93].    
 Diagnosis 
PHE recommends screening for CDI in patients with diarrhoea which cannot be attributed to an 
underlying condition or therapy [94].  Diagnostics for C. difficile target either the organism or Toxins 
A and B. Toxigenic culture utilises selective agar to isolate C. difficile from a faecal sample before 
testing for toxin using an established method such as PCR or cell culture. This method is sensitive 
and specific for C. difficile and allows for detection of toxin producing strains [95, 96] but is also time 
consuming. Therefore, enzyme immunoassay (EIA) based detection of the C. difficile metabolic 
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enzyme glutamate dehydrogenase (GDH), directly on patient samples is a more frequently utilised 
test for the detection of C. difficile [97]. Cytotoxin assays detect the toxins by exposing in vitro cell 
lines to faecal samples and monitoring cell morphology for cytopathic effects [95, 97, 98]. However, 
these assays are also time consuming and require cell culture facilities and therefore have been 
replaced by the more rapid, nucleic acid amplification tests (NAATs) and enzyme immunoassays 
(EIAs) [99]. NAATs are a rapid PCR-based test which usually amplify conserved regions of the genes 
encoding Toxin A (tcdA) and B (tcdB) but use of these alone without confirmation of actual toxin 
production runs the risk of over diagnosing CDI [100, 101]. EIAs allow detection of Toxins A and B in 
faecal samples and sensitivity of these has improved in recent years, but it is still very variable [95, 
99]. Crobach et al. reviewed the sensitivity and specificity for the different available EIAs and NAATs 
for toxin detection and GDH testing and compared these to use of toxigenic tissue culture. The 
sensitivity was lowest and most variable for the Toxin EIA, while the sensitivity and specificity of the 
Toxin NAAT and GDH EIA were comparable and both >80% [101]. Detection of the organism cannot 
differentiate between toxigenic and non-toxigenic strains, therefore both organism and toxin-
specific tests are required to confirm CDI [101]. PHE recommends initial testing with a GDH EIA or 
Toxin NAAT and positive results followed up with a Toxin EIA to confirm CDI [94].   
1.2. Epidemiology of infection 
 Typing and phylogeny 
C. difficile is an extremely diverse species with many strains that can be grouped into distinct clades. 
C. difficile harbours a large, mosaic genome which enables it to occupy different niches. The 
environmental challenges of occupying these niches both in and out of the gut are believed to have 
been the driving force behind the highly diverse C. difficile strains seen today. There are a number of 
mechanisms behind this diversity, particularly the presence of transposable elements, which are 
particularly prevalent within the C. difficile genome (~11%) [102]. Additionally, there are regions 
where mutations are more common, for example within the PaLoc locus which encodes the genes 
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required for toxin production. Toxinotyping is a method of typing strains based on mutations within 
this region [103]. 
A number of techniques are utilised to differentiate strains based on different factors. Multi-locus 
typing (MLST) is a well-established typing system throughout bacteria and is based on sequencing 
conserved house-keeping genes [104]. These have been identified for C. difficile and used to assign a 
sequence type to different strains [104, 105]. An alternative to this is toxinotyping, a typing method 
based on the genes encoding Toxins A and B, tcdA and tcdB, respectively [103, 106]. One of the most 
heavily relied upon systems is ribotyping, which groups strains based on the pattern of amplified 
intergenic regions of the 16S and 23S ribosomal RNA [107, 108].  
Stabler et al. used MLST of 385 diverse strains to assess evolutionary relatedness of these (Figure 
1.1). Five clades were identified, each including clinically relevant strains in humans [109]. Clade 1 
contains strain 630 (ribotype 012) which was isolated from a patient with PMC in 1982 and was the 
first C. difficile genome to be fully sequenced and annotated, and therefore is a routine lab strain 
[110, 111]. Clade 2 contains ribotype 027 strains, including the epidemic BI/NAP1/027 strains which 
are highly virulent and fluoroquinolone resistant [68, 112, 113]. Clades 3 and 4 harbour ribotypes 
023 and 017, respectively. Ribotype 017 strains are notable as they are Toxin A-B+ but still cause 
infection in humans, while ribotype 023 strains have increased in recent years and are capable of 
causing severe infections [114, 115]. Finally, strains from clade 5 are very distinct from the other 
clades and include the ribotype 078 strains which are also associated with hyper-virulence and are 


















Figure 1.1. Evolutionary relatedness of C. difficile strains. Clustering of strains by multi-locus sequence typing resulted in 5 distinct clades which all include 




 Changing pattern of CDI 
Historically, C. difficile was considered a serious yet manageable infection, even following the rising 
incidence of PMC in the 1970s, mirroring the beginning of widespread antibiotic use. However, in 
the early 2000s, reports began of increased incidence and severity of CDI in Quebec, Canada, which 
quickly spread to cover North America and arrived in the UK with the highly publicised Stoke 
Mandeville epidemic . The causative agent, an emerging hypervirulent BI/NAP1/027 strain was 
isolated and identified as a ribotype 027 strain [69, 112, 118-121]. R20291 is the hypervirulent 027 
strain isolated from the Stoke Mandeville epidemic [113]. Multiple features of this strain were 
associated with its increased severity of infection and spread, including increased toxin production, 
increased spore germination and a single nucleotide polymorphism (SNP) in DNA gyrase, conferring 
high-level fluoroquinolone resistance [68, 122-125]. This is of particular importance as the use of 
fluoroquinolones was widespread at the time. He et al. identified two distinct lineages (FQR1 and 
FQR2) of the epidemic BI/NAP1/027 strain which acquired the same SNP in DNA gyrase 
independently [68]. Increased toxin production was suggested to be a result of modifications within 
TcdC, the negative regulator of Toxin A and B expression, but there are conflicting reports over the 
influence of this [122, 126, 127]. Furthermore, comparing pre and post epidemic strains of 
BI/NAP1/027 found there was no difference in the sequence of the Pathogenicity Locus (PaLoc) 
encoding the toxins and their regulators and accessory genes [68].  
In 2007/8, over 55,000 cases of CDI were reported in the UK, with over 8000 deaths, 5 times higher 
than those caused by MRSA [67]. More recently, these figures have reduced but CDI remains a 
persistent burden, particularly in healthcare associated settings, with over 12,000 cases reported in 
the UK between April 2018 and March 2019 [128]. Although both hospital and community onset 
cases of CDI have reduced, including those caused by ribotype 027 strains, this reduction is much 
less rapid for community onset cases, which now account for 66% of annual diagnoses [128].  
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The increase in prominence of community infections changed the view of C. difficile as a 
predominantly nosocomial pathogen, although definitions of community infection can vary and do 
not always exclude recent hospital contact [83, 129-131].  Those with community acquired CDI tend 
to be younger and harbour fewer risk factors than nosocomial patients [131]. In terms of the source 
of infection, environmental contamination with C. difficile spores has been reported numerous times 
[132-134]. Furthermore, C. difficile has also been detected in a number of animals, including 
household pets and farm animals, but whether this a source of transmission to humans is still under 
investigation [135-138]. One study isolated strains from cats and dogs being kept as pets, which are 
known to also infection humans, including those from ribotype 078 and 027. However, no 
simultaneous cases of CDI were reported between the pet and their owner [139].Ribotype 078 
strains are particularly common in animals [117, 140]. Dingle et al. recently demonstrated 76.5% of 
sequenced ribotype 078 strains, which are frequently isolated from animals, carried the tetM gene, 
which confers tetracycline resistance, an antibiotic frequently used in agriculture [141].  Ribotype 
078 strains began to emerge in 2005 and cause similar levels of severe diarrhoea and mortality as 
hypervirulent ribotype 027 strains [116, 142, 143]. However, compared to these strains, 078 
infections are more often found in younger people and as a cause of community infections [116].  
The changing epidemiology described above primarily relates to Europe and North America, where 
formal surveillance programmes were introduced following the ribotype 027 epidemic of the 2000s. 
Such surveillance programmes are not universal, particular in low resource areas where other 
infections can pose a greater burden, which hampers understanding of the global epidemiology of 
CDI. Furthermore, this can result in C. difficile being labelled a low prevalence pathogen when in fact 
this is due to incomplete testing, typing and reporting [144]. A recent meta-analysis noted a lack of 
incidence data from Latin America, Eastern Mediterranean, South-East Asia and Africa [145]. 
Perhaps unsurprisingly, another study found guidelines for management and infection control of CDI 
were either lacking or completely absent in these same regions [146]. In Asia, including China and 
South Korea, it has been documented that 027 strains did not pose the same burden as they did in 
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the West but instead, clade 4 ribotype 017 strains, which are typically Toxin A negative and Toxin B 
positive, were prominent [147]. A recent phylogenetic analysis of these strains found these in fact 
emerged in North America and reached Asia via Europe [148]. CDI has been identified in a number of 
African countries but these tend to be small studies with limited associated data such as sequence 
type or ribotype of the strains [149]. One study in South Africa found 50% of the 32 strains 
recovered from patients were ribotype 017 [150].   
1.3. Virulence factors of C. difficile  
 Toxins 
The major virulence determinants of C. difficile are Toxins A and B, which are the primary mediators 
of the symptoms of CDI [53]. These toxins are composed of an enzymatic glucosyltransferase domain 
(including a catalytic and cysteine protease domain), translocation and receptor binding domain, 
which all have a functional role in toxin activity [151]. Upon secretion from C. difficile, the receptor 
binding domains of Toxins A and B bind intestinal epithelial cells, resulting in host-mediated 
endocytosis [152, 153]. Potential receptors have been identified for both Toxins A and B, namely a 
glycoprotein (gp96) on the surface of colonocytes for Toxin A and the polio virus-like 3 receptor on 
colonic epithelial cells for Toxin B [154, 155]. Once internalised, the pH drop in the acidified 
endosome initiates a conformational change of the toxin resulting in pore formation within the 
endosome membrane and release of the glucosyltransferase domain into the cytosol [156, 157]. This 
domain can then go on to glucosylate Rho and Rac GTPases, resulting in disruption of the actin 
cytoskeleton and breakdown of the epithelial barrier [158, 159]. Toxins A and B are encoded by tcdA 
and tcdB, respectively, within the 19.6 Kb PaLoc [111, 160]. Three other genes are also present 
within this locus; tcdR, tcdC and tcdE. TcdE is a holin-like protein thought to mediate release of the 
toxins into the gut lumen [161]. TcdR is a positively regulator of toxin production and TcdC was 
initially believed to be an anti-sigma factor that repressed toxin expression, but this has since been 
debated [126, 162-164].  
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Some strains such as those from ribotype 027 also harbour the ADP-ribosylating binary toxin, which 
is encoded separately to the PaLoc [118, 165]. This toxin is also internalised and acts on the actin 
mesh under the cell membrane, resulting in protrusions from the cell that increase adherence of C. 
difficile [166-168]. The role of binary toxin in infection is not as pronounced as for Toxins A and B but 
some studies have found an association between its presence and an increased severity of infection 
or occurrence of relapse [169, 170]. However, in a hamster model of infection, Toxin A- Toxin B- 
Binary+ strains were able to colonise but did not cause symptoms of CDI [170]. 
The relative contributions of the C. difficile toxins in disease remains a source of debate. Lyras et al. 
found inactivation of Toxin A resulted in death of hamsters in a similar manner to the wild-type 
infection, whereas inactivation of Toxin B resulted in a significant increase in survival. Therefore, the 
authors concluded only Toxin B was essential for infection [10]. However, two following studies by 
Kuehne et al. reported both Toxin A only and B only strains can cause fulminant disease in the 
hamster model [8, 9]. Continuing on from this, Carter et al. used three different animal models to 
evaluate the influence of the toxins and found virulence was only attenuated upon inactivation of 
Toxin B [53]. From a human infection perspective, Toxin A-B+ strains have been isolated frequently 
and can cause CDI, but Toxin A+B- infections are very rare [114, 171, 172]. Finally, there are 
circulating Toxin A and B negative strains which can colonise the host but are not believed to cause 
infection in humans, although a toxin negative strain did result in mild caecal pathology in a hamster 
model of infection [173, 174].  
 Sporulation and Germination  
As a strict anaerobe, survival of vegetative cells outside of the gut or indeed any anaerobic 
environment would not be possible, therefore C. difficile produces highly resistant spores which can 
tolerate aerobic conditions, high temperatures and environmental desiccation [64, 132, 175-177]. 
Spores are the major route of C. difficile transmission, and only germinate once in the gut, a process 
influenced by bile salt composition (section 1.1.1) [28-30, 178]. Recent work has identified the spore 
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proteins CspC and CspA as the receptors detecting bile salt germinants [179, 180]. It has also been 
suggested that spores may be a source of the high recurrence of CDI, persisting within the gut until 
conditions are suitable for germination and outgrowth [178, 181]. The difficulty in spore eradication 
contributes to the rapid spread of CDI within healthcare settings [182, 183]. Furthermore, as 
discussed above, people asymptomatically colonised with C. difficile shed spores into their 
environment, a process which is  enhanced in mice upon antibiotic treatment, which also 
contributed to transmission of C. difficile [46-48, 51]. Deakin et al. demonstrated that the master 
regulator Spo0A is essential for sporulation, and its inactivation still enables acute infection in mice 
but relapse of infection is lost, as is host to host transmission [178].  
 Motility 
 Flagella 
Flagella are whip-like structures that extend from the cell surface and propel bacteria towards 
nutrient sources or away from potential stressors. They are frequently associated with virulence, 
particularly for adherence and colonisation in the host. C. difficile flagella facilitate swimming 
through semi-solid agar in vitro which is lost upon inactivation of the flagella, through mutation of 
the major structural subunit (FliC) or flagella cap (FliD) [184-187]. Other phenotypes attributed to 
the C. difficile flagella differ between strains. For example, inactivation of the flagella in 630 
increased adherence to Caco2 cells in vitro but the opposite was found for strain R20291 [186, 188]. 
Dapa et al. found removal of the flagella resulted in reduced biofilm formation in R20291 [189].  
Post-translational modification of the flagella also influences its function. Glycan modification of FliC 
for strains 630 (Type A) and R20291 (Type B) has been characterised in detail and revealed two 
distinct structures [184, 187, 190] (Figure 1.2). This variation in glycan structure is reflected in the 
glycosylation gene content of the flagella locus from different C. difficile strains [185]. Glycosylation 
of the flagella is essential for motility in both strains. Furthermore, modification or loss of these 







Figure 1.2. Flagella glycosylation in C. difficile 630 and R20291. Schematic of the solved glycan 
structures of the Type A and Type B modifications on the flagellum subunit, FliC. This is modified from 
an image by Dr Alexandra Faulds-Pain [184, 187].  
 
Faulds-Pain et al. found wild-type 630Δerm colonised a mouse model to the same extent as 
630Δerm with no flagella or harbouring a truncated flagella glycan. However, C. difficile was 
detected in the faeces for fewer days post-inoculation for the glycosylation mutant, suggesting this 
does play a role in colonisation [184]. Regarding the flagella directly, Dingle et al. found 630Δerm 
lacking a flagella was more virulent in a hamster model and suggested increased toxin production 
could be behind this [186].  
The link between the flagella operon and toxin production was found to be the sigma factor SigD, 
encoded with the early stage flagella genes. SigD positively regulates expression of late stage flagella 
genes, including fliC and the glycosyltransferases, as well as tcdR, the positive regulator of Toxin A 
and B [191]. Consequently in a sigD mutant strain, expression of the flagella biosynthesis genes and 
Toxin genes tcdA and tcdB is reduced [191, 192]. Expression of these genes is further influenced by 
the regulation of sigD, via both cyclic-diguanylate-guanosine monophosphate (c-di-GMP) and a 
genetic switch controlling phase variation [192-194]. c-di-GMP is a secondary messenger with a 
whole array of regulatory targets, but at high level is primarily associated with promoting entry into 
the sessile lifestyle, including a reduction in motility and increase in pili formation and cell 
aggregation [195, 196]. Cellular levels of c-di-GMP are tightly controlled by the action of two sets of 
enzymes which respond to signals to either synthesise (diguanylate cyclases) or degrade 
(phosphodiesterases) this secondary messenger [197]. In 630, there are 37 of these enzymes, 31 of 
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which are conserved in R20291 [198]. C-di-GMP controls expression by binding to a riboswitch in the 
5’ untranslated region of its target gene. The binding of c-di-GMP to a class I riboswitch results in 
premature translational termination and consequently no production of downstream gene products 
[199]. Class II riboswitches undergo a conformational change when bound by c-di-GMP which 
enables expression of the downstream genes [198, 200, 201]. Binding of c-di-GMP to the class I 
riboswitch within the 5’ untranslated region of the early stage flagella genes results in translational 
termination and consequently SigD is not produced [202, 203]. Furthermore, orientation of a genetic 
switch downstream of this riboswitch but before start of the flagella genes can also controlSigD, 
which in turn affects the production of Toxins A and B and flagella biosynthesis via phase variation 
[193, 194].   
 Pilli 
Pili are filamentous structures which extend from bacterial cells and can mediate adhesion and 
exchange of genetic material. Type 4 pili (T4P) are a sub-type of these, found in Gram-positive 
organisms and are associated with gliding and twitching motility, adhesion and biofilm formation 
[204]. C. difficile is predicted to encode a major (CDR20291_3340-3350) and minor 
(CDR20291_3153-3158) T4P locus which show a low level of divergence between strains and are 
thought to be core components of the C. difficile genome [205, 206]. Additional pilins encoded 
elsewhere on the chromosome display greater strain variation [204, 207]. Predicted T4P structures 
have been identified on the surface of C. difficile in vitro and pili like structures have been identified 
in hamster models [208-210] (Figure 1.3). Although C. difficile is also decorated with flagella 
structures on the surface, these are usually thicker than pili and surface appendages could still be 
identified in a flagella mutant, suggesting pili are also present [195]. T4P are composed of several 
pilin units each with a specific role for formation of the full pilus structure. In C. difficile, PilA1 is the 
predicted major structural unit with no visible pili in a pilA1 mutant in R20291 [211]. 
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As with the flagella, pili expression is also regulated by c-di-GMP, but this is via a type II riboswitch, 
meaning expression is upregulated in the presence of c-di-GMP. This corresponds with the role of c-
di-GMP, mediating the switch to the sessile lifestyle [196, 197]. In C. difficile, cell aggregation 
increases following expression of a diguanylate cyclase for c-di-GMP synthesis which is lost when 
PilA1 is disrupted [195]. T4P have also been demonstrated to have a role in motility on solid surfaces 
and initial biofilm formation [195, 212]. Recently, McKee et al. reported that T4P negative mutants 
were less able to adhere to epithelial cells in vitro and were cleared more quickly compared to the 










Figure 1.3. Visualisation of the Type 4 pili on the surface of C. difficile. (A) Immunogold staining of 
the PilJ and PilA units on the surface of C. difficile (This research was originally published in the 
Journal of Biological Chemistry. Piepenbrink KH, Maldarelli GA, de la Peña CF, Mulvey GL, Snyder GA, 
De Masi L, von Rosenvinge EC, Günther S, Armstrong GD, Donnenberg MS and Sundberg EJ. 
Structure of Clostridium difficile PilJ Exhibits Unprecedented Divergence from Known Type IV Pilins. J 
Biol Chem. 2014; 289:4334-4345. © the American Society for Biochemistry and Molecular Biology or 
© the Piepenbrink KH, Maldarelli GA, de la Peña CF, Mulvey GL, Snyder GA, De Masi L, von 
Rosenvinge EC, Günther S, Armstrong GD, Donnenberg MS and Sundberg EJ)[209] (B) Comparison of 
flagella and pili structures on the surface of C. difficile [208].  
 
 The C. difficile cell surface  
 Proteins 
C. difficile harbours a dynamic cell surface. As a Gram-positive organism, it is encased within a single 




layer (S-layer), a paracrystalline array that covers cell [214]. This is composed of the SlpA protein, 
which is expressed then post-translationally cleaved into a high molecular weight (HMW) and low 
molecular weight (LMW) component, by the cysteine protease Cwp84 [215-217]. The HMW protein 
interacts with the cell membrane and is highly conserved between strains whereas the LMW protein 
is exposed and variable, leading to suggestions it is involved in immune invasion [218, 219]. After 
much difficulty, in 2017 Kirk et al. isolated a strain of C. difficile that harboured point mutations 
within SlpA and consequently did not produce an S-layer [220]. This had profound effects on the 
bacteria including defects in sporulation and toxin production and increased sensitivity to the innate 
immune response. Furthermore, although this strain could colonise the hamster gut, it was not 
virulent [220].   
In addition to the S-layer, there are a number of other surface proteins decorating the cell that can 
contribute to adherence. This includes collagen (CbpA) and fibrinogen binding proteins (Fbp68 and 
FbpA), sorted proteins (CD3392), lipoproteins and cell wall proteins [221-226]. CwpV is the largest 
cell wall protein and its expression is phase variable [227, 228]. Although its role in virulence and 
host colonisation is not well understood, CwpV does contribute to cell-aggregation and resistance 
from bacteriophage infection [228, 229].  
 Surface polysaccharides and glycosylation  
Both glycosylated proteins and surface polysaccharides have been identified in C. difficile, although 
for some their purpose within C. difficile is poorly understood and therefore their contributions to 
virulence are often putative. As described above, flagella glycosylation in strains 630 and R20291 has 
been characterised in detail, resulting in resolution of these two distinct glycan structures and in 
vitro demonstration of their essentiality for flagella-mediated motility (1.3.3.1) [184, 187, 190]. 
Glycosylation of the LMW component of the S-layer is also restricted to certain strains. 
Characterisation of the S-layer from a ribotype 005 strain identified a complex glycan composed of 
three domains; a core peptide–linked tetrasaccharide, a repeating pentasaccharide and a rhamnose-
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rich non-reducing end. Loss of or modification to this glycan via interrupting genes within its 
synthesis locus is associated with alterations in sporulation and adherence [230].  
C. difficile encodes three surface polysaccharides; PS-I, PS-II and PS-III [231-233]. The latter is a lipid-
bound glycosyl phosphate polymer of the lipoteichoic acid (LTA) family and is sometimes referred to 
as a LTA or as having LTA domains. To our knowledge, both PS-II and PS-III have been found in all 
strains examined so far whereas PS-I has only been found in a small number of strains so far and 
doesn’t appear to be unique to a particular ribotype [234]. The structures for all three polymers have 
been solved and investigated for their immunogenicity and as vaccine candidates (1.6.3, Table 1.2) 
but their role in virulence is largely unknown [234-238]. Willing et al. identified a set of genes 
downstream of the large S-layer biogenesis locus which they named the anionic polymer (AP) locus. 
This was predicted to encode the synthesis of the hexaglycosyl phosphate repeating polymer PS-II, 
based on the presence of glycosyltransferases and genes related to the synthesis of surface 
polymers. It was not possible to inactivate genes within this locus using insertional inactivation, 
suggesting its essentiality. However, using anti-sense RNA knockdown experiments targeting three 
of the genes within this locus, disruption of S-layer assembly was demonstrated, suggesting a role 
for this polymer in correct assembly of this para-crystalline array [218].  
 Mechanisms for persistence within the gut 
Although the mechanisms enabling C. difficile’s persistence within the gut are not fully characterised, 
a number of processes have been identified which are likely to contribute, including sporulation 
(1.3.2). C. difficile is one of few bacteria to produce the phenolic compound para-cresol, a result of 
tyrosine fermentation [239], which is toxic to some members of the gut microbiome- particularly 
Gram-negative bacteria [240]. As C. difficile itself is comparably tolerant to p-cresol [240-242], its 
production has been suggested to confer a competitive advantage over other gut bacteria and 
facilitate maintenance of gut dysbiosis, therefore inhibiting the recovery of microbiota-mediated 
colonisation resistance [10]. Indeed, Passmore et al. found that in a relapse mouse model of CDI, the 
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C. difficile colony forming units (CFU) in the mouse stool was significantly reduced in a mutant which 
could not produce p-cresol compared to the wild-type, suggesting production of this compound 
facilitates relapse of infection [240].  
Furthermore, like many bacterial species, C. difficile can form biofilms- compact bacterial 
communities encased in a protective polymeric matrix. These have been repeatedly identified in 
vitro and mat-like structures were identified in a hamster model of infection [189, 243-246]. Biofilms 
have been suggested as a source of C. difficile relapse by maintaining a pool of viable cells that are 
protected from environmental stressors and only released under suitable conditions. Dapa et al. 
found within these biofilms, C. difficile is less susceptible to vancomycin, one of the major antibiotic 
therapies for CDI [189].  
 Antimicrobial resistance 
 
Antibiotics remain the first line treatment for CDI, and metronidazole, vancomycin and fidaxomycin 
are all recommended in the UK (1.4.3) [75].  With the exception of fluoroquinolone resistance in 
epidemic ribotype 027 strains, antibiotic resistance against first line antibiotic treatments in C. 
difficile remains relatively low, and antimicrobial resistance (AMR) has not been identified as a cause 
of treatment failure [247]. Fidaxomycin has only relatively recently been introduced and as such 
AMR is very rare [248, 249]. Metronidazole resistance has increased in recent years but a study of 39 
sites across 29 European countries found average metronidazole resistance rates were 0.2% over 3 
years [249]. This does display geographic variation, as a study in China found metronidazole 
resistance rates of 15.6% [250]. The European study described above found vancomycin resistance 
was also low, and only found in 0.1% of isolates [249] and the mechanism of resistance was not 
investigated. 
In order to survive and proliferate within the gut environment, C. difficile also encodes resistance 
mechanisms to antimicrobial peptides, which are secreted by both host cells and the indigenous 
microbiota. C. difficile can expel AMPs from the cell via the ABC transporters CprABC and ClnRAB. 
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Additionally, interaction with AMPs is reduced by the dlt operon, which encodes for the addition of 
D-alanine esterases to teichoic acids within the cell membrane, conferring a positive charge on the 
cell [251-253].  
1.4. Prevention and treatment of C. difficile infection 
 The host response to C. difficile  
 
The host defences play a key role in preventing CDI, and can be broadly divided into three arms; the 
microbiome (1.1.1), innate immunity and adaptive immunity. Breakdown of the intestinal epithelial 
cell (IEC) lining by Toxins A and B enables influx of commensal and pathogenic bacteria into the 
lamina propria. In response to this, a pro-inflammatory cytokine and chemokine cascade is initiated, 
to recruit immune cells such as macrophages and mast cells to the site of infection, in an effort to 
restore intestinal homeostasis. Studies have demonstrated increased release of IL-23, IL-8, IL-1β and 
IFN-γ in response to CDI, which can recruit immune cells such as neutrophils and dendritic cells [254-
258]. The latter is particularly important in initiation of adaptive immunity and T-cell responses [256, 
259]. Furthermore, surface layer proteins (SLPs) and flagellin proteins of C. difficile are also 
recognised via pathogen recognition receptors, TLR4 and TLR5, respectively [260-262].  
This innate response acts to clear the invading pathogen, and is required for the initiation of the 
adaptive immune response but overwhelming inflammation can in fact exacerbate host tissue 
damage [263, 264]. Furthermore, leucocytosis, a sign of the systemic inflammatory response, is 
associated with increased severity of CDI [265]. Buonomo et al. demonstrated a reduction in CDI-
associated mortality in two different mouse models which both lacked IL-23 signalling [266]. Overall, 
it appears that the strength and type of inflammation can differentiate between a protective or 
pathogenic innate immune response. 
Although there is a T-cell component to the adaptive immune response to C. difficile, this is 
predominantly B-cell driven, especially to Toxins A and B. The toxins were believed to be 
38 
 
immunologically distinct with no cross protection between them but in one study, mice immunised 
with Toxin A only also developed anti-Toxin B antibodies [267, 268]. Understanding of the humoral 
immune response to C. difficile is largely based on comparisons between the anti-Toxin A and B 
antibody titres of healthy controls and those with CDI, under the assumption that higher antibody 
responses in healthy participants relates to protection from infection. These studies have 
demonstrated an important role for humoral immunity in protection from CDI, with a number of 
studies finding higher anti-Toxin A and anti-Toxin B antibodies in healthy control groups compared 
to those with CDI, or those who have a single infection compared to those who experience 
recurrences [89, 264, 269-271]. However, this is not a consistent phenomenon and other studies 
reported no difference in antibody response between healthy and patient groups [272, 273]. Warny 
et al. found patients on immunosuppressants mounted a weak antibody response to C. difficile but 
only suffered from mild CDI. Although not demonstrated in the study, the authors suggest a link back 
to the inflammatory response in CDI and how the suppression of the immune system dampened this 
response, limiting the host tissue damage associated with severe CDI [274].  
Regarding antibody responses to non-toxin antigens, Pechine et al. found a significantly higher 
antibody response to the surface proteins Cwp66 and Cwp84 and the flagella proteins FliC and FliD 
in a healthy control group compared to patients with CDI [273]. As a gut pathogen, a robust mucosal 
response, mediated primarily by secretory IgA, is presumably important for protection from 
infection. There is evidence for a mucosal antibody response to C. difficile but these studies are 
limited, in part due to the challenges in obtaining appropriate samples to measure this response 
[274-276]. Oberli et al. (2011) screened the PS-II surface polysaccharide against stool supernatants 
from 10 hospitalised patients with and without CDI. Anti-PS-II antibodies were detected in 6 patient 
samples, three of which had CDI or were borderline for infection [235].  
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 Healthcare Practice 
Since mandatory reporting began in in 2007/08, there has been a 77.9% reduction in cases of CDI. 
This has largely been attributed to changes in healthcare practices, which focused on reducing 
antimicrobial prescribing and improved infection control [277]. Furthermore, these were enforced 
by fining NHS Trusts for cases of CDI [278].  
A number of infection control practices were implemented including hand washing with soap, 
improved C. difficile-specific decontamination of rooms and equipment, patient isolation and 
protective clothing for healthcare workers but it appears that targeting antibiotic use has had the 
greatest effect on the reduction of hospital-acquired CDI [277, 279-281]. A study of US hospitals by 
Kazakova et al. found an over 20% reduction in the administration of fluoroquinolones and 3rd and 
4th generation cephalosporins resulted in an 8% and 13% reduction in cases of hospital-acquired CDI, 
respectively. [282]. Similar findings have been reported for the UK [280, 283]. Dingle et al. reported 
that it was fluoroquinolone restriction specifically that resulted in the decline of CDI, via the 
substantial reduction of fluoroquinolone-resistant cases that were a major problem at the time [70].  
 Antibiotics 
Antibiotics are the first line treatment for CDI. Current UK guidelines recommend metronidazole for 
mild and moderate cases of CDI, while vancomycin and fidaxomycin are reserved for severe 
infections. There is a lack of definition as to what constitutes severe infection but current markers 
include raised blood creatine levels and white cell counts, a temperature over 38.5 oC and severe 
colitis [75]. Although vancomycin is superior to metronidazole for treating severe CDI [57], both 
antibiotics are broad-spectrum, meaning their use can result in collateral damage to the gut 
microbiome, which delays the restoration of colonisation resistance [24, 284]. This has been 




Fidaxomycin is narrow-spectrum and recommended for treating recurrent infections or those at high 
risk of recurrence [75, 286-289]. Louie et al. compared treatment of CDI patients with vancomycin 
and fidaxomycin and found perturbation of the microbiome following treatment in the vancomycin 
group only, where recurrence of infection was also higher (23% compared to 11% for fidaxomycin 
[26]. This supports the notion that preservation of the microbiome is important in the prevention of 
recurrent infection. However, recurrence in 11% of cases is still concerningly high and similar levels 
of recurrence post-fidaxomycin treatment have been reported elsewhere, demonstrating the 
challenges in antibiotic management of CDI [287]. Fidaxomycin is also more expensive than 
vancomycin, costing £1350 for a 10-day course as opposed to £189 to £378 for vancomycin [290]. 
Interestingly, a modelling study conducted from the perspective of NHS Scotland found the total cost 
of the two treatments was actually quite similar when factoring in the reduced need for 
hospitalisation in the fidaxomycin treatment group. They determined that fidaxomycin was cost-
effective for treating severe and first recurrence CDI [290].  
 Faecal microbiota therapy 
For those experiencing recurrent CDI, faecal microbiota therapy (FMT) offers an effective alternative 
to antibiotics. Here, faecal extracts from healthy donors are administered to patients with chronic 
CDI to repopulate the gut and reinstate colonisation resistance [289, 291, 292]. van Nood et al. 
reported 81% of patients with recurrent CDI were free from infection 10 weeks following 
administration of vancomycin with bowel lavage and nasoduodenal administration of FMT, as 
opposed to 23% in the vancomycin plus bowel lavage only group [293]. Additional studies have also 
demonstrated the superiority of FMT over antibiotics alone, even fidaxomycin, for the treatment of 
recurrent CDI [294-296]. The British Society of Gastrology recommends FMT for patients with two 
recurrent episodes of C. difficile, or a single recurrent case but at risk of further recurrence [297].  
Logistically, delivery of FMT is more complex than for antibiotics. It requires careful sourcing and 
screening of faecal samples to prevent transmission of pathogenic material to the patient. Infections 
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arising from FMT have so far been rare but there have been cases of norovirus and Escherichia coli 
bacteraemia [298-300]. Isolation, screening and administration of fresh faecal matter in a timely 
manner is challenging, but this can be overcome by sample freezing, which does not influence 
treatment efficacy [301]. Finally, a number of routes of administration have been trialled, including 
using nasogastric and nasointestinal tubes or colonoscopy [294, 295]. These have all proved effective 
delivery systems but there are concerns over conducting such invasive procedures in patients who 
are already unwell. Youngster et al. and Hirsch et al. both used orally ingested capsules for delivery 
of FMT and reported clinical cure rates of 90% and 89% for CDI patients, respectively. However, in 
some cases repeat administration of the FMT capsules was required and both studies had very small 
sample sizes- maximum 20 patients [302, 303].   
 CDI therapies in development  
Following on from FMT, there has been interest in the identification of a “minimal microbiota” that 
can be given to the patient to restore colonisation resistance. Lawley et al. administered six different 
gut bacteria to mice and found restoration of a healthy microbiome and clearance of CDI [304]. As 
discussed (1.1.1), Buffie et al. administered C. scindens to mice which resolved CDI [30], but this 
approach should be pursued with caution, due to the possible link between bile salts and 
gastrointestinal cancers [30, 305]. Alternatively, there has been promising progress in the use of 
non-toxigenic C. difficile strains to prevent CDI, which have now entered clinical trials [306-308]. A 
Phase II trial administered non-toxigenic C. difficile to patients who had already completed 
metronidazole or vancomycin treatment for primary CDI. The rate of relapse in the group colonised 
with non-toxigenic C. difficile was 2% as opposed to 31% in the colonised group [307]. One possible 
drawback of this approach is the opportunity for transfer of the PaLoc locus from toxigenic strains in 
the gut, resulting in the treatment strains becoming toxigenic and therefore capable of causing 
infection [309].  
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Bezlotoxumab is a humanised monoclonal antibody raised agaisnt Toxin B [310]. Monoclonal 
antibodies can be delivered to the patient for immediate protection agaisnt CDI and doesn’t rely on 
the immune status of the host, an important note considering how many CDI patients are unwell or 
immuncompromised. Bezlotoxumab has been evaluated in Phase II and III clinical trials and has been 
licensed for use in Europe [310-313]. It is specifically targeted for the recurrence of infection. A study 
in Finland found of those receiving bezlotoxumab, 73% did not experience recurrent infection within 
the three months following treatment, and found this was as effective as using FMT for recurrent 
infections [314]. Using probiotics to protect against CDI is not currently recommended in the UK, due 
to the lack of evidence of their efficacy and need for large scale evaluations [75]. The Cochrane 
Library recently published a systematic review of the use of probiotics for prevention of CDI. Meta-
analysis of 31 randomised control trials found moderate evidence that probiotics are effective at 
preventing C. difficile-associated disease [315]. Finally, Nale et al. found bacteriophage therapy 
delays the onset of symptoms of CDI in a hamster model of infection [316].   
1.5. Vaccine Development 
Immunisation is one of the most successful public health interventions ever implemented and mass 
immunisation programmes are credited in saving approximately 2.5 million lives, annually [317]. 
Immunisation can provide long-term or even lifelong protection from infection, reduce carriage and 
transmission and in some cases even result in total eradication of the pathogen, as was the case for 
smallpox in 1980, and the animal pathogen rinderpest in 2011 
(https://www.who.int/csr/disease/smallpox/en/) [318]. The basis of vaccination involves presenting 
the immune system with all or part of the target pathogen, to enable generation of a protective 
immune response without development of infection. There are many different vaccine designs 
available, which can be grouped into live attenuated, where the whole organism is presented but 
not capable of causing fulminant infection, or inactivated which can be the whole cell or 
components of it (Table 1.1).   
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Type of vaccine Description Licensed example 
Live attenuated 
Modified version of the whole organism 
which can no longer cause full infection  
Measles, mumps and rubella 
Whole cell  




Inactivated or de-toxified toxins normally 
released by the pathogen during infection 
Tetanus and diphtheria 
Recombinant 
Expression of an immunogenic antigen from 
the target pathogen in another organism 
that is safer to handle and generates high 
yields of the desired antigen  
Human papilloma virus 
Glycoconjugate 
Immunogenic polysaccharide conjugated to 
a protein carrier to enable development of 
immunological memory  
Haemophilus influenza Type 
B and meningitis C 
Table 1.1. Different types of vaccination used for human infections. The information in this table 
was obtained from “The Green Book”, the UK guide on immunisation, printed by the Government 
and updated annually (https://www.gov.uk/government/collections/immunisation-against-
infectious-disease-the-green-book#the-green-book).  
 Glycoconjugate vaccines- use and production 
Bacterial cell surfaces are decorated with a host of glycans, many of which are immunogenic and 
therefore attractive vaccine candidates. However, polysaccharides alone induce a T-cell independent 
response, which does not result in immunological memory and is particularly weak in young 
children, the elderly and the immunocompromised [319-322].   
This can be overcome by covalent attachment of the polysaccharide to a carrier protein [323]. The 
resulting glycoprotein can be processed by antigen presenting cells and presented within the major 
histocompatibility complex II, enabling T-cell recognition. This induces a robust T-cell mediated 
response, including antibody isotope switching and the generation of immune memory [324-326]. 
The carrier proteins used to present the glycans are typically well-characterised immunogenic 
proteins, such as the inactivated diphtheria or tetanus toxin [327]. A more recent approach uses an 
immunogenic carrier protein from the same species as the glycan, to boost the organism-specific 
immune response, or from a different species, to produce a multipathogen vaccine [238, 328-330].  
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The development of glycoconjugate vaccines have been an invaluable contribution to the 
immunisation field and has resulted in the licensing and wide-spread use of vaccines against 
Haemophilus influenza Type b and meningitis C, among others [331]. These vaccines are synthesised 
using chemical conjugation, whereby the individual protein and glycan components are produced 
and isolated separately before being covalently joined (Figure 1.4) [332]. Both before and after 
conjugation, all components are subject to a series of purification steps, to remove any 
contaminating material. This technique is vital for the production of the currently available 
glycoconjugate vaccines but does carry certain limitations. These include cost and yield loss resulting 
from the multiple rounds of purification, batch to batch variation and working with pathogenic 
bacteria to isolate immunogenic material [332, 333]. As a result of this, alternative means of 
synthesising these vaccines is of great interest, particularly bioconjugation, whereby bacterias’ 
innate ability to synthesis and conjugate complex glycans is re-appropriated for vaccine synthesis.  
 
Figure 1.4. Chemical conjugation of glycoconjugate vaccines. The glycan and protein components of 
the vaccine are first produced separately, either recombinantly or in the native host. These are then 
isolated, purified to remove contaminating material then conjugated together before a final round 
of purification. Image from Kay et al. [332] (no changes were made to the original image 
(http://creativecommons.org/licenses/by/4.0/)). 
 
 Bacterial Glycosylation  
Bacterial glycosylation is a relatively recent discovery, with glycoproteins originally believed to be 
restricted to higher organisms. Investigations into prokaryotes has identified glycosylation 
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machinery and glycoproteins in a diverse range of bacterial species, and this is a continuing area of 
research [334, 335]. Glycoproteins can serve a multitude of functions for the cell, including 
conferring motility, colonisation of the host and immune evasion [184, 187, 336-339]. Glycans have 
been identified on the FliC protein of the flagella and S-layer proteins in C. difficile, but this is not 
universal to all strains (1.3.3.1, 1.3.4.2) [184, 185, 187, 230]. 
Glycosylation is one of the most predominant post-translational modifications of bacterial proteins, 
and bacteria employ a number of mechanisms to achieve this. Firstly, glycoproteins can be N-linked 
or O-linked, primarily characterised by the attachment of the glycan to an asparagine or 
serine/threonine residue within the acceptor protein, respectively. Furthermore, glycan synthesis 
can either be en bloc, where the whole polysaccharide is fully synthesised on a lipid linker within the 
inner membrane, prior to conjugation, or can be built via the addition of monosaccharides directly 
onto the carrier protein, sequentially [335, 340-344].  
The glycosyltransferase class of enzymes are central to these processes, and catalyse both the 
assembly of the glycan and its transfer to the target protein. In relation to glycan synthesis, the 
individual specificity of the glycosyltransferase dictates which monosaccharides are incorporated 
into the glycan and the glycosidic linkages by which they are joined [345, 346]. 
Oligosaccharyltransferases (OSTs) are a type of glycosyltransferase which mediate attachment of the 
glycan to the acceptor protein. These also hold their own specificities including the type of glycan 
they can transfer and the glycosylation sequence they recognise in the acceptor protein [347-351].  
Examples of two distinct glycosylation systems can be found in Campylobacter jejuni. O-linked 
glycans are often associated with flagella and are an important component of flagella assembly and 
function [336, 352, 353]. Indeed, the FlaA flagellin subunit from C. jejuni is O-glycosylated and the 
glycan is assembled sequentially, directly onto serine and threonine residues within FlaA before it is 
trafficked to the surface of the cell [335, 354-356] (Figure 1.5b). The mechanism of glycosylation for 
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the flagella has not yet been characterised in C. difficile but is proposed to follow a similar method to 
the one described here.  
The N-linked glycosylation pathway in C. jejuni was the first example of a bacterial N-linked 
glycosylation system [357, 358] (Figure 1.5a). Synthesis of the C. jejuni heptasaccharide utilises the 
en bloc mechanism of glycan assembly, whereby the sugar is built onto the undecaprenol 
pyrophosphate (UndPP) lipid linker on the cytoplasmic face of the inner membrane, to produce lipid-
linked oligosaccharide (LLO). This LLO can then be trafficked to the periplasm by the flippase 
enzyme, PglK. Once in the periplasm, the CjPglB OST transfers the glycan onto the asparagine 
residue within the target acceptor protein [335, 342, 359-361]. CjPglB recognises a specific sequon 
within the acceptor protein that includes the target asparagine residue, D-X-N-Y-S/T, where X and Y 
can be any amino acid except proline [348]. N-linked glycosylation systems harbouring enzymes 
orthologous to PglB have now been identified in a number of bacteria, including Helicobacter, 
Sulfurovum and Deffibacter [362, 363]. A similar system has not been identified in C. difficile 
although there are genes within the anionic polymer locus for synthesis of the surface 
polysaccharides that have putative functions similar to those within this system, including a putative 
















Figure 1.5. Campylobacter jejuni N-linked and O-linked glycosylation pathways. (A) The N-linked 
glycosylation locus from C. jejuni. Here, the glycan is assembled onto the undecaprenol 
pyrophosphate (UndPP) lipid linker at the cytoplasmic face of the inner membrane. The UndPP-
bound glycan is then transferred to the periplasm by the flippase PglK, before it is picked up by the 
oligosaccharyltransferase PglB and conjugated to a specific asparagine residue within the acceptor 
protein. (B) The O-linked glycosylation system from C. jejuni involves sequential addition of the 
individual monosaccharides onto the FlaA subunits of the flagella, before it is trafficked out of the 
cell. Image from Nothaft and Szymanski [335]. Reprinted by permission from Copyright Clearance 
Centre: Springer Nature, Nature Reviews Microbiology, Protein glycosylation in bacteria: sweeter 
than ever, Nothaft H and Szymanski CM, 2010. 
 Bioconjugation  
Bioconjugation harnesses the naturally occurring bacterial glycosylation pathways described above 
and repurposes them for glycoconjugate vaccine synthesis. The idea behind this is to build a 
“bacterial vaccine factory” which can overcome some of the shortfalls of chemical conjugation 
already discussed (1.5.1). Bioconjugation is often conducted in E. coli as the host organism, which 
offers a number of advantages over working with the target pathogen include, safety and ease of 
culture and the number of existing tools available for genetic manipulation.  
The development of bioconjugation and in particular the use of CjPglB is a result of a series of 
pioneering studies conducted in the mid-2000s. In 2002, Wacker et al. reconstituted the entire C. 
jejuni pgl locus in E. coli and demonstrated glycosylation of the acceptor protein AcrA [341] which 
was followed by further in depth characterisation of the biosynthesis locus [342]. Feldman et al. 
demonstrated CjPglB mediated transfer of O-antigens from E. coli and Pseudomonas aeruginosa, 
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which are distinct from its native heptasaccharide substrate. This demonstrated the promiscuity of 
CjPglB, a fundamental component of biocojugation. Further studies then defined the requirements 
of CjPglB, including an accessible D-X-N-Y-S/T recognition sequon within the acceptor, which 
contains the asparagine residue to be glycosylated and the need for an acetoamide group at the 
reducing end of the glycan substrates [347, 348, 364].  
Based on this understanding, it has become possible to build a diverse range of glycoconjugates 
which in its simplest form, can be achieved with plasmid mediated expression of three components; 
the carrier protein, the glycan synthesis locus and the OST, which conjugates the two together. How 
this work in practice when co-expressed in the same host is depicted in Figure 1.6. The glycan is 
synthesised onto the undecaprenol pyrophosphate lipid linker within the inner membrane then 
transferred into the periplasm by a dedicated flippase enzyme. CjPglB can then recognise the lipid-
linked glycan and transfer it to the provided acceptor protein, which harbours the recognised 
glycosylation sequon. This results in a synthesised glycoconjugate which can be purified from the cell 







Figure 1.6. Production of glycoconjugates using C. jejuni PglB-mediated bioconjugation. The glycan 
biosynthesis locus is expressed in the host cell to enable its synthesis on the undecaprenol lipid 
linker within the inner membrane. This is then transferred into the periplasm by a specific flippase 
enzyme. Once in the periplasm it can be recognised by the oligosaccharyltransferase PglB from C. 
jejuni which transfers the glycan from the lipid linker onto an asparagine residue in the D-X-N-Y-S/T 
glycosylation sequence, within the carrier protein. GP, glycoprotein, IM, inner membrane, OM, outer 
membrane. Image from Cuccui et al. [365]. 
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Obviously within this, the requirements of CjPglB have to be adhered to, including the D-X-N-S/T 
recognition sequon and presentation of the polysaccharide on a lipid linked donor. Regarding the 
acceptor protein, some may contain natural glycosylation sites, such as C. jejuni AcrA, but others 
have to be modified first, either through mutagenesis to introduce internal glycosylation sites or 
through the addition of a series of glycosylation sequons at the N- and/or C-terminus of the protein, 
known as a glycotags [366]. Furthermore, as a lipid-linked glycan is required, the glycosylation locus 
transferred into the host cell, must encode the requisite components to assemble this, including 
glycosyltransferases to build the glycan onto UndPP and a flippase to transfer it to the periplasm.  
There are now multiple examples of CjPglB-based glycoconjugate synthesis, including for Francisella 
tularensis, Streptococcus pneumoniae, Burkholderia pseudomallei, and Staphylococcus aureus [365, 
367-369]. Importantly, this has also evolved from academic research into real world applications, 
with bioconjugation-synthesised vaccines against S. pneumoniae (NCT03303976), extra-intestinal E. 
coli, Shigella flexnerii and Shigella dysentariae now in Phase I clinical trials [370-372].  
1.6. Vaccine development in C. difficile 
All current C. difficile management approaches are unified by their requirement for further 
interaction with the gut microbiota and lack of long-term protection. The ideal model of CDI 
prevention would circumvent these issues and may be achievable through immunisation. This would 
not necessarily be a vaccine administered universally, but instead would target those harbouring risk 
factors that increase their susceptibility to infection, similar to the method already applied for the flu 
and pneumonia vaccines [373-375]. People with increased risk for acquiring CDI include the elderly, 
those on certain antibiotics and people in, or with planned stays in hospital [376, 377]. Additionally, 
this could be used in those who have already suffered from an episode of CDI to prevent recurrence 
of infection [378]. Increased interest in a C. difficile vaccine has also emerged from the AMR field, 
where vaccination has been targeted as a means of reducing AMR. This currently focuses on those 
pathogens where AMR is considered the greatest burden, which includes C. difficile [317].  
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 Analysis of the humoral immune response  
Identification and analysis of antigenic proteins, for example during vaccine candidate discovery, can 
be laborious but is necessary before assessment in animal models of infection. Enzyme-linked 
immunosorbent assays enable measurement of the humoral immune response to antigens of 
interest by binding the protein to the bottom of a 96-well plate then exposing it to the test sample 
which is detected with a labelled secondary antibody. Although widely applied and very useful, 
ELISAs are laborious and therefore unsuitable for mass screening for multiple antigens and samples. 
In recent years the same principle has been scaled up to a protein array format, whereby proteins of 
interest are bound to a glass slide then probed with the same antibody-containing patient sample 
simultaneously [379, 380]. This platform enables whole proteome screening of organisms of 
interest, with patient samples (usually sera or plasma), offering a rapid means of profiling the 
humoral immune response to these proteins and from there identifying potential vaccine or 
diagnostic candidates. Furthermore, combining these arrays with a cell free transcription translation 
system can enable rapid and high-throughput antigen production, which would otherwise be a rate 
limiting step [380-383]. These arrays have now been used for a multitude of infectious diseases, 
including but not limited to; N. meningitidis, Burkholderia pseudomallei, Brucella melitensis, human 
papilloma virus and Salmonella Typhi [384-389]. 
 Infection models for C. difficile 
Animal models have enabled study of C. difficile in the host, including identification of the factors 
involved in colonisation and pathogenesis and as a means of evaluating novel antimicrobials or 
vaccine candidates prior to human trials.  
Hamster models have been in use since the 1970s and are a favourable infection model as the 
course of CDI within them shares similarity with that seen in humans, including the development of 
diarrhoea, intestinal injury, pseudomembranous colitis and death [390]. They have enabled 
elucidation of a variety of aspects of CDI, including the effects of different strains on the host, 
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treatment of CDI and the role of the toxins in disease, although this remains controversial (1.3.1) [8, 
10, 173, 210, 391, 392]. Prior to inoculation with C. difficile spores, clindamycin is administered to 
induce gut dysbiosis and provide an environment suitable for C. difficile outgrowth and the 
development of CDI. The same process is less effective in mice, believed to be a result of a more 
robust gut microbiota. To overcome this, Chen et al. used an antibiotic cocktail that induces 
sufficient gut dysbiosis that following treatment with clindamycin, mice developed CDI [393]. As 
mouse models are less sensitive to C. difficile, it is possible to use them to study other aspects of 
infection, such as colonisation and relapse [240, 394-396]. Furthermore, these models can enable in 
vivo assessment of vaccine candidates, including analysis of antibody functionality towards a specific 
target, such as neutralising activity. 
 Current vaccine development for C. difficile  
Using immunisation to manage CDI has been of interest since the late 1980s, when investigations 
into the protective effects of Toxins A and B first began [397]. Since then, there has been substantial 
research in both animal models and humans, dedicated to characterising the immunogenicity of 
these antigens and into their use within a C. difficile vaccine, using whole inactivated toxins or 
specific immunogenic domains (1.3.1) [267, 276, 398-406]. Leuzzi et al. demonstrated immunisation 
with both toxins was required to provide optimal protection from infection [267]. Both anti-C. 
difficile vaccines in active clinical trials are based on the use of both Toxins A and B. 
In 2017, the C. difficile vaccine development field suffered a major setback when Sanofi Pasteur’s 
Phase III clinical trial of Cdiffense, based on formalin inactivated Toxins A and B, was terminated 
prematurely (NCT01887912) [407]. This was due to interim results indicating it was unlikely the trial 
would meet its primary objective of preventing primary CDI. Consequently, Sanofi Pasteur have now 
halted their C. difficile vaccine development programme (https://www.sanofi.com/en/media-
room/press-releases/2017/2017-12-01-22-00-00). Pfizer are currently undertaking Phase III testing 
of their detoxified Toxins A and B vaccine, but as mutation of the glucosyltransferase domains did 
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not sufficiently reduce toxicity, these are also chemically detoxified (NCT03090191). Previous Phase 
II trials of this vaccine found it was safe and immunogenic within their target population of 65-85 
year olds (NCT02561195) [408, 409]. A chimeric vaccine consisting of a single fusion protein 
combining the binding domains of Toxins A and B is being developed by Valneva and has completed 
a Phase II trial (NCT02316470) which demonstrated this vaccine was safe and immunogenic [410]. 
However, concerns have been raised over how removal of other immunogenic domains of the toxin 
would influence the overall immune response [375].  
There has also been interest in alternative mechanisms of toxin delivery, including the use of DNA 
vaccines and expression of Toxins A and B from Vibrio cholera, Salmonella typhimurium and 
Lactococcus lactis [411-415]. Permpoonpattana et al. demonstrated the production of specific serum 
IgG and faecal IgA antibodies to the C-terminal repeats of Toxin A, when presented on the surface of 
Bacillus subtilis spores and orally administered to mice. Furthermore, 6/8 hamsters orally immunised 
with these recombinant spores survived challenge with C. difficile strain 630 [268]. One drawback of 
this approach is the risk of these spores germinating within the gut, leading to release of genetically 
modified organisms. This offers a novel delivery system with the opportunity of induction of both 
the systemic and mucosal antibody responses and is being prepared for Phase I clinical trials. Only 
one study has investigated the binary toxin as a potential vaccine candidate. Secore et al. (2017), 
found that administering the binary toxin with Toxins A and B increased survival in immunised 
hamsters when challenged with a NAP1 strain of C. difficile, when compared to use of Toxins A and B 
alone [416].   
Despite significant effort into the production and testing of toxin-based immunisation, there remains 
no commercially available C. difficile vaccine, and termination of the Cdiffense trial so late in 
development highlights the challenges faced. Additionally, a frequently raised concern over the toxin 
approach is the lack of protection from colonisation, meaning shedding and transmission of infection 
can continue [267, 403]. Understandably, there are now increased calls for use of a combination of 
53 
 
antigens that can protect against symptomatic infection, colonisation and possibly even against 
spores.  
Investigations into antigens that could offer this has been almost exclusively restricted to pre-clinical 
development, using antigens from a variety of sources, including spores and the cell surface (Table 
1.2). Immunisation of mice with S-layer protein resulted in a reduced faecal bacterial count  [417] 
and serum antibodies were raised in hamsters sub-cutaneously immunised with the cell wall protein 
Cwp84 [395]. All three surface polymers have been investigated and found to induce a PS-specific 
antibody response in a mouse model of infection, when chemically conjugated to CRM197, a non-
toxic version of the diptheria toxin and a widely employed carrier protein within glycoconjugate 
vaccines [235, 418-420]. Interestingly, PS-II conjugated to the Toxin B glucosyltransferase domain 
induced a PS-specific antibody response while also retaining immunogenicity of the toxin [238]. This 
is promising for the combination of toxin and non-toxin antigens in future vaccine formulations. Only 
PS-III-CRM197 has been evaluated in challenge experiments, where colonisation was significantly 
reduced in immunised mice compared to controls [420]. Matrivax are currently testing a combined 
toxin and PS-II vaccine in Phase I clinical trials (https://www.matrivax.com/c-difficile-vaccine).  
Two of the most promising antigens emerging from pre-clinical development are the C. difficile 
exosporium proteins, CdeC and CdeM. These conferred protection in mouse and hamster models of 
infection (higher dose in the hamster model) and were delivered via the intra-peritoneal route with 
an aluminium adjuvant. 10/10 mice and 10/10 hamsters survived challenge with C. difficile following 
immunisation with CdeC, compared to 9/10 of mice and 8/10 hamsters immunised with CdeM [421].  
It is notable that the functionality of the antibodies detected to the cell surface antigens above was 
not assessed and therefore their role in an opsonophagocytic or neutralisation response is unknown. 
The above immunisation was delivered parentally. Although C. difficile is a gut pathogen and 
therefore the gut immune response is very important, the studies described above demonstrating 
protection from CDI using toxin fragments was achieved using parental administration. Furthermore, 
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attempts to provide protection and generate antibody responses using oral vaccination of non-toxin 
antigens have had limited success [422-424]. 50% of hamsters survived challenge with C. difficile 
spores following oral immunisation with pectin beads loaded with FliC, compared to 17% of 
hamsters which were immunised with beads only. However, these hamsters did not demonstrate 
increased serum anti-FliC antibody responses and no FliC specific antibodies could be detected in 
their faeces [422]. 
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PS-I PS-I-CRM197 + FA Mouse (C57BL/6), 3 N/S Antibody titre Anti-PS-I serum IgG response [419] 
PS-I and PS-
II 
PS-I and PS-II free 
polysaccharide 
Pregnant sow, 2 IM Antibody titre Anti-PS-I and anti-PS-II IgM response [234] 
PS-II 
PS-II-CRM197  Mouse (C57BL/6), 3 SC  Antibody titre Serum anti-PS-II IgG response  [235] 
PS-II-CRM197 + 
MF59  
Mouse (BALB/c), N/S N/S Antibody titre Serum anti-PSII IgG response.   [236] 
PS-II chemically 
conjugated to 
binding domain of 
Tox A or 
glucosyltransferas
e domain of Tox 
B, both + MF59 
Mouse (BALB/c), 3 IP Antibody titre 
Serum PS-II-Tox B IgG response comparable to 
using PS-II-CRM197 (lower for PS-II-Tox A). 
Antibody response lower in PS-II-Tox A 
glycoconjugate compared to Tox A alone. Toxin 
neutralising antibodies detected for both.  
[238] 
PS-III 
LTA of PS-III-ExoA 
or HSA, Rabbit FA, 
mouse SA 






Antibody titre Serum anti-PS-III IgG response [237] 
PS-III 
Portion of PS-III-
CRM197  alone or + 
FA or Alum  
Mouse (C57BL/6), 3, 
clindamycin 
SC 
Antibody titre and 
CFU for C. difficile 
colonisation 
Serum anti-PS-III IgG response and significant 














O, IP, IR 
Antibody titre, 
faecal cell count, 
survival 
50% hamsters survived when orally immunised 
with FliC loaded pectin beads as opposed to 17% 
with beads only. Using FliC only, 0%, 17% and 
33% survived challenge when immunised by the 
O, IR and IP route, respectively. No surviving 
hamster had detectable C. difficile in faeces but 
only the increased serum anti-FliC response was 




 Target Formulation 
Model, dosage, 










alone or with 
recombinant 
receptor binding 
domains of Tox A 
and B. All + Alum 
Hamster, 3, 
clindamycin  Mouse 
(C57BL/6), 3, 




stool spore count 
and survival 
Serum anti-FliC antibodies. Increased anti-Tox A 
antibodies when administered with FliC. All mice 
immunised with FliC +/- Tox A and B survived 
challenge and had significantly lower stool spore 
count compared to controls. 5/14 hamsters 
immunised with low dose FliC died following 







spores alone or 
also expressing 
CotB- human IL-2  
Mouse (BALB/c), oral 
9 and IN 8 
O and IN Antibody titre 
No anti-FliD antibodies detected following O 
immunisation. IN immunised mice had 
significantly higher serum anti-FliD IgG compared 
to controls but no difference in IgA in 
gastrointestinal tract. Serum IgG highest in spore 




preparation + CT 
Mouse (C3H), 3, 
amoxicillin + 
clavulanic acid  
IR 
CFU for C. difficile 
colonisation 
6 days post-challenge: colonisation higher in the 
immunised compared to controls, by day 30 
colonisation in the immunised group was 







Mouse (C3H), 3, 
amoxicillin + 
clavulanic acid  
IR 
CFU for C. difficile 
colonisation 
6 days post-challenge: colonisation higher in the 
immunised group compared to the control group. 
By day 30 colonisation in the immunised group 




Cwp84 + FA (SC) 
or CT (R) 
Hamster, 3, 
clindamycin 
SC, IR, IG 
Antibody titres and 
CFU for C. difficile 
colonisation 
Serum antibodies to Cwp84 highest via SC route, 
no significant difference in antibody response 





GroEL + CT 
Hamster, 3, 
clindamycin Mouse 







mouse, survival in 
hamster 
No difference in survival between control and 
immunised for hamster. Colonisation significantly 
reduced in immunised mice 10 days post-
challenge, also had significantly higher serum 




 Target Formulation 
Model, dosage, 











SlpA + CT or 
recombinant C. 
difficile FliC 





Faecal bacterial count significantly reduced 10 
days post-challenge for immunised compared to 





amounts of LMW 
and HMW 
proteins + Alum, 
Ribi or CT  
Hamster,3, 
clindamycin 
Mouse (BALB/c), 3 




Mice: immunised via IP with SLP+CT or Ribi 
developed serum anti-SLP IgG, more modest 
response for serum IgA. Mucosal IgA no different 
from controls. Hamsters: immunised via IP route 
with SLP+Alum, developed serum anti-SLP IgG 
but all died on challenge. Immunised via IP with 
SLP+Ribi- 2/5 survived challenge or SLP+Ribi+CT- 








protein + CT   
Mouse (C3H) IR 
CFU for C. difficile 
colonisation 
6 days post-challenge: colonisation higher in the 
immunised group compared to the control group. 
By day 30 colonisation in the immunised group 









Mouse (C3H), 3, 
cefoxitin  Hamster, 3, 
clindamycin 
Mouse- 




Antibody titres and 
colonisation by CFU 
count in mice, 
survival for 
hamsters 
Anti-membrane fraction IgG antibodies detected 
in sera for all routes of immunisation except O, 
with highest via SC. Overall lower intestinal IgA 
response, highest via IR. Hamster survival 7 days 
post challenge was 2/40 for controls and 14/40 









BcIAI, SleC, CotA, 
all + Alum 








Serum IgG response for all proteins. Best 
protection 15 days post-challenge for CdeC 
(100% survival) and CdeM (90% survival).  
[421] 
Table 1.2. Pre-clinical development of non-toxin antigens for inclusion within a C. difficile vaccine. LTA, lipoteichoic acid, CFU, colony forming units, SLP, surface layer 
protein, HMW and LMW are the high and low molecular weight products of the cleaved S-layer protein, SlpA. Carrier proteins; CRM197, detoxified diphtheria toxin, regions 
of C. difficile toxins A and B and HSA, human serum albumin. Adjuvants; MF59, squalene-based, CT, non-toxic derivative of the cholera toxin, Alum, aluminium hydroxide, 
SA, Sigma adjuvant, FA, Freund’s adjuvant and Ribi, oil in water emulsion of bacterial cell wall components. Route of administration; IP, intraperitoneal, IR, intrarectal, SC, 




This research aimed to use the output of a novel pan-proteome array to identify reactive C. difficile 
antigens in both C. difficile patients and healthy age-matched controls. The results of this array were 
used to identify novel immunogenic vaccine candidates and characterise these to determine their 
function within C. difficile. Additionally, this study aimed to develop novel bioconjugation technology 
to produce a C. difficile-specific glycoconjugate, as proof of principle for C. difficile vaccine synthesis 
using this system. 
1. Identify potential C. difficile vaccine candidates using data from a high throughput pan-proteome 
array.   
• Analyse data resulting from a high-throughput C. difficile pan-proteome array designed to 
detect antibody response to C. difficile proteins with samples from infected patients 
compared to matched controls. 
• Identify potential vaccine candidates, with a higher response in healthy controls compared 
to CDI cases.   
2. Characterise novel vaccine candidates for C. difficile in vitro and validate their immunogenicity. 
• Make clean gene inactivation mutants in these strains using allele exchange mutagenesis 
and characterise the phenotype of these mutants in vitro based on their putative function.  
• Clone, express and purify these vaccine candidates for validation of their immunogenicity 
with patient samples using indirect ELISA assays. 
3. Design and construct a protein carrier for bioconjugation with the C. difficile flagella glycan.  
• Design a carrier protein suitable for bioconjugation and optimise in vitro glycosylation of the 
carrier protein using the oligosaccharyltransferase PglB and the heptasaccharide from C. 
jejuni.    
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 4. Employ bioconjugation to synthesise the flagella glycan from the hypervirulent C. difficile strain 
R20291 on a suitable acceptor protein. 
• Design, test and optimise an E. coli system to facilitate the production of the C. difficile 
flagella glycan and its conjugation onto a carrier protein.  
• Use a potential vaccine candidate identified on the pan-protein array as an acceptor protein 


















2. Materials and Methods 
2.1. Materials 
All oligonucleotides were ordered from Integrated DNA Technologies (IDT) and enzymes from New 
England Biolabs (NEB), unless otherwise stated (Appendix A). Plasmid construction is detailed in 
Appendix B.  
2.2. Growth conditions 
Strains used in this work are listed in Table 2.1. All strains were stored in 20% glycerol (Sigma 
Aldrich) at -80oC. 
 C. difficile growth 
Clostridium difficile strains were routinely cultured on brain heart infusion supplemented (BHIS) 
agar; brain heart infusion (BHI) agar (Oxoid) supplemented with 0.5% w/v yeast (Sigma Aldrich or 
Bacto) and 0.1% w/v L- cysteine (Sigma Aldrich), or in liquid cultures of BHIS broth; BHI broth 
supplemented with 0.5% w/v yeast and 0.1% w/v L- cysteine. All work with live C. difficile was 
performed at 37oC in an anaerobic atmosphere (10% CO2, 10% H2, 80% N2) in a Whitley MG500 
workstation and liquid cultures incubated shaking at 65 rpm. When required, the following was 
added; 0.1% w/v sodium taurocholate (Sigma Aldrich) for germination of C. difficile spores, 250 
µg/ml D-cycloserine and 8 µg/ml cefoxitin (ThermoFisher Scientific) for selection of C. difficile and 15 
µg/ml thiamphenicol (Sigma Aldrich) for selection of C. difficile harbouring plasmids with a 
thiamphenicol resistance cassette. With the exception of BHIS agar used to reactivate strains from 
glycerol, all media and reagents were pre-equilibrated for a minimum of 4 hours in the anaerobic 






Strain Details Source 
Clostridium difficile  
630Δerm  
Erythromycin sensitive derivative of PCR-




630Δerm with ClosTron insertion with CD1910, 




630Δerm with ClosTron insertion with CD1911, 
encoding EutW of the ethanolamine utilisation 
locus 
Alexandra Faulds-Pain  
R20291 
Fully sequenced PCR-ribotype 027 hypervirulent 




CDR20291_0330 gene deletion mutant in 
R20291, a putative cobalt binding protein 
This study 
R20291Δ3343 
CDR20291_3343 gene deletion mutant in 
R20291, a putative pilin protein 
This study 
R20291Δ0342 
CDR20291_0342 gene deletion mutant in 
R20291, a putative lipid transporter 
This study 
R20291_fliC::CT R20291 with ClosTron insertion within fliC  [187] 
R20291_fliC::CTΔ3343 
R20291 with ClosTron insertion within fliC and 




Commercially available strain, electro-
competent. F− mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 












Protein expression strain: F-ompT hsdSB(rB - mB 
- ) gal dcm(DE3) 
Invitrogen 
CA434 
Kanamycin resistant conjugation donor strain. E. 
coli HB101 [F− mcrB mrr hsdS20(rB− mB−) 
recA13 leuB6 ara-14 proA2 lacY1galK2 xyl-5 mtl-












E. coli isolate harbouring the O13 antigen, from 
Public Health England Culture collection 
Public Health England 
Culture Collection 
Table 2.1 List of strains used in this study.  
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 C. difficile minimal media  
The C. difficile minimal media  recipe used was based on that described by Karasawa et al. [32] and 
simplified by Cartman et al. [431] (Table 2.2). tThis was used for motility assays performed in 
minimal media agar. Growth kinetics in ethanolamine minimal media were performed as described 
by Nawrocki et al. [36] (Table 2.3) which uses a reduced concentration of cas-amino acids and 
glucose compared to the Cartman recipe. Finally, the valine utilisation experiments were performed 
according to Cartman et al., [431] but cas-amino acids were replaced with individual amino acids as 
described in the Karasawa method (Table 2.4) [32]. All components were dissolved in d.H2O before 
sterilising with 0.22 µM syringe filter units (Merck Millipore). Iron sulphate (FeSO4) solution was 
prepared anaerobically and added to pre-equilibrated liquid media. For solid minimal media, agar 
was added to the required percentage and FeSO4 added prior to pre-equilibrating due to the 



















Amino acids  
Cas-amino acids  50  10  
L-tryptophan 2.5  0.5  
L- cysteine  2.5  0.5  
Salts 
Na2HPO4 50 5 
NaHCO3 50 5 
KH2PO4 9 0.9 
NaCl 9 0.9 
Trace Salts 
(NH4)2SO4 2 0.04 
CaCl2·2H2O 1.3 0.026 
MgCl2·6H2O 1 0.02 
MnCl2·4H2O 0.5 0.01 
CoCl2·6H2O 0.05 0.001 
Glucose 200 10 
FeSO4·7H2O 0.4 0.004 
Vitamins 
D-biotin 0.1 0.001 
Calcium-D-pantothenate 0.1 0.001 
Pyridoxine 0.1 0.001 
 

















Amino acids  
Casamino acids  12.5 1.25 
L-tryptophan 0.625 0.0625 
L- cysteine  0.625 0.0625 
Salts 
Na2HPO4 50 5 
NaHCO3 50 5 
KH2PO4 9 0.9 
NaCl 9 0.9 
Trace Salts 
(NH4)2SO4 2 0.04 
CaCl2·2H2O 1.3 0.026 
MgCl2·6H2O 1 0.02 
MnCl2·4H2O 0.5 0.01 
CoCl2·6H2O 0.05 0.001 
Glucose 9 0.9 
Ethanolamine 14.6 1.46 
FeSO4·7H2O 0.4 0.004 
Vitamins 
D-biotin 0.1 0.001 
Calcium-D-pantothenate 0.1 0.001 
Pyridoxine 0.1 0.001 



















Table 2.4. Amino acid composition for valine utilisation in minimal media. Recipe from Karasawa et 
al.[32].  
 
 E. coli growth 
Escherichia coli strains were cultured in lysogeny broth (LB) or on LB agar (Merck). LB was purchased 
(Merck), or prepared using 1% w/v tryptone (Sigma Aldrich), 0.5% w/v yeast and 0.5% w/v sodium 
chloride (Sigma Aldrich). Unless otherwise stated, all cultures were incubated at 37oC in an aerobic 
atmosphere, and liquid cultures shaken at 180 rpm. When required, LB was supplemented with 
antibiotics, as described in Table 2.5. 
Antibiotic Final concentration for E. coli 
(µg/ml) 
Final concentration for C. difficile 
(µg/ml) 
Thiamphenicol N/A 15 
Chloramphenicol 25 N/A 
Kanamycin 50 N/A 
Ampicillin 25 N/A 
Spectinomycin 250 N/A 
Table 2.5. List of antibiotics used in C. difficile and E. coli. N/A- not used for this bacteria.  
 
2.3. Bioinformatics 
The GENtle software was routinely used for viewing DNA sequences 
(http://gentle.magnusmanske.de/), designing plasmids and primers and analysing DNA sequencing 
results. The assembled genome sequences of C. difficile strains 630 and R20291 were downloaded as 














EMBL genome files from the Wellcome Trust Sanger website 
(https://www.sanger.ac.uk/resources/downloads/bacteria/clostridium-difficile.html) and viewed 
using Artemis (https://www.sanger.ac.uk/science/tools/artemis) [432]. DNA and protein sequences 
of interest were extracted from these genome files and used for further analysis, including BLAST 
searches for prediction of gene function and for the identification of related genes 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=bla
sthome).  
For putative protein analysis, the Phyre2 Server (Protein Homology/analogY Recognition Engine V 
2.0) (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id) [433] and pFam 32.0 database 
(https://pfam.xfam.org/) [434] were used for predicting protein function and structure, and 
identification of conserved domains. SignalP 4.1 Server (http://www.cbs.dtu.dk/services/SignalP/) 
[435] was used for detection of possible signal peptides, TMHMM Server v 2.0 
(http://www.cbs.dtu.dk/services/TMHMM/) [436] for identification of transmembrane domains and 
Protein Molecular Weight for the estimation of protein size from the amino acid sequence 
(https://www.bioinformatics.org/sms/prot_mw.html). Peptide2 
(https://www.peptide2.com/N_peptide_hydrophobicity_hydrophilicity.php) was used for 
hydrophobicity predictions based on amino acid sequence.  
2.4. DNA manipulation  
 DNA isolation 
DNA was isolated from C. difficile by Chelex preparation. 1.5 ml of overnight liquid culture was 
centrifuged at 14, 500 x g for 2 mins, the supernatant discarded and pellet resuspended in 300 µl 5% 
w/v Chelex (Sigma Aldrich). Suspensions were vortexed thoroughly before boiling then chilling on ice 
for 10 mins each. Following a final centrifugation step at 14, 500 x g for 1 min, 200 µl of the 
supernatant was stored at -20oC.  DNA concentration and purity was measured using a 
NanoDrop1000 spectrophotometer (NanoDrop Technologies, Inc). For DNA purification, the 
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QIAquick PCR Purification Kit (Qiagen) or the Monarch PCR & DNA Cleanup Kit (NEB) were used. For 
isolation of plasmid DNA from E. coli, the QIAprep Spin Miniprep Kit (Qiagen) or Monarch Plasmid 
Miniprep Kit (NEB) were used. All kits were used according to manufacturer’s instructions and DNA 
products stored at -20oC.   
 Polymerase chain reaction 
All oligonucleotides used are listed in Appendix A. Prior to ordering, these were checked for melting 
temperature and secondary structures using the NEB Tm calculator (https://tmcalculator.neb.com/) 
and NetPrimer (http://www.premierbiosoft.com/netprimer/), respectively. PCR reactions were 
performed using 1 unit of high-fidelity Phusion DNA polymerase (NEB), 1x Phusion HF buffer (20 mM 
Tris-HCl, 100 mM KCl, 1 mM DTT, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 200 μg/ml BSA, 
50% Glycerol, 1X stabilizers) (NEB), 0.2 µM dNTPs (NEB), 0.2 µM of each primer and approx. 10 ng of 
template DNA. Annealing temperature and extension times were tailored to the specific reaction but 
the standard protocol followed; 98oC for 30 secs then 35 cycles of the following, 98oC for 10 secs, 
melting temperature (Tm) of the primers for 30 secs and 72oC for 2 mins then a final 4 min step at 
72oC. These were run in a DNA Engine Tetrad 2 thermal cycler (Bio-Rad Laboratories Inc.).   
 Agarose gel electrophoresis 
DNA samples were run on 1% w/v agarose gels containing a 1:10,000 dilution of GelRed Nucleic Acid 
Gel Stain (Biotium), in 1x TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA). Between 20 and 
50 µl of DNA were mixed with 1x DNA Gel Loading Dye (NEB) before running on the gel alongside a 1 
Kb DNA Hyper Ladder (Bioline). Routine conditions for resolving the gel were 100-120 volts for 30 to 
60 mins. Gels were visualised using a Gene Genius Bio Imaging System (Syngene) and DNA purified 
from the extracted agarose band using the QIAquick Gel Extraction Kit (Qiagen) or Monarch DNA Gel 
Extraction Kit (NEB), according to manufacturer’s instructions.  
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 Restriction digestion  
A list of plasmids used in this study can be found in Appendix A. Digestion reactions to be used for 
cloning contained 1x CutSmart reaction buffer (10 mM Bis-Tris-Propane-HCl, 10 mM MgCl2, 100 
μg/ml BSA (NEB), 50-100 ng of insert or plasmid DNA, 20 units of each restriction enzyme and d.H2O 
to a final 50 μl volume. Reactions were incubated at 37oC for 3 hours for plasmid DNA or 1 hour for 
insert DNA. 5’ phosphate groups were removed from the digested plasmid to prevent self-ligation by 
adding 5 units Antarctic phosphatase (NEB) and 1x Antarctic phosphatase buffer (50 mM Bis-Tris-
Propane-HCl, 1 mM MgCl2, 0.1 mM Zn6`Cl2) (NEB), directly to the digestion reaction, incubating at 
37°C for 15 mins then inactivating the enzyme at 65°C for 5 mins. Dephosphorylated digested 
plasmid was resolved on an agarose gel, extracted and purified (2.4.3) while the insert was purified 
directly after digestion (2.4.1). For test digests to confirm presence of an insert, reactions included 
1x CutSmart reaction buffer, 500 ng/ml BSA, 5 µl plasmid DNA and 10 units of each restriction 
enzyme, made up to a total 20 µl reaction volume with d.H2O.  
To remove any residual backbone when amplifying large fragments from plasmid DNA, 20 units DpnI 
and 1x CutSmart reaction buffer was added to 50 µl PCR reactions immediately after amplification. 
These were incubated for 1 hour at 37oC then the enzyme inactivated with incubation at 80oC for 20 
mins.  
 DNA ligation 
Ligation reactions contained insert and plasmid DNA at a 3:1 concentration ratio, 1 unit of T4 DNA 
ligase buffer (10 mM Tris-HCl pH 7.4, 50 mM KCl, 1 mM DTT, 0.1 mM EDTA and 50% glycerol) 
(Promega) and 1x T4 DNA ligase (Promega). Reactions were either incubated for 1 hour at 16°C or on 
ice overnight then dialysed on 0.45 µM membrane filters (Millipore) in sterile d.H2O for 30 minutes, 
before using immediately for E. coli transformation (2.6.2) or freezing at -20oC.  
69 
 
 Gibson assembly  
In addition to restriction/ligation cloning, plasmids were also constructed using Gibson assembly 
[437]. This involves the amplification of insert and plasmid DNA to include overlapping regions which 
can anneal following incubation with exonuclease, an enzyme which creates single-stranded 3’ 
overhangs. DNA polymerase then completes each annealed fragment and DNA ligase seals any nicks 
in the assemblies.    
Plasmids were constructed using the NEBuilder HiFi DNA Assembly Cloning Kit (NEB), according to 
manufacturer’s instructions. Briefly, the NEBuilder online tool (https://nebuilder.neb.com/) was 
used to design oligonucleotides for amplification of the plasmid and insert fragments with 5’ and 3’ 
overhangs. Following PCR amplification of each fragment (2.4.2) and DpnI treatment of the plasmid 
(2.4.4), these were resolved on an agarose gel and purified (2.4.3). 50-100 ng of the purified plasmid 
fragment was incubated at 50oC for 15-30 mins with 2x excess of the insert fragment, 1x NEBuilder 
DNA Assembly HiFi DNA Master Mix and d.H2O to a 20 µl total reaction volume. Reactions were then 
chilled on ice before either immediate transformation into competent cells (2.6.2) or storage at -
20oC.  
 DNA sequencing 
DNA and plasmid samples were sequenced using the Eurofins or Source Sanger sequencing services, 
according to company requirements.  
 Screening of transformants and colony PCR 
Colonies were screened for the desired construct using test digestion or colony PCR. For the former, 
single colonies to be screened were grown overnight in LB supplemented with appropriate antibiotic 
before plasmid isolation (2.4.1) and digestion with restriction endonucleases flanking the insert site 
(2.4.4). These were then visualised on a 1% w/v agarose gel (2.4.3) to determine if the released 
product equated to the size of the desired insert. Colony PCR was used to screen the transformants 
directly from the plate by resuspending each colony in 50 µl 1x sterile phosphate buffered saline 
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(PBS). 2 µl of resuspension was used in a 50 µl PCR reaction with d.H2O volume adjusted accordingly 
(2.4.2). The initial 98oC denaturation step was extended to 8 mins to aid cell lysis and release of DNA. 
When possible, oligonucleotides were used that annealed to the regions of the plasmid flanking the 
insert to ensure that amplification was not from residual insert, carried over from the ligation 
reaction. Test digestion and colony PCR results indicating presence of the insert were confirmed by 
sequencing (2.4.7).  
2.5. Manipulation of E. coli  
 Preparation of electrocompetent E. coli  
An overnight culture of the E. coli strain to be made electro-competent was diluted 1:100 into 100 
ml LB, supplemented with antibiotic as needed and incubated shaking at 180 rpm until OD595nm of 0.5 
and 1 was reached. Cells were chilled on ice for 15 mins before harvesting at 14, 500 x g, 4oC for 15 
mins. Supernatant was discarded and cells re-suspended in 100 ml pre-chilled d.H2O and centrifuged 
as described previously. Pelleted cells were re-suspended in 8 ml pre-chilled 10% glycerol and 
centrifuged. Supernatant was discarded and cells re-suspended in 500 μl 10% glycerol and stored at -
80oC in 55 μl aliquots.  
 Transformation of competent E. coli 
An aliquot of competent cells were thawed on ice and mixed with approx. 1-5 ng plasmid DNA. 
Electro-competent cells were electroporated at 2.5 KV in a Gene Pulser Xcell (Bio-Rad Laboratories 
Inc.) before recovery in 500 µl super optimal broth (SOC) (0.5% Yeast Extract, 2% Tryptone, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM Glucose) for 1 hour at 37°C, shaking 
incubation. Chemically competent NE5 alpha cells (NEB) were chilled on ice for 30 mins, incubated at 
42oC for 30 secs, chilled on ice for another 2 mins then incubated with 950 µl SOC buffer for 60 mins 
at 37oC, shaking incubation. Following recovery, both cell types were transferred to 5 ml LB or 100 µl 
was plated neat or 1:10 dilution on LB agar plates. Both broth and plates were supplemented with 
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the antibiotic corresponding to the resistance cassette on the plasmid and incubated overnight at 
37°C. 
2.6. Manipulation of C. difficile  
 Transformation of C. difficile  
As transformation of C. difficile cells requires conjugation with a competent donor strain of E. coli, 
the kanamycin resistant E. coli CA434 strain was used. CA434 cells were grown overnight in 5 ml LB 
broth supplemented with 50 µg/ml kanamycin and 25 µg/ml chloramphenicol to select for the strain 
and plasmid, respectively. Cells were prepared for mating by pelleting 1.5 ml of overnight culture for 
2 mins at 14,500 x g, discarding the supernatant, then gently re-suspending cells in 500 μl 1x PBS 
before centrifugation for 1 min at 14, 500 x g. Supernatant was again discarded and cells transferred 
to the anaerobic workstation and re-suspended in 200 μl overnight C. difficile culture before plating 
in 20 μl aliquots on BHI agar. When needed, a heat shock protocol was used to try and increase 
conjugation efficiency [438]. Here, pelleted E. coli cells were resuspended in 200 µl overnight C. 
difficile culture immediately after the first centrifugation step, without washing the cells with PBS, 
and incubated at 52oC for 5 minutes then 37oC for 2 minutes before spot plating as described. 
Following 24 hour conjugation, growth was re-suspended in sterile 1x PBS and spread plated in 100 
μl aliquots on BHIS agar supplemented with D-cycloserine and cefoxitin, for isolation of C. difficile 
only and thiamphenicol to select for the plasmid. Following 48-72 hours incubation, colonies were 
restreaked to confirm successful transformation.  
 C. difficile mutagenesis  
Genes of interest were deleted from the C. difficile chromosome using allele exchange mutagenesis 
[439]. This approach does not require a negative selection marker and instead relies on homologous 
recombination to remove the gene from the chromosome. This results in the generation of in-frame 
deletion mutants without polar effects to downstream genes, as can occur with insertional 
mutagenesis methods, such as ClosTron [440, 441].  
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 Plasmid construction for allele exchange mutagenesis 
Allele exchange cassettes were built using splicing by overlap extension (SOE) PCR [442] then cloned 
into pMTL82151 (http://www.clostron.com/) for conjugation into C. difficile. Each cassette consisted 
of the two ~1200 bp DNA regions (homology arms) immediately flanking the gene for deletion, 
which enable the homologous recombination event to occur. Homology arms 1 and 2 (HA1 and HA2) 
were amplified from C. difficile R20291 genomic DNA (gDNA) to include 5’ (HA1) and 3’ (HA2) 
restriction endonuclease sites for cloning into pMTL82151 and 3’ (HA1) and 5’ (HA2) complimentary 
overhangs, comprised of the first and last 21 bp of the gene for deletion. These complimentary 
regions permit joining of the two constructs in a second round of amplification, using the forward 
primer of HA1 and reverse primer of HA2. Allele exchange constructs were inserted into pMTL82151 
using restriction-ligation cloning (2.4.4, 2.4.5), with correct plasmid assembly confirmed using test 
digestion (2.4.4) and DNA sequencing (2.4.7).  
 Conjugation 
Each pMTL82151 plasmid carrying a different allele exchange cassette was transformed into electro-
competent CA434 cells (2.6.2) and conjugated with C. difficile R20291 (2.7.1). Following 
resuspension and spread plating of the conjugations, plates were incubated for 72 hours, before re-
streaking the largest colonies 3-4 times on BHIS agar, supplemented with D-cycloserine, cefoxitin 
and thiamphenicol. Larger colonies were preferentially restreaked, as these were most likely to have 
undergone the single cross over event and therefore harbour the plasmid on the chromosome 
(Figure 2.1). This is due to the use of the “pseudo-suicide” plasmid, pMTL82151, which replicates 
poorly in C. difficile so better growth is obtained when the plasmid has integrated and the 
















Figure 2.1. Diagram of allele exchange mutagenesis. Example of deletion of ermB from the 
chromosome using allele exchange mutagenesis. (A) Single cross event resulting from one of the 
regions of homology (dark grey), leading to incorporation of the whole plasmid onto the 
chromosome. (B) Second cross over event with the second regions of homology (light grey), resulting 
in deletion of ermB from the chromosome (C) If the second recombination event occurs at the same 
region of homology as the first, the plasmid is lost and the strain reverts to wild-type sequence. 
Image taken from Faulds-Pain et al. [439]. 
 
 Isolation and screening of gene deletion mutants  
Predicted single cross over colonies were passaged 4-5 times on non-selective BHIS agar to remove 
the selection pressure to maintain the plasmid and enable the second recombination event to occur 
(Figure 2.1). Following passage, colonies were patch plated on non-selective BHIS agar and BHIS agar 
containing thiamphenicol to identify those which were had lost the plasmid. Colonies demonstrating 
thiamphenicol sensitivity were screened by PCR to differentiate between wild-type revertants (those 






primers flanking the gene for deletion. Primers annealing upstream of the 5’ of HA1 and 
downstream of the 3’ of HA2 were used to amplify this region for sequencing, to ensure the gene 
had successfully been deleted from the chromosome and results were not due to interference from 
residual plasmid DNA.  
2.7.  Phenotypic assays 
 Growth kinetics of C. difficile  
To determine the growth rate of C. difficile, three colonies were used to inoculate a primary culture 
of 5 ml BHIS or BHI broth. Following overnight incubation, this was used to inoculate 25 cm3 vented 
tissue culture flasks containing 15 ml BHI or BHIS broth to a starting OD595nm 0.05. OD595nm readings 
were taken every hour for the first 8 hours then a final reading at 24 hours using a CO 8000 Cell 
Density Meter spectrophotometer (Biochrom WPA). Cultures were set up in duplicate and three 
independent replicates were performed. 
 Ethanolamine Utilisation 
An overnight 5 ml BHIS culture of C. difficile was diluted 1:100 into 10 ml fresh BHIS broth and 
shaking incubated to OD595nm 0.6. This was back-diluted in ethanolamine minimal media (Table 2.3) 
containing either 0.9 mg/ml glucose (Sigma Aldrich), 1.46 mg/ml ethanolamine (Sigma Aldrich) or 
water (no carbon control) to OD595nm 0.1.  Dilutions were used to inoculate 15 ml or 20 ml minimal 
media to a starting OD595nm 0.01. Cultures were incubated shaking for 72 hours, with OD595nm taken 
at; 16, 20, 24, 40, 44, 48, 64, 68 and 72 hours. Cultures were set up in duplicate and assay performed 
in three independent replicates.  
To investigate the role of cobalt in ethanolamine utilisation, an overnight 10 ml minimal broth, 
containing 0.9 mg/ml glucose and no cobalt was inoculated using three colonies of C. difficile. This 
was diluted 1:100 into a 10 ml minimal broth containing 0.9 mg/ml glucose and no cobalt, grown to 
OD595nm 0.6 then back-diluted to OD595nm 0.1 in media matching the final growth media, specifically 
ethanolamine minimal media +/- cobalt and either 0.9 mg/ml glucose (Sigma Aldrich), 1.46 mg/ml 
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ethanolamine (Sigma Aldrich) or water (no carbon control). This was used to inoculate a single 
minimal media flask per condition to OD595nm 0.01, then readings taken as above. The assay 
performed in two independent replicates.  
 Valine Utilisation 
Three colonises from a plate culture were used to inoculate 10 ml minimal media containing all 11 
amino acids plus glucose and incubated overnight (Table 2.4). This overnight was used to inoculate 
fresh 15 ml minimal media to a starting OD 0.05. Minimal media was either plus or minus glucose, and 
contained either all 11 amino acids (Table 2.4), 6 amino acids (proline, leucine, cysteine, valine, 
isoleucine, tryptophan) or 5 amino acids (proline, leucine, cysteine, isoleucine, tryptophan). 200 µl of 
culture was removed every hour for 8 hours then at a final 24 hours for OD595 readings taken using a 
plate reader.  This was performed in two independent replicates.  
 Colony forming units  
In order to determine the number of colony forming units (CFUs) of C. difficile, liquid cultures were 
serially diluted 1:10 until the 1:100,000 dilution, in 1x PBS. Each sample was vortexed between 
dilutions. 10 µl of neat C. difficile and each dilution were plated in triplicate on BHIS plates (without 
L-cysteine) containing 0.1% w/v sodium taurocholate to ensure germination of spores. For spore 
counts, 1 ml of neat C. difficile culture was transferred to 1.5 ml microcentrifuge tubes and heated at 
65oC for 20 mins, before serial dilution and plating. Plates were incubated anaerobically overnight at 
37oC and number of colonies counted by eye to the lowest dilution where colonies could still be 
differentiated. Colony counts were multiplied by 100 to obtain the number of colonies per ml then 
multiplied by the relevant dilution factor to determine the final CFU. Vegetative cell count was 




 Antimicrobial susceptibility 
The sensitivity of C. difficile to different antibiotics and antimicrobial peptides (AMPs) was measured 
using the broth dilution method [148, 443] under anaerobic conditions. 24-well flat-bottom plates 
contained each antibiotic concentration in duplicate (doubling dilutions were prepared from 32 to 
0.5 µg/ml for lincomycin and 512 to 0.5 µg/ml for bacitracin and erythromycin), a growth control (no 
antibiotic) and broth sterility control (no inoculant). Antibiotic stocks were prepared at either 10 
mg/ml or 1 mg/ml then diluted to the desired concentration in BHI broth, before aliquotting 990 µl 
into each well. An overnight C. difficile liquid culture was diluted 1:100 in 10 ml BHI broth and 
incubated shaking until OD595nm 0.3. 10 µl of culture was added to each well and plates were 
incubated shaking for 16 hours.  If C. difficile growth had sedimented to the bottom of the plate well, 
this was resuspended before OD595nm readings were taken using an ELx800 Absorbance microplate 
reader (Biotek). The minimum inhibitory concentration (MIC) determined in the first assay was 
confirmed with two more replicates at three concentrations; the MIC, and 2x and 0.5x this 
concentration (no 2x concentration was used for bacitracin and erythromycin as there was no 
growth at the highest concentration tested, 512 µg/ml).  
 Colony morphology 
To visualise colony morphology, overnight cultures in BHIS broth were diluted 1:100 into fresh BHIS 
and left to grow until OD595nm reached between 0.3 and 0.4. These were then diluted to between 
1:10,000 and 1:100,000 in sterile 1x PBS and 100 µl of each spread plated on 1.8% BHIS agar 
supplemented with thiamphenicol, 1% glucose, and 0 or 25 ng/ml anyhydrotetracycline (Atc), for 
induction of the Ptet promoter. Following 5 days incubation, the colonies were photographed using 
a Canon 600D SLR. 
 Swimming motility  
Swimming motility of C. difficile was assessed using minimal media with 0.3% agar and 
thiamphenicol. When required for induction of the Ptet promoter, anhydrotetracycline was added at 
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25, 50, 100 or 250 ng/ml. C. difficile colonies growing for 24-48 hours were picked using a sterile 
toothpick and the centre of the swimming plate stab inoculated to approximately halfway through 
the agar. Plates were incubated statically for 5 days then two perpendicular measurements of the 
diameter taken (Figure 2.1a), which were averaged. Plates were also photographed using a Canon 
600D SLR. Each plate was set up in duplicate and the assay performed in three independent 
replicates.  
 Surface motility 
Surface motility of C. difficile was assessed using 1.8% BHIS agar. Higher agar percentages increase 
surface hardness which enables the swarming movement to occur. An overnight broth culture of C. 
difficile was diluted 1:100 into fresh 10 ml BHIS and 5 µl spotted in quadruplicate onto BHIS agar 
plates supplemented with thiamphenicol, 1% glucose and 0 or 25 ng/ml Atc, once OD595nm reached 
0.3-0.4. Plates were incubated statically and 2 measurements taken for each spot every day for 5 
days- at the widest diameter of the colony and perpendicular to this measurement, which were then 
averaged (Figure 2.1b). Plates were also photographed on day 5 using a Canon 600D SLR. The assay 





Figure 2.2. Motility measurements. Schematic of measuring diameter of bacteria in motility assays. 
(A) Swimming motility diameter, taking two perpendicular readings (B) swarming motility 







 Biolog  
Biolog Phenotypic Microarrays assays enable high-throughput analysis of bacterial growth through 
comparing growth in many different conditions, simultaneously. Biolog assays were performed at 
the Wellcome Trust Sanger Institute by Dr Hilary Brown and Dr Kevin Vervier. In brief, these were 
conducted using an AN MicroPlateTM (Biolog) that was exposed to oxygen for 30 mins before 
transfer to the anaerobic cabinet. A plate culture of C. difficile was swabbed from the agar surface 
and resuspended in pre-reduced AN Inoculating Fluid (Biolog) then transferred to the AN Microplate, 
100 µl per well. Plates were sealed in an oxygen impermeable bag then transferred to the OmniLog 
incubator for 24 hours, which takes automated OD readings of cell growth. 
2.8. Protein techniques 
 SDS-PAGE 
15 µl of protein sample was mixed with 1x NuPAGE LDS sample buffer (ThermoFisher Scientific) to a 
total 20 µl volume and heated at 70oC for 5 mins. Standard conditions used a pre-cast 10% or 4-12% 
NuPAGE Bis-Tris gel (ThermoFisher Scientific) with PageRuler Prestained Protein Ladder 
(ThermoFisher Scientific) or PageRuler Plus Prestained Protein Ladder (ThermoFisher Scientific) in 1x 
3-(N-morpholino)propanesulfonic acid (MOPS) SDS Running Buffer (50 mM MOPS, 50 mM Tris Base, 
0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA, pH 7.7) (ThermoFisher Scientific) for 50-60 mins at 
180 V. For resolution of smaller proteins, 1x 2-(N-morpholino)propanesulfonic acid (MES) SDS 
Running Buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3) was used. For 
separation and visualisation of proteins under 15 KDa, the same protocol was followed, but samples 
were resolved on 16% Tricine Protein Gels (ThermoFisher Scientific) in Tricine SDS Running Buffer 
(ThermoFisher Scientific) with SeeBlue Pre-Stained Protein Standard ladder (ThermoFisher 
Scientific). Gels were visualised using Western blotting (2.8.3) or by staining with Coomassie (2.8.2).  
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 Coomassie Staining 
Gels were incubated rocking with Coomassie Brilliant Blue R-250 stain (10% acetic acid, 10% ethanol, 
1 mg/ml Coomassie) at room temperature (RT) for 20-60 mins, then destained overnight in 10% 
ethanol, 10% acetic acid. Gels were visualised on an Azure c600 Gel Imaging System (Azure 
Biosystems).  
 Fluorescent Western Blotting 
The iBlot 2 Dry Blotting System (ThermoFisher Scientific) was used for transfer of samples from the 
SDS-PAGE gel to a nitrocellulose membrane (ThermoFisher Scientific). Transfer stacks were 
assembled and loaded onto the iBlot according to manufacturer’s instructions and transferred for 7 
mins (1 min at 20 V, 4 mins at 23 V, 2 mins at 25 V). Following transfer, membranes were washed for 
5 mins in 1x PBS + 0.1% Tween20 (Sigma Aldrich) then incubated with blocking buffer (1x PBS + 0.1% 
Tween20 and 5% skimmed milk) for 1 hour. When blotting with the soy bean agglutinin (SBA) lectin 
(Vector Laboratories), milk was not included as this lectin binds galactose. All incubation and wash 
steps were conducted at RT on a rocker. The blocking buffer was replaced with 10 ml fresh blocking 
buffer containing primary antibody and incubated for 1 hour. A list of antibodies used in this work 
are listed in Table 2.6. Membranes were washed 3 x 5 min with 1x PBS + 0.1% Tween20 before 
incubation with the secondary antibody at the appropriate dilution, in the dark. The membrane was 
again washed 3 x in 1x PBS + 0.1% Tween20 before visualisation on an Odyssey near-infrared imager 
(LI-COR Biosciences). Images were scanned at either 680 nm or 800 nm wavelengths, depending on 
the IRdye conjugated to the secondary antibody.  
Antibody Dilution Suppllier 
Mouse anti-Histag 1:5000 AbCam 
Rabbit anti-Histag 1:5000 AbCam 
Goat anti-mouse IRDye conjugated 
600CW 
1:5000 LI COR 
Goat anti-mouse IRDye conjugated 
800CW 
1:5000 LI COR 
Goat anti-rabbit conjugated to HRP 1:20,000 Sigma Aldrich 
Goat anti-human IgG 1:10,000 Sigma Aldrich 
Table 2.6. List of antibodies used in this study.  
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 Indirect Enzyme Linked Immunosorbent Assay (ELISA) 
Indirect ELISAs were performed in Nunc Maxisorp or Medisorp 96-well flat-bottom plates 
(ThermoFisher Scientific). Protein samples were serially diluted to the concentrations required in 
sodium carbonate buffer (Na2CO3, pH 9.6) or 1x PBS, and 50 µl added to each well before static 
incubation overnight at 4oC. Wells were washed 4 x 2 mins with 1x PBS + 0.05% Tween20 before 2 
hour shaking incubation at 500 rpm with 300 µl blocking buffer (1x PBS + 0.05% Tween20 + 10% milk 
(5% milk for human sera samples). Wells were washed once for 2 mins with 1x PBS + 0.05% Tween20 
then incubated shaking for 2 hours with 50 µl of human sera sample diluted 1:00 in 1x PBS + 0.05% 
Tween20 + 1% milk or primary antibody. (Table 2.6). Wells were washed again 4 x 2 mins before 
incubation with 50 µl horse radish peroxidase (HRP)-conjugated secondary antibody in 1x PBS + 
0.05% Tween20 + 1% milk for 90 mins, shaking incubation. A final 4 x 2 mins wash steps were 
performed with 1x PBS + 0.05% Tween20 before 100 µl of the 3,3',5,5'-tetramethylbenzidine (TMB) 
substrate (ThermoFisher Scientific) was added and the plates incubated in the dark for 2-15 minutes, 
until colour development had saturated. At this point, the reaction was stopped with 1 M H2SO4 and 
plates read at a 450 nm wavelength.  
 Protein expression in E. coli  
For protein expression tests in E. coli, 5 ml LB supplemented with appropriate antibiotic was 
inoculated with a single E. coli colony or directly from a glycerol stock and incubated overnight. This 
was diluted 1:100 into fresh 10 ml LB supplemented with antibiotic to maintain the plasmid and grown 
to OD595nm 0.4-0.8, before induction with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(ThermoFisher Scientific) or 0.02-1% L-arabinose (Sigma Aldrich). L-arabinose can be metabolised by 
E. coli so was added again before leaving the culture shaking overnight at 30oC or 37oC. Following 
overnight growth, 200 µl of culture was removed to analyse the whole cell lysate and the remaining 
culture centrifuged at 14, 500 x g for 5 mins at 4oC. The supernatant was discarded and pellet either 
immediately extracted or stored at -20oC. For large scale expression using 1 to 2 litres of LB, the same 
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process was followed but the initial overnight culture was increased as necessary and cells pelleted at 
7459 x g for 30 mins at 4oC.  
 Protein extraction from E. coli  
 Ribolyser 
Pelleted bacteria were resuspended in 1-2 ml binding buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 
10-25 mM imidazole) and loaded into Lysing Matrix B- 2 ml Bead Beating Tubes (MP Biomedicals) 
before ribolysing in a FastPrep-24 Classic Instrument (MP Biomedicals) for 40 secs. Ribolysed 
extracts were centrifuged a 14,500 x g for 2 mins and the supernatant stored at 4oC, to reduce 
protein degredation.   
 Cell homogeniser  
Bacterial pellets obtained from the 1-2 litre cultures were resuspended in binding buffer to a 
maximum 50 ml volume which was diluted further in binding buffer for viscous resuspensions, 
before passing through the cell homogeniser, which uses high pressure to break the cells open. The 
homogeniser was first washed with 50 ml 20% ethanol, 50 ml 70% ethanol and 50 ml d.H2O before 
20 ml binding buffer was added. Once the last 10 ml of binding buffer was in the chamber of the 
homogeniser, the resuspended pellet was added, a maximum of 50 ml at a time, keeping the lysate 
on ice between runs. Cells were homogenised in 10 ml aliquots and the whole slurry was passed 
through three times or until the lysate started to become less opaque and viscous. The cell lysate 
was then centrifuged at 30, 966 x g for 1 hour before filtering the supernatant with a 0.22 µM filter 
and storing at 4oC. cOmplete™ mini EDTA-free Protease Inhibitor Cocktail tablets (Merck) (1 tablet 
per 10 ml lysate) were added to cell lysates to reduce proteolytic activity and protein degradation.  
 Protein purification  
 NiNTA agarose purification of His-tagged recombinant proteins  
Proteins harbouring a hexa-histidine tag (His-tag) were purified using nickel affinity chromatography. 
This was done in three different ways, depending on the volume of sample and intended use of the 
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purified protein. For clarified cell lysates under 1 ml, the supernatant was incubated with 100 µl Ni-
NTA agarose (Qiagen) in a microcentrifuge tube, rotating for 20-40 mins at 4oC. The agarose-protein 
complex was harvested at 14,500 x g for 1 minute, resuspended in 1 ml binding buffer and rotated 
for 10 mins at 4oC, a total of three times. After the last wash and centrifugation step, the cells were 
centrifuged again to remove any residual wash buffer and supernatant discarded. 100 µl of elution 
buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 300 mM imidazole) was added to the pelleted resin 
and the tube inverted for 2 mins at RT. Following a final centrifugation step at 14,500 x g for 1 
minute, 100 µl of the supernatant containing the eluted protein was stored at 4oC.  
For separation of Histagged and non-Histagged protein following incubation with tobacco etch virus 
(TEV) protease (Sigma Aldrich and NEB), a gravitational flow column was used. Here, protein samples 
were incubated with 500 µl to 1 ml Ni-NTA resin (depending on the volume of sample and amount of 
protein predicted) for 1 hour at 4oC, rotating. The column was then stood upright to allow the resin 
to settle to the bottom and the flow through released. The resin was then washed three times using 
20 column volumes (volume of resin) of binding buffer each time. The sample was eluted using 1 
column volume of elution buffer.  
 NiNTA agarose purification using HPLC  
Clarified and filtered cell lysate was passed over a 1 ml HisTrap HP column (GE Healthcare Life 
Sciences) to isolate His-tagged protein, using an AKTApurifier system (GE Healthcare Life Sciences). 
Applying a flow rate of 1 ml/min for the entire procedure, the column was washed with d.H2O then 
pre-equilibrated with binding buffer before loading of the sample. The column was washed again 
with 7 column volumes of binding buffer, before elution in 1 ml fractions using a gradient of 25 mM 
to 300 mM imidazole over 30 column volumes. The column was washed with d.H2O then 20% 
ethanol before storage. Protein from fractions corresponding to a peak on the UV280nm trace of the 
nickel affinity purification were run on an SDS-PAGE gel (section 2.8.1) to detect fractions harbouring 
the protein of interest.  
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 Gel filtration  
Proteins requiring additional purification were passed over a gel filtration column (GE Healthcare 
Life Sciences) using the AKTApurifier, for size exclusion chromatography (SEC). The column was 
washed with 1 column volume of d.H2O then SEC buffer (50 mM Tris-HCl pH 8.0 and 300 mM NaCl) 
before the protein sample was eluted in 1 ml fractions over 1.5 column volumes. The column was 
washed with 1 column volume of d.H2O and 20% ethanol before storage. As with His-purification, 
protein from fractions corresponding to a peak on the UV280nm trace were run on an SDS-PAGE gel 
(2.9.1) to detect the protein of interest. 
 Cleavage with the tobacco etch virus (TEV) protease 
When required, proteins were expressed with a TEV cleavage site between the His-tag and protein 
coding sequence, enabling removal of the Histag following nickel affinity purification. Eluted 
fractions confirmed to harbour the protein of interest by SDS-PAGE were pooled and exchanged into 
TEV buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM DTT) using Vivaspin protein concentrator 
spin columns (GE Healthcare Life Sciences). These were incubated with 1 µg of TEV protease (NEB or 
Sigma Aldrich) for every 100 µg of target protein in a Slide-A-Lyser Dialysis Cassette (ThermoFisher 
Scientific), stirring overnight in 3 l of TEV buffer at 4oC. Following incubation, samples were purified 
using nickel affinity chromatography section 2.8.7.2) to remove the His-tagged TEV protease and 
isolate the cleaved protein of interest in the flow through fraction.    
 Protein identification 
To confirm the identity of purified proteins, samples were sent to King’s College London- Centre for 
Excellence for Mass Spectrometry for liquid chromatography-mass spectrometry (LC-MS/MS) 
analysis. Samples were run on an SDS-PAGE gel (section 2.9.1), the band corresponding to the 
protein of interest excised and stored in MilliQ d.H2O before processing. Results were viewed using 
Scaffold Proteome Software (http://www.proteomesoftware.com/products/scaffold/).  
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 Protein quantification 
The bicinchoninic acid assay (BCA) assay (ThermoFisher Scientific) was used for quantification of 
protein samples in a 96-well plate format, using known concentrations of BSA to generate a standard 
curve, according to manufacturer’s instructions. Results were read at a 595 nm wavelength on a plate 
reader and data plotted in Microsoft Excel to generate a standard curve, from which protein 
concentration could be calculated by rearranging the formula y=mx+c, where y= absorbance of 
protein of interest, m=gradient, c=y-intercept, and x=concentration of the protein of interest.  
2.9. Bioconjugation 
The expression, extraction, purification and visualisation of proteins within the bioconjugation work 
was conducted as described in 2.8.  
 In vitro glycosylation 
For in vitro glycosylation experiments, 1 L cultures of the strains carrying the acceptor protein, 
oligosaccharyltransferase (OST) and lipid-linked glycan donor were grown separately overnight at 
37oC and induced with 1 mM IPTG or 0.2% L-arabinose, as required (2.8.4). Cells were harvested at 
7459 x g for 30 mins at 4oC then washed three times in S30 buffer (10 mM Tris acetate, 14 mM 
magnesium acetate, 60 mM potassium acetate, pH 8.2) at a total 50 ml volume, centrifuging for 15 
mins at 2880 x g between each wash. Following the final wash step, pellets were resuspended in 20 
ml S30 buffer and lysed in the cell homogeniser (2.8.6.2). Lysates were clarified at 2880 x g for 15 
mins then stored at -80oC in 1 ml aliquots or used immediately in the reaction set up. When 
concentration of the glycan bound to the inner membrane was required, the supernatant isolated 
following clarification of the cell lysate was centrifuged at 100, 000 x g for 1 hour at 4oC and the 
pellet resuspended in 1 ml S30 buffer containing 1 mM n-dodecyl-β-D-maltoside (DDM). Each 
reaction contained 20 µl of the PglB OST, 1 mM DDM, 1% MnCl2 and a range of volumes of the 
acceptor protein and lipid-linked glycan, made up to a total 600 µl volume with S30 buffer. Reactions 
were incubated overnight at 100 rpm, 30oC then purified as described in section 2.8.7.1.  
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2.10. Statistical Analysis 
For all statistical tests, p<0.05 was considered significant linear regression was performed in Stata 
and data transformed to Log10 prior to analysis. Students t-tests were performed in Microsoft Excel 



















3. Identification of novel immunogenic C. difficile proteins and 
expression and purification in E. coli 
 
3.1. Introduction 
Significant research has been dedicated to identifying candidates for inclusion within an anti-C. difficile 
vaccine. This has mostly centred on the use of Toxins A and B to provide protection from the symptoms 
of C. difficile infection (CDI). However, despite numerous toxin-based approaches entering clinical 
trials, there remains a lack of licensed vaccine against C. difficile [375]. The focus on the toxins as key 
targets for immunisation partly stems from their induction of the humoral immune response. Higher 
systemic antibody responses towards Toxin A and/or Toxin B have been associated with protection 
from infection, reduced duration of infection, prevention of mortality and reduced chance of 
recurrence [86, 269-271, 274, 444, 445]. However, these associations are not consistent, with some 
reports describing no difference in antibody response or higher antibody responses in those who 
developed infection or relapsed compared to healthy controls or asymptomatic carriers of C. difficile 
[272-275, 446].  
Beyond the toxins, there has been some interest in alternative antigens for inclusion in a C. difficile 
vaccine, but none of these have reached later stage clinical trials. Higher sera IgG was found towards 
the cell surface proteins Cwp66 and Cwp84 and the flagella components FliC and FliD in healthy 
controls compared to patients with C. difficile associated-disease [273]. In addition, the major surface 
layer protein SlpA has been demonstrated to be immunogenic in mice [447] and higher anti-SLP IgG 
titres were reported for healthy controls compared to those with CDI [272]. However, the exposed, 
low molecular weight portion of SlpA is variable between strains, which could limit vaccine coverage 
[448]. Overall, understanding of C. difficile antigens other than the toxins remains limited. This in turn 
restricts development of vaccines which target both the symptoms of CDI and colonisation by the 
pathogen, an approach which has received increased interest in light of the challenges associated with 
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toxin-only vaccines [449]. Antigen discovery can arise from a number of avenues, including antigenic 
components from other bacterial species, analysis of patient antibody responses during natural 
infection and rational hypotheses, such as the use of conserved cell surface proteins, which are 
exposed to the immune system. Once identified, typical in vitro characterisation of these as 
immunogenic proteins usually utilises immunoblots or enzyme-linked immunosorbent assays (ELISAs). 
Although different protocols are available, the basic principle of ELISAs is antibody-mediated detection 
and quantification of a specific ligand, including antigens and other antibodies.  These have been 
widely used to investigate antibody responses to C. difficile, particularly in relation to the toxins and 
are a well-established and valuable technique in quantifying humoral immune responses [86, 450]. 
However, both upscaling production of the antigens to be screened and testing these within a 96-well 
plate format  are labour intensive and unsuitable for the screening of multiple antigens and/or human 
samples and can also suffer from inter-assay variability.    
Just as DNA microarrays have been influential in the understanding of bacterial genomes and 
expression profiles, particularly before the advent of widely accessible and affordable sequencing 
technologies, protein microarrays offer a high-throughput means of quantifying antibody responses 
to a large number of antigens [380]. Here hundreds or thousands of antigens are expressed and 
printed onto glass slides, which can be probed with the sample of choice, usually human sera or 
plasma, simultaneously. Reactivity to the antigens is measured as with plate-type ELISAs, i.e. antigen-
bound sera or plasma antibodies are probed with anti-human antibodies harbouring a reporter 
enabling their fluorometric or colourmetric detection. This large-scale characterisation of the humoral 
response supports understanding of infection progression as well as vaccine and diagnostic discovery 
and has been used for investigation of a number of pathogens, including but not limited to; Leptospira 
interrogans, Francisella tularensis, Salmonella typhi, Coxiella burnetii and Plasmodium falciparum 
[384, 386, 451-453].   
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In this chapter it was aimed to use the results of a human C. difficile-specific protein array from an 
ongoing Medical Research Council programme grant of my supervisors, to identify novel vaccine 
candidates and purify these candidates to validate their immunogenicity for potential use in an anti-
C. difficile vaccine.  
3.2. Design, probing and analysis of the C. difficile protein array 
The C. difficile protein array was funded by a Medical Research Council Programme Grant entitled 
“Interactions between C. difficile, the intestinal microbiota and the host response in hospitalised 
patients”. This was awarded to a consortium of institutions, lead by London School of Hygiene and 
Tropical Medicine (LSHTM), comprising the University of Liverpool (UoL), Wellcome Trust Sanger 
Institute (WTSI) and the University of California, Irvine (UCI). The project was established to investigate 
the factors relating to progression and outcome of CDI, through analysis of a large cohort of 
longitudinal patient samples with accompanying clinical metadata. Analysis covered a range of 
approaches including profiling of the humoral immune response using a pan-protein array and 
sequencing of stool samples for analysis of the gut microbiota. The results from analysis of the 
humoral immune response were used for the identification of novel vaccine candidates in this study, 
as described below. Section 3.2 describes the work conducted by the consortium, both prior to and 
during my PhD, with those who completed the work named throughout.   
 Sample collection 
Patient recruitment and sample collection was conducted between 2013 and 2015. Patient 
recruitment and sample collection, storage and processing were conducted by UoL and the Royal 
Liverpool University Hospital. This was led by Professor Sir Munir Pirmohamed and involved a team of 
researchers, medics and NHS staff, including but not limited to: Dr Paul Roberts, Dr Neil French, Dr 
Fabio Miyajima and Ms Alejandra Doce-Carracedo. Patients were recruited from hospitals across 
Merseyside and Cheshire, including; Royal Liverpool and Broadgreen Hospitals, Aintree University 
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Hospitals, Wirral (Arrowe Park) Hospital, St. Helens & Knowsley (Whiston) Hospital and Countess of 
Chester Hospital.  
For recruitment into the study, participants had to be over 18 years of age and capable of providing 
written consent to confirm their willingness to participate. Patients/participants were recruited if they 
met the criteria for one of the three study groups; C. difficile infection (CDI), diarrhoea of unknown 
cause (CDU) and healthy controls (CDH) (Table 3.1). The patients were recruited in line with the ethics 
sought by UoL and awarded by Liverpool Research Ethics Committee (REC Reference 08/H1005/32) 
with additional approval granted by LSHTM for working with the samples at LSHTM (Appendix C). 
Diagnosis of C. difficile was conducted on patient stool samples by the NHS microbiology laboratory 
using NHS-approved methods, including an ELISA-based detection of the C. difficile Toxins A and B. 
During the study an additional test was adopted by participating hospitals for CDI detection- the 
glutamate dehydrogenase assay (GDH). Additional diagnostics available for some but not all samples 
included Toxin B PCR and microbiological culture. CDI patients were differentiated into mild and 
severe infection based on faecal white cell count.  
 
Table 3.1. Description of participant study groups for the C. difficile protein array. ELISA, enzyme-
linked immunosorbent assay, GDH, glutamate dehydrogenase assay, CDI, C. difficile infection.  
 
Study Group Definition Description 
CDI 
Patients with C. difficile 
infection  
Positive for C. difficile by Toxin A/B ELISA, 
as diagnosed by the NHS lab. Later into the 
study, GDH testing was also adopted at the 
recruiting hospitals and microbiological 
culture was performed. 
CDH Healthy controls 
Healthy people who were not hospitalised, 
had no history of CDI within the last 12 
months and Toxin A/B and culture 
negative. Where possible these were age 
and sex-matched to the CDI group. 
CDU 
Patients with diarrhoea of 
unknown origin 
Patients with diarrhoea but negative for C. 
difficile by Toxin A/B ELISA. These were 
either GDH positive or negative. 
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Upon recruitment, stool, urine and blood baseline samples were taken. The blood was fractionated 
into plasma and sera. Where possible, a maximum of three follow-up samples were taken 
longitudinally at 2, 4 and 6 weeks post-baseline. Time between initial NHS lab diagnosis and baseline 
sample collection ranged from approximately 1 to 7 days, in which time the patients may have already 
begun antibiotic treatment for C. difficile with metronidazole, vancomycin and/or fidaxomycin, as per 
NHS guidelines (Figure 3.1) [454]. Metadata was obtained throughout the study for recruited 
participants, including; previous history of CDI and/or previous antibiotic usage, severity of CDI and 
the PCR ribotype of infection, relapse or continuous colonisation, date, duration and type of 
antibiotics, proton pump inhibitors and nutritional supplements. The NHS diagnostic results for each 
















Figure 3.1. Timeline for diagnosis and collection of participant samples. Baseline represents samples 
taken on recruitment into the study, with up to three additional samples taken in follow-up. Antibiotic 
prescription describes those administered for treatment of CDI.  
 
 Probing of the array 
The proteome of the hypervirulent C. difficile strain R20291 was used as the base for selection of 
proteins to be screened on the pan-protein array, with additional proteins included from three other 
lineages of C. difficile namely strains 630 (ribotype 012), CF5 (ribotype 017) and M120 (ribotype 078). 
Putative protein function as annotated in the C. difficile genome and pBLAST analysis enabled selection 
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of proteins for screening. This consisted of a number of different potential antigens, including surface-
associated proteins, virulence factors and strain specific unique proteins, including transposases. 
Analysis and selection of the proteins was performed by Dr Richard Stabler and Dr Lisa Dawson at 
LSHTM.  
The Felgner group at UCI have established a pan-protein array platform for the screening of bacterial, 
viral and parasitic proteomes against human samples, in the pursuit of vaccine and diagnostic 
discovery [380, 385, 455]. Production and probing of the C. difficile pan-protein array was undertaken 
by the consortium partners in the Felgner group at UCI Irvine, as described previously [380, 456]. 
Briefly, the coding sequence of the target proteins and the pXT7 plasmid for protein expression were 
amplified by PCR with complimentary overhangs to one another. Amplicons were transformed 
together into competent E. coli DH5α cells and incubated overnight in LB supplemented with 50 µg/ml 
of kanamycin for plasmid selection. From this, the ligated plasmids were isolated and a proportion of 
these confirmed by sequencing to encode the correct insert, with a total cloning efficiency rate of 
~93%.  
Protein expression was achieved using an in vitro transcription/translation (IVTT) cell free system, 
using the RTS 100, E. Coli HY Kit (Roche) [457]. Synthesised plasmids encoding the construct for 
expression with ribosome binding site and T7 promoter and terminator, were incubated with all the 
components required for transcription and translation, including T7 polymerase for production of 
mRNA and an E. coli lysate providing the ribosomal machinery required for translation [380]. Instead 
of purifying the protein, the IVTT reactions were centrifuged with 0.2% Tween20, then the 
supernatants printed directly onto nitrocellulose-coated glass FAST slides (Whatman) using an Omni 
Grid 100 microarray printer (Genomic Solutions). To confirm protein expression, the coding sequences 
for each protein also harboured a 5’ 10XHistag (HIS) and 3’ haemagluttinin tag (HA), enabling detection 
of full protein. In total, 3165 proteins were cloned, then successfully printed and screened on the 
array, by UCI. Arrays were printed throughout the study, as required. 
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 Optimisation of the pan-protein array and pilot study 
Plasma samples were selected as preliminary work found no difference in antibody response between 
plasma and sera samples. It was also attempted to use the stool samples to probe the array, to assess 
the level of secretory IgA present within the gut. However, unacceptable levels of background were 
produced in these assays which made it impossible to determine C. difficile-specific signal, therefore 
this was reserved for later use following optimisation.  
A pilot study was performed in 2015 using 189 plasma samples from the CDI (split into severe CDP and 
mild CDN) and CDU group, and a third control group collected by UCI, called GCRC. This is a standard 
healthy control group utilised in their arrays, constituting students and staff recruited from the UCI 
campus. This protein array was probed separately with IgG and IgA, using anti-human antibodies 
conjugated to the Cy5 fluorophore. As the IgA response was low across the sample set, the IgG 
response was analysed. This analysis was conducted by UCI following probing of the array, who then 
provided a short list of the top 70 reactive antigens which were significantly different in signal in at 
least one of the between group comparisons (CDI vs CDU,  CDP vs CDU, CDI vs GCRC) (Appendix D). 
The healthy control group from California were not age and sex matched to the CDI patients and little 
was known about these samples. As these were likely to be younger people these samples were 
deemed unsuitable as C. difficile primarily affects those over 65 years of age and therefore this is the 
target group for investigation. The CDU group was therefore used as a comparator. This group had 
diarrhoea but were negative for the C. difficile toxin and therefore assumed to be C. difficile negative. 
At this stage, the results were used to look for immunogenic proteins in the CDI group, to confirm 
these antigens are recognised by the human immune response. The proteins within the shortlist fell 
into many different functional categories but the majority came from one of four groups; enzymes, 
transport, cell surface proteins and hypothetical/uncharacterised proteins. From the shortlist of 
immunogenic proteins, three were selected for further characterisation in vitro. Proteins were 
preferentially selected that were predicted to be surface exposed and present in multiple clinically 
relevant strains as identified by pBLAST. Furthermore, proteins with a putative function that suggests 
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an important role in survival that would be valuable to characterise were also prioritised. This resulted 
in the selection of three proteins for characterisation in vitro, CDR20291_0330, a putative cobalt 
binding protein, CDR20291_3343 a putative pili protein and CDR20291_0342 a putative ABC 
transporter permease, as described in Chapter 4, 5 and 6, respectively. 
 Screening of CDI patients against matched healthy controls 
The protein arrays were probed in 2016 with 279 baseline plasma samples, from the CDI (128), CDH 
(71) and CDU (80) groups. The CDH group are matched controls from the Liverpool cohort of samples. 
The printed slides were incubated for 30 mins with protein array-blocking buffer (GVS Life Sciences, 
Sanford, USA) then incubated at 4oC overnight with 1:100 plasma, diluted in blocking buffer. Prior to 
probing, plasma samples were pre-absorbed with E. coli lysate to quench any anti- E. coli antibodies, 
which can mask organism-specific antibody responses [380]. Slides were washed, then incubated with 
anti-human IgG or IgA simultaneously, before washing again and visualising the results using an 
ArrayCAM imaging system, which enables two colour scanning of the arrays. IgG and IgA signals were 
differentiated by the Quantum dot conjugated to the anti-human antibodies, which have different 
fluorescent spectral profiles [456, 458].  
 Analysis of array results  
Processing and analysis of the raw data obtained following probing of the array was conducted by Dr 
Li Liang at UCI and Dr Lisa Dawson and Professor Taane Clarke at LSHTM, between 2016 and 2017. 
Firstly, background signal was removed by subtracting the mean of the no DNA control spots from the 
raw data values for each protein. The no DNA controls represent plasmid-free E. coli lysate from the 
IVTT system.  From this, the mean IgG reactivity for each protein was calculated for the different 
patient groups and any statistically significant differences between the CDI and CDH groups was 
determined using a Student’s t-test and Wilcoxon Rank test, where p<0.05 was considered significant. 
The IgA signal was consistently much lower than the IgG response and it was difficult to extract 
94 
 
meaningful data, therefore the IgG response was used for identification of potential vaccine 
candidates. 
3.3. Identification of novel immunogenic C. difficile proteins 
In order to identify immunogenic antigens that could serve as potential vaccine candidates, those 
proteins where the IgG reactivity signal was higher in CDH over the CDI group were investigated. It 
was hypothesised that a higher response in the CDH group suggests antibody development against 
the target protein has a protective effect against infection.  
 Identification of immunogenic proteins for recombinant expression in E. coli 
A table of the normalised intensity values for each antigen on the array was compiled, including the 
total number of samples reacting to each antigen (out of a total 279), where a minimum signal 
intensity of 0.5 was produced in both groups (Table 3.2). To identify potential vaccine candidates, 
these were sorted by the largest difference in signal intensity between the CDH and CDI group, where 
the CDH signal was significantly higher than in the CDI group, as determined by t-test or Wilcoxon rank 
test. From this antigen shortlist, 6 targets were selected for further investigation (in bold, Table 3.2), 
taking into consideration conservation across different C. difficile strains from the 5 clades; (630 
(ribotype 012), R20291 (ribotype 027), M120 (ribotype 078), M68 (ribotype 017) and CD305 (ribotype 
023)), as determined by pBLAST and sequence analysis. Additional factors include the mean signal in 
the two groups and putative annotation of the protein, selectively choosing those most likely to be 
surface exposed and a range of different putative functions to screen a variety of different candidates. 
Signal to purified Toxin A was significantly higher in the CDH compared to the CDI cases, but was 
excluded due to volume of existing research [86, 274, 445]. Two proteins were not conserved through 
all strains but were included for analysis, especially considering any eventual C. difficile vaccine would 
unlikely to be based on a single antigen, meaning the lack of the protein in all strains wouldn’t 
necessarily limit vaccine coverage. CDR20291_2697 was present in M68 but contained multiple stop 
codons and therefore was unlikely to produce a functional protein. However, the IgG response to this 
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protein was one of the highest for the CDH group and a high proportion of samples recognised this 
protein (228/279) (Table 3.2). CDR20291_0342 was found to not be present in the ribotype 023 CD305 
strain but as before, this wouldn’t be used in a vaccine alone and was one of the immunogenic proteins 
chosen for in vitro characterisation based on the pilot study. Of the three proteins selected for further 
investigation from the pilot study, both CDR20291_0330 and CDR20291_0342 demonstrated a 
significantly higher IgG response in the CDH group in this analysis, confirming their potential as vaccine 
candidates. The response to CDR20291_3343 was higher in the CDH group although this was not 
significant. 
Three additional proteins were also included for use as controls. These covered three different 
reactivity profiles- higher in the CDI group compared to the CDH group (CDR20291_3064) (negative 
control), high in both groups (CDR20291_2503) (positive control) and low in both groups 
(CDR20291_2536) (negative control). Therefore in total, 10 candidates were taken forward for 
expression, purification and testing in the ELISAs. 
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Name Putative Annotation 
No. of samples 
with signal 
(279) 









CDCF5_2692 Cell surface protein 135 4.51 1.24 3.27 0.01 0.00 Not conserved 
CDM120_orf03606 Putative class B sortase 210 6.02 2.76 3.26 0.01 0.04 Not conserved 
CDCF5_0223 Flagellin subunit 213 6.67 3.51 3.16 0.00 0.02 Not conserved 
CDR20291_2697 Hypothetical membrane protein 228 6.79 4.02 2.77 0.01 0.20 CANDIDATE 
CDM120_0411 Signaling protein 278 24.95 22.69 2.26 0.00 0.42 Not conserved 
CD0416 Exported protein 207 3.29 1.15 2.14 0.00 0.01 Not conserved 
CD0386 Collagen-binding surface protein 243 6.85 4.76 2.09 0.00 0.11 Not conserved 
CDR20291_2235 Membrane protein (HP) 213 10.07 8.16 1.91 0.01 0.63 High response in CDI 
CD1105 DNA primase 270 7.82 6.30 1.52 0.00 0.13 Not conserved 
CDR20291_2226 Hypothetical membrane protein 179 4.49 3.01 1.49 0.00 0.41 Unknown function 
CDR20291_2640 Accessory gene regulator 220 3.07 1.64 1.43 0.00 0.12 CANDIDATE 
CDM120_2021 
Type I-B CRISPR-associated endonuclease 
Cas1  
190 2.40 1.06 1.33 0.03 0.41 Not conserved 
CDR20291_2491 CdtA (adp-ribosyltransferase 192 5.25 4.01 1.24 0.00 0.41 Not conserved 
CDR20291_0330 Cobalt transport protein 156 2.07 0.86 1.21 0.15 0.03 CANDIDATE 
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Name Putative Annotation 
No. of samples 
with signal 
(279) 









CD0430 Membrane protein 238 2.46 1.32 1.14 0.00 0.00 Not conserved 
CDR20291_2389 Competence protein 175 2.05 0.92 1.13 0.02 0.15 
Unlikely to be surface 
exposed 
CDR20291_0342 ABC transporter, permease protein 212 2.55 1.44 1.11 0.01 0.04 CANDIDATE 
CDR20291_3155 Type IV pilin 179 2.12 1.02 1.10 0.02 0.13 CANDIDATE 
CD0453B Hypothetical protein 247 2.49 1.46 1.03 0.00 0.00 Not conserved 
CDR20291_0781 Hypothetical membrane protein 188 2.03 1.01 1.03 0.00 0.03 Unknown function 
CDR20291_0966 Transglycosylase 169 1.94 0.92 1.01 0.01 0.01 
Unlikely to be surface 
exposed 
CDM120_0286 Hypothetical protein 198 2.69 1.68 1.01 0.00 0.11 Not conserved 
CDR20291_1324 Uncharacterized protein 272 4.54 3.54 0.99 0.00 0.06 Not conserved 
CDR20291_0002 Mechanosensitive ion channel protein 176 1.96 1.00 0.96 0.00 0.24 
Low signal in both 
groups 
CDR20291_2253 Exported protein 167 2.59 1.68 0.91 0.03 0.33 CANDIDATE 
CDR20291_3343 Pilin protein 101 0.28 0.19 0.09 0.1 0.3 CANDIDATE 
Table 3.2. Top vaccine candidates from the protein array, based on difference in IgG reactivity. The IgG response of the 279 samples to the screened proteins was compared 
to identify the top 25 antigens with the largest difference in signal between the CDH and CDI sample groups, where the signal was significantly higher (p<0.05) in the CDH 
group, as determined by t-test or Wilcoxon rank test. From this list, six proteins were selected for purification and further screening with patient samples (bold). This was 
based on those with interesting putative functions that were likely to be surface exposed and conserved across multiple C. difficile strains. Proteins were considered conserved 
when they were identified in 4/5 strains investigated using pBLAST; 630, R20291, CD305, M68 and M120. The seventh bolded antigen is CDR20291_3343 which was selected 
for characterisation based on the result of a pilot study. CDH, healthy controls, CDI, patients with C. difficile infection.   
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3.4. Selection of regions for recombinant expression in E. coli  
Cell surface proteins often encode transmembrane domains (TMDs) for their anchoring into the cell 
membrane. As these are hydrophobic, when expressed recombinantly it can make isolation of soluble 
protein challenging. It was therefore decided to use a combination of bioinformatics approaches, 
namely Phyre2 and TMHMM Server v2.0, to identify predicted TMDs within each array candidate. 
Additionally, Phyre2 and SignalP were used for identification of signal sequences, which would not be 
present in the mature protein in vivo. Few signal peptides were identified during protein analysis, 
however many harboured putative N-terminal TMDs. It is possible that these TMDs are in fact signal 
peptides as both harbour a number of hydrophobic residues.  
In some instances, it was not possible to exclude all TMDs. For example, CDR20291_0330 is a small 
protein with two putative TMDs. Selecting the region between these domains would result in 
expression of a very small peptide which was not practical, therefore the region between these 
domains was expressed with the second TMD. CDR20291_2640 is TMD rich and there were no 
predicted exposed regions of suitable length for expression therefore the whole protein was included. 
Finally, as CDR20291_0342 is a large protein, two regions were selected for expression which were 
predicted to be extracellular, S1 and S3. Modified protein sequences were codon optimised for 
expression in E. coli and ordered for synthesis as G-block gene fragments (IDT) for downstream cloning 































































Figure 3.2. Analysis of the C. difficile protein array candidates for recombinant expression in E. coli. 
Each array candidate was assessed for transmembrane domains (TMDs) (underlined) and signal 
peptides (bold) using a combination of Phyre2, TMHMM server v2.0 and SignalP. Both signal peptides 
and TMDs were removed where possible as these are hydrophobic and can hinder purification of 
soluble protein. Regions selected for expression are shaded in grey. Two regions of CDR20291_0342 
were proposed to be surface exposed and were selected for expression; S1 and S3.    
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3.5. Expression of recombinant C. difficile proteins in E. coli  
The array candidates selected for screening were recombinantly expressed in E. coli (Table 3.3). Large 
scale protein expression and purification is routine procedure and optimised for E. coli. Using this host 
also enabled expression from the pETM11 plasmid (Figure 3.3) [459], where  protein expressionis IPTG 
inducible. The candidate protein is cloned downstream of an IPTG inducible promoter, and 
transcriptionally fused to an N-terminal 6XHistag for nickel affinity purification of the desired protein, 
which is separated from the protein coding sequence by a tobacco etch virus (TEV) protease cleavage 
site. This enables cleavage of the 6XHistag following translation and purification, which provides an 


























Pilin protein from the minor pili 
locus, PilA2 
Higher in CDH 12.37 9.23 
R20291_0342 S1 
Permease component of an 
ABC transporter (S1 region) 
Higher in CDH 26.39 23.25 
R20291_0342 S3 
Permease component of an 
ABC transporter (S3 region) 
Higher in CDH 36.37 33.23 
R20291_0330 Cobalt binding protein Higher in CDH 10.83 7.69 
R20291_3343 
Minor pilin, PilK, encoded 
within the major pili locus 
Higher in CDH 58.74 55.6 
R20291_2253 Exported protein  Higher in CDH 20.14 17 
R20291_2697 Membrane protein  Higher in CDH 22.03 18.89 
R20291_2640 Accessory regulator Higher in CDH 25.3 22.16 
R20291_2503 Cell-division initiation protein 
High in CDH 
and CDI 
20.3 17.16 
R20291_2536 Exported protein  
Low in CDH 
and CDI 
27.73 24.59 
R20291_3064 Membrane protein insertase Higher in CDI 6.11 2.97 
 
Table 3.3. Protein array candidates selected for recombinant expression in E. coli. Putative function 
of the C. difficile proteins selected for recombinant expression in E. coli, along with the predicted size 
before and after cleavage of the 6XHistag. IgG response is also included to describe the different 
candidates- higher in CDH (vaccine candidate), High in CDH and CDI (positive control), higher in CDI 
and low in both CDI and CDH (negative controls).  
 
 
 Cloning and test expression of recombinant proteins 
Codon optimised G-block fragments encoding the recombinant C. difficile protein sequences were 
inserted immediately downstream of the TEV cleavage site in pETM11 (Figure 3.3) using either 
restriction digest (section 2.4.4), for 0342 S1, 0342 S3, 2253, 3155 and 0330 or Gibson assembly 
(section 2.4.6), for 2697, 3343 and 2640. It was not possible to successfully clone 2536, 2503 and 3064 
into pETM11, therefore these were not taken further. All plasmids were confirmed to be correct by 
















Figure 3.3. Plasmid map of pETM11, used for recombinant expression of C. difficile protein array 
candidates in E. coli. Plasmid map and sequence of the pETM11 plasmid for protein expression. This 
harbours an N-terminal 6XHistag followed by a TEV protease cleavage site, enabling removal of the 
6XHistag following protein purification. Image from Dümmler et al. [459] and the EMBL Protein 
Expression and Purification Facility 
(https://www.embl.de/pepcore/pepcore_services/strains_vectors/vectors/pdf/pETM-11.pdf).  
 
The pETM11 plasmids harbouring the different recombinant proteins were transformed into the E. 
coli protein expression strain, BL21. As an initial test to confirm expression of the proteins, 10 ml 
cultures of the BL21 strain carrying the different pETM11 plasmids were induced overnight with 1 mM 
IPTG and cells harvested the next day. Extracted protein was purified using nickel affinity resin then 












Figure 3.4. Recombinant expression of C. difficile protein array candidates in E. coli. Each pETM11 
plasmid harbouring a different construct for expression was induced overnight in 10 ml LB with 1 mM 
IPTG. The cells were disrupted and protein extracted and purified by nickel affinity chromatography. 
Purified protein samples were run on an SDS-PAGE gel then detected on an anti-his immunoblot 
(green). UI, uninduced, I, induced. Arrows indicate the band corresponding to the desired protein.    
 
When induced with 1 mM IPTG, a His-reactive band was detected at approximately the correct size 
for 0342 S1, 0342 S3, 3155, 3343, 2640, 2697 and 0330. Although for some proteins the level of 
expression appeared to be low (CDR20291_0330 and CDR20291_3155), it was deemed sufficient to 
be taken forward into upscale and further purification. A double band was produced for 2253 and 
therefore was excluded from further study. Higher levels of expression were achieved for 
CDR20291_2697 and CDR20291_2640, which was presumably the reason for detection of protein in 
the uninduced control, due to the promoter not being completely off.  
 Purification of the C. difficile recombinant proteins from E. coli  
In order to obtain sufficient protein for screening with the serum samples, eight litres of E. coli culture 
was prepared for expression of each C. difficile protein; 0342 S1, 0342 S3, 0330, 3155, 3343, 2697 and 
2640. Cultures were induced overnight at 37oC with 1 mM IPTG then cells harvested and lysed using a 
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cell homogeniser. The supernatant of the lysate was obtained by centrifugation then passed over a 1 
ml HisTrap HP column on an AKTA purifier system for isolation of the target protein via the N-terminal 
6XHistag. The purified protein was eluted from the column in 1 ml fractions and an aliquot of each 
corresponding to the AKTA peak were run on an SDS-PAGE gel to identify which held the protein of 
interest. Even though 0342 S3, 3343 and 2640 were detected in the test cultures, and despite repeated 
attempts with the large scale cultures at different temperatures and in difference flask sizes, very little 
or no protein was detected following purification of these in the larger scale set up and would not 
have been sufficient for downstream processing, therefore these were also not taken forward. This 
left four purified proteins to take forward; 0342 S1, 0330, 3155 and 2697.  
The fractions containing the eluted protein were pooled for each candidate then incubated overnight 
with TEV protease to remove the 6XHistag. Following incubation, the samples were run through an 
additional nickel affinity purification step but in this instance, any protein still harbouring the 6XHistag 
and the 6XHis-tagged TEV protease bind to the column, allowing the isolation of cleaved protein only 
in the flow-through. This also served as an additional purification step, as any histidine rich proteins 
pulled out in the first nickel affinity purification, also bound to the column (Figure 3.5). We thank the 















Figure 3.5. Cleavage of the 6XHistag from the nickel affinity purified proteins using TEV protease. 
Proteins purified using nickel affinity chromatography were incubated overnight with tobacco etch 
virus (TEV) protease for removal of the N-terminal 6XHistag. The protease cleaves at a recognition site 
upstream of the start of the recombinant protein, which can then be isolated in the flow-through 
fraction of a nickel affinity purification, where the 6XHistagged TEV protease remains bound to the 
column. Each protein isolated in the flow-through of the nickel affinity purification was run on an SDS-
PAGE gel to ensure the correct protein had been isolated and visualise the size shift resulting from 
removal of the 6XHistag. The predicted size of the protein pre and post incubation with TEV, 
respectively, is 26.4 KDa to 23.3 KDa for 0342 S1, 22 to 18.9 KDa for 2697 and 12.4 to 9.2 KDa for 3155. 
Lanes represent the different stages of purification; Pre- pre-TEV cleavage and the rest of the different 
stages of nickel affinity purification; FT- flow-through, W1- wash 1, W2- wash 2, W3- wash 3, W$- wash 
4, E-elution.   
 
The concentration of 0330 was low even before incubation with the TEV protease, and very little was 
left following the second nickel affinity purification, therefore this was not taken forward. As a final 
step, to ensure only the protein of interest would be tested on our ELISAs and minimise the risk of E. 
coli contamination, the three 6XHistag cleaved proteins were purified by gel filtration, which separates 
protein based on size. Again the fractions eluted from the column were run on an SDS-PAGE gel to 
confirm the protein location and presence (Figure 3.6). To ensure the correct protein had been 
purified, an aliquot 3155 and 0342 S1 was sent to Kings College London Centre of Excellence for Mass 
Spectrometry for liquid chromatography mass spectrometry (LC MS/MS). 2697 was analysed using LC 
MS/MS by Dr Sherif Abouelhadid at Imperial College London. Analysis for all three revealed the correct 
protein had been purified. This provided further confirmation that the correct protein had been 
purified for 3155, which was running at approx. 6 KDa on the SDS-PAGE gel as opposed to the 

















Figure 3.6. Purification of the C. difficile recombinant array candidates using gel filtration. Flow-
through samples isolated form the nickel affinity purification following TEV mediated cleavage of the 
6XHistag were passed through a gel filtration column as an additional purification step. This separates 
protein based on size and was successful for all three proteins, as demonstrated in the corresponding 
SDS-PAGE gels.  
 
3.6. Screening of recombinant C. difficile proteins against CDI patient sera  
Three of the potential vaccine candidates identified on the protein array (2697, 0342 S1 and 3155) 
were purified to a sufficient concentration for screening against serum samples from patients with CDI 
and controls. To do so, an indirect ELISA was utilised. In this method, the protein antigens were bound 
to the bottom of a 96-well plate before probing with human sera (using a protocol from [460] and 
modified by Dr Tim Scott). Serum-derived antibodies bound to the protein were then detected using 
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a HRP-conjugated anti-human IgG antibody which enables colourmetric quantification of antibody 
binding when incubated with the 3,3',5,5'-tetramethylbenzidine (TMB) substrate.  
 Optimisation of ELISAs for protein screening  
The initial optimisation steps for the ELISAs, to determine the optimal plate type and coating buffer 
for adhering the protein to the plate, were performed using each protein still harbouring their 
6XHistag, to enable detection with an anti-His antibody rather than the limited human serum samples. 
Each protein was serially diluted in coating buffer, either carbonate/bicarbonate or PBS, and used to 
coat a Nunc Maxisorp flat-bottom or Nunc Medisorp flat-bottom plate. These plates are designed for 
use in immunoassays, with the Medisorp plate recommended for more hydrophobic proteins. Plates 
were incubated with the protein overnight then probed with rabbit anti-His antibody followed by HRP-
conjugated goat anti-rabbit IgG, with thorough washing steps between incubations. The TMB 
substrate which reacts with the HRP-conjugate was added to each well and the reaction stopped with 
1 M H2SO4 when the two highest concentrations of protein appeared to be the same colour by eye, 
suggesting the reaction had reached saturation point. OD450 readings were taken and the absorbance 
of each protein in the different conditions compared. All proteins were successfully bound to the plate, 
as demonstrated by the increase in absorbance reading with increasing protein concentration (Figure 
3.7). There was no difference between the Maxisorp and Medisorp plates, however, carbonate-
bicarbonate buffer did appear to confer improved protein coating over PBS (Figure 3.7). From this, 
Medisorp plates with carbonate-bicarbonate coating buffer were selected for the screening 

















Figure 3.7. Optimisation of ELISAs using 6XHistagged protein. Plate type and coating buffer for use in the ELISAs were determined prior to testing with human 
sera using each of the purified proteins still harbouring their 6XHistag. Each protein was serially diluted (32 µg/ml to 0.5 µg/ml) in carbonate-bicarbonate 
buffer or phosphate buffered saline and bound to a Nunc Maxisorp or Medisorp plate overnight. Proteins were identified using anti-his primary antibody 
followed by a secondary antibody conjugated to horseradish peroxidase which was detected using TMB substrate. Reactions were stopped with 1 M H2SO4 
following appropriate colour development and results read using a plate reader at OD 450nm. Each protein concentration was tested in duplicate and the 




 Testing patient samples  
A total of 39 serum samples were provided by UoL for screening against the three purified proteins. 
These samples are in the pipeline for screening on the protein array by UCI (includes longitudinal 
sampling of CDI patients). The samples provided by UoL consisted of 10 samples from the CDI group, 
nine from the CDH group (Table 3.1) and 20 from a diarrhoea CDU group. Due to time and protein 
sample limitations 10 samples from the CDU group were run for 2697 and 0342 S1. There was 
insufficient protein available to run these against 3155. As it wasn’t possible to clone the desired 
control, purified human IgG was used as a positive control for secondary antibody binding and buffer 
only as a negative control.  
To optimise the assay for use with human serum samples, one CDI and one CDH sample were screened 
against serial dilutions of the three purified proteins, from 1.5 µg/ml to 50 µg/ml. A broader dilution 
range was used compared to the anti-his ELISAs as the reactivity of the serum with the purified protein 
was unknown. A buffer only control was used to determine background signal for each serum sample 
and purified human IgG was used as a positive control for the secondary antibody.  
A signal was generated for all three proteins with both CDI and CDH serum samples, resulting in 
saturation at the highest protein concentrations (Figure 3.8). Signal strength varied greatly between 
both proteins and samples, therefore three concentrations of protein were selected for the full scale 
sample testing; 12.5 µg/ml, 6.25 µg/ml and 3.125 µg/ml. These concentrations translated to a signal 























Figure 3.8. Optimisation of ELISAs using human plasma samples. To determine the concentration 
range of each protein for screening human plasma samples, a range of protein concentrations were 
first probed with one CDI and one CDH plasma sample. Plasma was diluted 1:100 before incubating 
with the serially diluted protein (50 µg/ml to 1.5 µg/ml). Human antibodies in the plasma were 
identified using anti-human IgG secondary antibody which was conjugated to horseradish peroxidase, 
enabling colourimetric detection upon addition of the TMB substrate. Reactions were stopped with 
1M H2SO4 following appropriate colour development and results read using a plate reader at OD 
450nm. This assay was performed once, as a screen to ensure sera responses could be detected.  
 
 
Concentration µg/ml Concentration µg/ml 
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Sample testing was conducted for the 10 CDI and 9 matched CDH samples, as described above, and 
the difference between the IgG signal in response to the different antigens was plotted for both groups 
and assessed using both a Students t-test and Wilcoxon rank test (Figure 3.9a). Any significant 
differences were set at a cut off p< 0.05. As seen in the optimisation steps (Figure 3.8), there were 
variations in the signal between the three protein antigens tested. The IgG response varied between 
protein antigen and sera samples (Figure 3.9a), with a similarly varied response pattern also seen in 
the results from the protein array when all patients’ screened are plotted individually (Figure 3.9b). 
However, unlike in the array results where all three proteins were associated with a significantly higher 
IgG response in the CDH group (Figure 3.9b), there was no significant difference in IgG response 
between the CDH and CDI groups for any protein, although the mean IgG signal against 0342 S1 and 
2697 did look to be higher by ELISA in the CDH compared to the CDI group (Figure 3.9a).   
Proteins 2697 and 0342 S1 were also screened against 10 serum samples from the CDU group. These 
samples were included as an additional group of patients who were in hospital and negative for the C. 
difficile toxin by ELISA, but still had diarrhoea of an unknown cause. Further investigation of these 
samples by the UoL using additional C. difficile diagnostics found some samples within this group were 
GDH and C. difficile culture positive, suggesting these patients had CDI. Therefore, the available 
metadata was used to categorise our CDU samples into two groups i) GDH positive culture positive 
(GDH +) which were most likely CDI positive patients and ii) GDH negative culture negative (GDH-), 
which potentially have diarrhoea from an unrelated source (non-CDI) (Figure 3.9a). There was no 
significant difference in response for either antigen when comparing the response in the GDH positive 















Figure 3.9. Screening of human blood samples to quantify IgG reactivity towards three C. difficile proteins. Three C. difficile proteins were screened against 
human samples in either an ELISA or protein array format. (A) Three recombinant proteins from C. difficile were screened against 29 sera samples; 10 from 
patients with CDI (CDI), nine from healthy controls (CDH) and 10 from people with diarrhoea of unknown cause (CDU) which were further split depending on 
if the glutamate dehydrogenase (GDH) test was positive or negative. This was performed in an indirect ELISA using a horseradish peroxidase conjugated 
secondary antibody which recognises human IgG and enables chemiluminescent detection of IgG binding. (B) Results of the three C. difficile proteins on the 
protein array when screened against 279 human plasma samples; 128 CDIN, 71 CDH and 80 CDU. Statistical significance was determined by t-test or Wilcoxon 
rank test where p<0.05 was significant, *p<0.05, **p<0.005, NS- non-significant.  Each protein was tested in duplicate at three concentrations and the assay 
performed once.  Error bars denote standard deviation from the mean. 
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Additional data for each patient in the CDI group is detailed in Table 3.4, including culture result, 
ribotype of current infection, previous cases of CDI, severity of infection, relapse and antibiotic 
treatment prior to and during the study. The response to each protein on the ELISA was conditionally 
formatted, with highest responses in red and lowest in green and compared against this patient data 
to investigate whether there appear to be an association between sample response and patient 
outcome.  
From this, there did not appear to be a clear association between response to the samples in the ELISA 
and the outcome of C. difficile infection. Patients CDI 04 and CDI 05 were both continuously colonised 
with C. difficile throughout the study period and demonstrated a low IgG response to all three 
proteins. This suggests that they had not mounted a strong immune response to these antigens. 
However, there were also instances of patients clearing the infection whilst demonstrating no 
response to 0342 S1 or 2697 (CDI 09) and on the reverse, patient CDI 01 demonstrated a comparably 
high IgG response to all three proteins yet relapse of CDI was reported 2 weeks post-diagnosis. 
Therefore, from this sample set it was not possible to conclude as to whether 0342 S1, 3155 or 2697 




ELISA IgG response of serum samples from the CDIN group 
0342 S1 0.087 0.009 0.111 0.004 0.032 0.097 0.014 0.129 0.000 0.056667 
2697 0.590 0.074 0.092 0.029 0.013 0.067 0.163 0.037 0.000 0.063333 
3155 0.068 0.517 0.008 0.001 0.080 0.031  0.317  0.018833 
Clinical data for participants in the CDIN group 
Sample No. CDI 01 CDI 02 CDI 03 CDI04 CDI 05 CDI 06 CDI 07 CDI 08 CDI 09 CDI 10 
Culture 
result 
POS POS POS POS POS POS POS POS POS POS 
GDH result N/A N/A N/A N/A POS N/A N/A N/A N/A POS 
Ribotype 049 002 078 017 002 002 N/A 027 014 N/A 
Previous CDI NO NO NO NO NO NO NO NO NO NO 
Severity of 
CDI 













NO NO NO NO 
Previous 
antibiotics 


















- - - - FLU, BEN MEM - - - - 
PPIs or H2Bs YES YES NO YES NO YES YES NO YES YES 
 
Table 3.4. IgG reactivity of three C. difficile proteins screened against sera samples from patients with CDI, with matching clinical data. CDIN, blood samples 
from patients with CDI, POS-positive, NEG-negative, CIP-ciprofloxacin, BEN-benzlycillin, AMX-amoxicillin, GEN-gentamicin, AMC-co-amoxiclav, TZP-tazocillin, 
MEM-meropenem, SXT-co-trimoxazole, FID-fidaxomycin, CEF-ceftriaxone, MEZ, metronidazole, VANC-vancomycin, FLU-flucloxcillin, N/A- not available, PPI- 





This chapter describes the identification of novel, immunogenic C. difficile antigens that hold potential 
as vaccine candidates for protection against CDI. These were identified based on the results of a C. 
difficile-specific protein array, a high-throughput platform for rapid screening of multiple antigens 
against human samples. Array-based characterisation of the humoral immune response during CDI is 
one component of an ongoing programme grant investigating progression of CDI, including analysis of 
host biomarkers and the intestinal microbiota.  
Protein arrays are yet to be fully exploited for the investigation of C. difficile. Negm et al. demonstrated 
their utility for screening purified Toxin A and B and three ribotype specific SLPs from C. difficile, with 
sera samples from patients with CDI, cystic fibrosis patients negative for symptomatic CDI and healthy 
controls [272]. Here, higher anti-SLP IgG responses were identified in the healthy controls compared 
to those with CDI, but there was no difference in the two groups when comparing the anti-toxin 
response [272]. An additional study found a higher anti-Toxin A and B IgA response and a higher level 
of neutralising IgA towards Toxin A in those with cystic fibrosis compared to those with CDI and healthy 
controls [461].  
The studies described above screened samples against array slides printed with purified protein. 
Although this is possible for a small number of antigens, it becomes impractical to prepare purified 
antigenic material for whole proteome analysis. The use of IVTT for the arrays described in this chapter 
enabled transcription and translation of the target protein in a one tube, cell-free system which is 
directly printed on the slides for probing [457]. Consequently, over 3000 C. difficile proteins were 
screened with plasma samples from patients with CDI, healthy controls (CDH) and those with 
diarrhoea of an unknown aetiology (CDU).  
From the primary pilot screen three candidates were prioritised to follow-up with for phenotypic 




in the second array of 279 samples, 25 potential vaccine candidates were shortlisted, which displayed 
a significantly higher IgG response in the CDH over the CDI group. Two of these were CDR20291_0330 
and CDR20291_0342, those proteins chosen in the pilot screen. The third protein, CDR20291_3343, 
was associated with a higher response in the CDH group but this was not significant. However, this 
antigen was still investigated as pilins are a popular target for vaccines in many species [462-465]. A 
higher antibody response in healthy people suggests a protective effect from infection. This has been 
demonstrated for other protein in multiple studies which showed higher anti-toxin and anti-cell 
surface protein antibodies, such as FliC and Cwp84, in those without CDI or asymptomatic carriers of 
C. difficile, compared to those with CDI [86, 270, 273, 461]. However, these associations are not 
consistent across all studies. The relative contribution of antibodies to Toxin A versus Toxin B, the 
antibody isotype (IgG and IgA) and the overall role of anti-toxin antibodies in acquisition of infection, 
severity and duration of CDI and relapse, varies between reports [269, 271, 272, 275, 444-446]. 
Indeed, in our antigen shortlist, purified toxin A was present (but not pursued due to the wealth of 
information already available), yet purified toxin B and domains of toxins A and B produced using IVTT 
were not. One possible reason for the inconsistencies across the existing literature is the large 
variation in sample cohorts between reporting studies, including; geographical location, antibiotic 
administration, average age of the patient, co-morbidities, control groups selected for comparison 
and the overall number of samples. Further investigations should aim to stratify the existing data to 
facilitate meaningful comparisons in conjunction with the design and performance of additional 
research. 
In relation to the study groups investigated here, the IgG response between the CDI and CDH group 
were compared as the third group, the diarrhoea, C, difficile toxin negative CDU group has not been 
fully characterised. This group consists of hospitalised patients with diarrhoea of an unknown cause 
and negative for C. difficile Toxins A and B. Further analysis of these has found a subset of patients to 




indicate a false-negative result by Toxin A/B ELISA or asymptomatic colonisation [466, 467]. 
Stratification of this group is ongoing, but in order to provide a valuable contribution towards analysis 
of the humoral immune response, would ideally include: 
CDI positive. Patients with toxigenic C. difficile causing symptomatic infection that was initially missed 
due to lack of sensitivity in toxin detection.   
Asymptomatic carriage. Patients negative for the toxins but still colonised with C. difficile. Ideally 
these would be differentiated into toxigenic and non-toxigenic colonising strains.  
CDI negative. Toxin, GDH and culture negative. This presents another control group who are 
hospitalised but free from both C. difficile infection and colonisation.  
Those who are asymptomatically colonised with toxigenic C. difficile are an interesting control group, 
as it suggests a host response is preventing the development of CDI. Previously, higher anti-toxin 
antibodies have been found in those asymptomatically colonised with C. difficile compared to CDI 
patients [86]. The existing sample cohort described here lacks a specified asymptomatic colonisation 
group but this could be derived from further analysis of the diarrhoea-positive CDU patients, including 
samples that are stool culture positive for C. difficile but free toxin negative. However, for these it 
would be very important to confirm the absence of free C. difficile toxin, ideally in combination with a 
diagnosis of the actual cause of diarrhoea, to confidently exclude symptomatic C. difficile infection. 
Following categorisation of these patients, associated longitudinal samples could be analysed to aid 
differentiation between transient and persistent colonisation, and how this relates to humoral 
immunity [7, 52]. Within this, it is obviously important to consider other factors that could prevent the 
switch from asymptomatic colonisation to CDI, such as the presence of certain bacterial taxa within 
the gut microbiota and antibiotic exposure [7, 468, 469].  
Ideally, an anti-C. difficile vaccine would prevent both the symptoms of CDI and colonisation of the 




further dissection of humoral immunity in these different states, with an aim to identify antibody 
responses specific to each. For example, by taking those patients who are in hospital with diarrhoea 
but negative for symptomatic CDI and comparing between those who are positive or negative for C. 
difficile colonisation, it may be possible to identify a specific anti-colonisation antibody signature.  
Screening of a larger proportion of the total sample cohort could aid in answering some of the 
questions raised above, especially when including the analysis of longitudinal samples and the host 
microbiota. This work is ongoing, with additional plasma samples being screened against a smaller 
number of antigens on a specifically designed down selected array than tested previously, focusing on 
proteins which were identified by the IgG response in the whole proteome screen as potential 
diagnostic or vaccine candidates.  
High sera IgG responses to C. difficile in healthy people has been reported previously and was the basis 
for selection of potential vaccine candidates in this study. It has been postulated that the high rate of 
circulating, systemic antibodies to C. difficile in healthy people is a result of prior exposure, for example 
in the environment or during colonisation in infancy [272, 470, 471]. This enables the development of 
immune memory which is activated upon exposure to or transient colonisation with C. difficile [472, 
473].  
However, this does raise the question as to why serum antibodies are so important for protection 
from a gut pathogen, as the secretory IgA response within mucosal immunity would presumably be 
more relevant. Robust mucosal immunity has been demonstrated to provide protection from 
numerous enteric pathogens, such as Salmonella Typhi [474]. Indeed, Warny et al. found higher faecal 
anti-Toxin A IgA in patients with mild CDI over those with more severe or recurrent infections [274] 
and comparisons of colonic biopsies between CDI patients and healthy controls found higher numbers 
of IgA-secreting cells in the latter group [475]. Furthermore, Hong et al. demonstrated protection from 
C. difficile colonisation in hamsters orally immunised with Bacillus subtilis spores expressing a portion 




immunisation [276]. As for the systemic response, its development and role is not fully understood. 
Suggestions include toxin-mediated disruption of the epithelial cells lining the gut enables circulating 
antibodies to encounter C. difficile, either by C. difficile antigens entering the mucosal tissue or 
systemic antibodies moving into the gut lumen [476, 477].  
The main limitation of protein arrays is the lack of information on antibody functionality. Antibody 
binding does not necessarily equate to a protective immune response and it is the activity of that 
antibody when bound to the antigen that is important. This is therefore an important area for future 
work, focusing on antibody binding to bacteria cells and neutralisation and opsonophagocytic assays 
to determine the response of the antibodies to the antigen of interest. It is also important to note that 
C. difficile is a complex infection and acquisition of CDI is influenced by a number of factors in addition 
to the antibody response, including immune capacity of the patient, previous exposure to C. difficile, 
state of the gut microbiome and co-morbidities. This can be addressed in part using patient metadata 
in conjunction with the antibody response results.  Another drawback to using this technology in C. 
difficile is that the E. coli background can mask immunogenicity of the C. difficile proteins as the 
systemic antibody response is not high enough to overcome it.  Blood-borne pathogens have a much 
higher systemic antibody response meaning this background is less of a problem [384]. This was the 
reason behind the use of purified protein for the ELISAs in this study. Regions of the protein selected 
for expression were based on likelihood of exposure to the immune system, meaning signal peptides 
and transmembrane domains were removed. As these are regions of hydrophobicity, their removal 
also aids purification of soluble protein. The regions selection for expression are therefore unlikely to 
be identical to those printed for the array, which were not purified and instead spotted directly on the 
slides. It is therefore possible that removal of the hydrophobic domains may have influenced the 
immune recognition of the proteins, not necessarily in terms of reactivity of the domains themselves, 
but how their removal may alter folding of the protein, and consequently the loss of certain 




recognise numerous epitopes, both conformational and linear, but the measured response could still 
be reduced if particularly immunodominant epitopes were lost. Indeed, if the whole protein were 
required for future investigations, a denaturing agent such as urea could be used to solubilise the 
protein, enabling purification [478]. It is also noteworthy that one limitation of protein arrays, even 
when the whole protein is successfully expressed, is the difficultly in ensuring the protein is folded 
correctly when printed on the array, in order to ensure conformational epitopes are presented as they 
would be in vivo [479]. In addition to protein folding, the success in cloning and expression of the 
protein may also affect the antibody response as protein concentration is not quantified before 
spotting on the array when using the IVTT system. Prior to testing, the ELISAs were optimised using 
both anti-His antibodies and human sera samples. When detecting bound anti-IgG antibodies using 
the TMB substrate, following incubation it was necessary to stop all reactions at the same point in 
order to enable comparison across the different serum samples. However, due to the natural variation 
in reactivity between protein antigens and serum samples, both found here and reported previously, 
some samples reached saturation before others had a detectable response [273, 445]. In the future, 
and with unlimited protein and sera samples, checkerboard assays could be performed to enable 
detection of the optimal combination of protein concentration and serum dilution. Here all 
combinations of protein and serum concentrations are tested until the correct ratio is determined 
[480]. Final testing could then use this information to include a larger range of protein concentrations 
and serum dilutions to better determine antibody responses in a varied sample population.  
Although this study provided a valuable starting point in the identification of novel vaccine candidates 
using a protein array, only a small sample set was investigated in the ELISAs, which limited conclusions 
to be drawn over the immunogenicity of the antigens of interest. The IgG response to 2697, 3155 and 
0342 S1 was significantly higher in healthy controls compared to those with CDI when assessed by 
protein array, whereas although 0342 and 2697 signals were higher in the CDH group by ELISA, these 




analysis compared to the 279 samples from the protein array which would likely have resulted in a 
higher power analysis. Furthermore, as noted, there was substantial variation in samples responses 
and as these were randomly selected, it may be that those tested were skewed towards a particular 
response. Regarding antigen choice, if this were to be repeated it would be useful to also include those 
proteins where a high response was identified in all patient groups. This would be a means of 
validating the array and identifying immunoreactive candidates, before then undergoing further 
analysis of any differences in response between patient groups groups. The down selected protein 
arrays that are currently underway will probe 250 IVTT expressed antigens, including 2697, 0342 S1 
and 3155 both purified and expressed using IVTT, against a number of additional samples including 
those tested here by ELISA. This will facilitate comparison of purified versus IVTT expressed protein, 
as well as between the protein arrays and ELISAs for measuring IgG reactivity. Previously, Negm et al. 
found significant correlation between ELISA and protein array quantification of anti-toxin antibodies, 














4. Functional characterisation of CDR20291_0330, a putative cobalt 
transport protein 
4.1. Introduction 
The C. difficile protein array identified a number of immunogenic proteins, including 
CDR20291_0330. In the pilot study this protein was found to be immunogenic then in a follow up, 
using healthy matched controls to the CDI patients, a higher serum IgG response to the protein was 
detected in healthy controls compared to patients with CDI. This response is associated with 
potential vaccine candidates, as a higher response in the control group suggests a protective effect 
of harbouring antibodies to these proteins.  
CDR20291_0330 is a putative cobalt binding protein. Cobalt, along with many other micronutrients, 
is essential for bacterial survival, although it is usually only required in minute concentrations by the 
cell. Cobalt is primarily required for synthesis of the different cobalamin compounds through its 
incorporation into the corrin ring [481, 482]. Vitamin B12 (cyanocobalamin) is one of the most 
notable members of this groups and is important in many cellular processes, as are its derivatives 
(hydroxycobalamin, methylcobalamin and adenosylcobalamin), particularly as enzyme co-factors 
[483]. For clarity, from here on the different vitamers will all be referred to as B12.  
Some bacteria, along with archaea, are unique in their ability to synthesise B12, with both aerobic and 
anaerobic biosynthesis pathways identified in a broad range of organisms [484, 485]. Additionally, 
dedicated transporters can be utilised for direct uptake of B12 from the environment [486]. Cobalt and 
other micronutrients are often scarce within the environments that bacteria reside, meaning high 
affinity uptake transporters are employed to scavenge for necessary substrates. This includes energy 
coupling factor (ECF) transporters which mediate the uptake of micronutrients via hydrolysis of ATP 




universal units; an A unit with ATPase activity, a T unit forming the transmembrane channel and an S 
unit for substrate binding [488, 489].   
Without in vitro characterisation, identification of transporters and more importantly, their targeted 
substrate is often based on a combination of factors, including; phylogenetic analysis, associated 
regulatory elements and the putative or actual function of genes with which they are co-localised 
[490]. Using this system, Rodionov et al. identified the cobalt ECF transporter, CbiMNQO (Figure 4.1) 
[490]. This transporter encodes two substrate binding components (CbiM and CbiN), a permease, 
(CbiQ) and an ATPase, (CbiO). It was confirmed to mediate high affinity uptake of cobalt when 
CbiMNQO transporters from Rhodobacter capsulatus and Salmonella enterica serovar Typhimurium 






Figure 4.1. Organisation of the CbiMNQO transporter. (A) Schematic of the suggested organisation 
of the CbiMNQO cobalt transporter in bactera, including the ATPase (CbiO), transmembrane 
components (CbiQ) and substrate binding domains (CbiM and CbiN). Image taken from Rodionov et 
al. [490]. (B) Genomic organisation of the putative CbiMNQO transporter in C. difficile R20291 
including; CbiM (CDR20291_0329), CbiN (CDR20291_0330), CbiQ (CDR20291_0331) and CbiO 
(CDR20291_0332).  
 
CbiMNQO and other genes encoding cobalt/B12 transporters or B12 synthesis pathways are often 
encoded downstream of a B12 riboswitch. These regulatory elements are encoded within the 5’ 
untranslated region of their associated gene and can be directly bound by B12 leading to structural 
changes within the RNA, resulting in transcriptional termination or translational sequestration [492, 




cbiMNQO operon, a putative B12 transporter (BtuFCD) and within the putative B12 biosynthesis 
pathway [111, 492]. Micronutrient uptake transporters such as CbiMNQO are encoded with a 
riboswitch to prevent build-up of their substrate within the cell, whichcan be toxic [494].  
CDR20291_0330 is the putative cobalt binding protein (CbiN) from CbiMNQO and we sought to 
characterise the role of this protein within the cell, specifically in terms of the requirements for cobalt 



















When searching the amino acid sequence of CDR20291_0330 against other strains of C. difficile, this 









Table 4.1. Conservation of CDR20291_0330 amino acid sequence across C. difficile strains. The 
conservation of the CDR20291_0330 amino acid sequence across a number of C. difficile strains from 
diverse ribotypes was assessed using pBLAST searches with R20291 as the comparator sequence.  
 
Phyre2 analysis identified CDR20291_0330 as a putative membrane protein with a signal peptide (1 to 
21 amino acids) and single transmembrane domain. However, CbiN has previously been identified as 
harbouring two transmembrane domains flanking an extracytoplasmic loop [490]. This organisation 
was supported when the amino acid sequence was analysed using the transmembrane domain 
prediction software, TMHMM Server v. 2.0., which identified two transmembrane domains. As with 
the Phyre2 analysis, SignalP 5.0 also identified a signal peptide, belonging to the Sec pathway. For 
annotation of the CDR20291_0330 sequence with this domains, see Chapter 3, Figure 3.2.  
In addition to the presence of a B12 riboswitch, the annotation of CbiMNQO as a cobalt transporter is 
supported by the relatively high degree of sequence similarity between CDR20291_0330 and CbiN 
from S. typhimurium (92% query cover and 60% percentage identity) and R. capsulatus (query cover 
90% and percentage identity 49%) (Figure 4.2). As discussed above, both of these transporters have 
Strain Ribotype Percentage identity (%) 
R20291 027 100 
CD196 Historic 027 100 
630 012 96.8 
M120 078 96.8 
M68 017 96.8 




been demonstrated to be highly specific for cobalt uptake, and inactivation of CbiN abolished 








Figure 4.2. Alignment of amino acid sequences of CbiN. The amino acid sequence of CDR20291_0330 
from C. difficile was aligned with the CbiN sequence from Salmonella typhimurium (92% query cover 
and 60% percentage identity) and Rhodobacter capsulatus (query cover 90% and percentage identity 
49%) using pBLAST.   
 
 Cobalt and B12 uptake in C. difficile  
As discussed, prokaryotes encode many transport mechanisms to ensure they maintain sufficient 
intracellular levels of B12 and cobalt, but no putative cobalt or B12 transporters from C. difficile have 
been characterised in vitro. Genes were investigated that have been annotated as cobalt or B12 
transport proteins in C. difficile, in addition to CbiMNQO, using pBLAST to analyse both the putative 
transporter and any associated genes (Table 4.2). Of note are two putative CorA transporters, which 
are typically associated with magnesium uptake, but have also been found to transport zinc and cobalt 
other bacteria [495]. Neither of these putative transporters were encoded with B12 riboswitches or 





Table 4.2. Putative cobalt transporters in C. difficile. List of putative cobalt transporters in C. difficile, analysed using pBLAST. The presence of B12 riboswitches 
and B12-related genes was also investigated. The previously identified CbiMNQO transporter (CDR20291_0329-0332) is not included.  
Gene (630/R20291) Putative function Co-localisation B12 riboswitch? Comments 
CD0313/CDR20291_0317 
Cadmium translocating ATPase. 
Heavy metal domain, 
implicated in inorganic ion 
transport including cobalt, 
cadmium, lead, and zinc 
Encoded with CD0312, 
putative metalloregulator 
from the SmtB/ArsR family 
No  
CD0591/CDR20291_0516 
Heavy metal translocating 
ATPase 





Putative ATPase and permease 
components of an ECF 
transporter 
None No 
No S unit or riboswitch could be 
identified 
CD0430-CD0431/not 
found in R20291 
CD430 and CD431 are putative 
cbiQ and cbiO components of 
an ECF transporter  
 
Encoded with a putative S unit 
(CD0429) and two predicted 
transcriptional regulators 
(CD0427 and CD0428) 
No 
No CbiN component identified, low 
homology of putative S unit with 
CbiM, could not be found in R20291 
CD1044/CDR20291_900 
HlyC/CorC family of 
transporters for metal ion 
uptake, including cobalt 
None No  
CD1831/CDR20291_1725 
Magnesium transporter within 
CorA family. CorA transporters 
are also associated with zinc 
and cobalt transport 
 
None No  
CD2122/ 
CDR20291_2029 
Magnesium transporter within 
CorA family. CorA transporters 
are also associated with zinc 
and cobalt transport 
 




In relation to B12 uptake, the only probable B12 transporter is BtuFCD (CD2997-2999/CDR20291_2832-
2835). This is a well-established B12 transporter in other organisms but has not been investigated in C. 
difficile [486, 496, 497]. In the C. difficile genome it is encoded downstream of a B12 riboswitch [111, 
492]. Interestingly, both 630 and R20291 encode this transporter yet in R20291, there is a transposase 
insertion towards toward the 3’ of BtuC (CD2998/CDR20291_2833) which encodes the permease 












Figure 4.3. Comparison of the putative BtuCDE B12 transporter from C. difficile 630 and R20291.   The 
putative BtuFCD transporter for uptake of vitamin B12 was identified in the genome of C. difficile strains 
630 and R20291. There is a transposase insertion (CDR20291_2834) within the BtuC gene in R20291 
(CDR20291_2833).   
 
4.3. Construction of a CDR20291_0330 gene deletion mutant   
The major function for cobalt within bacteria is for B12 synthesis. C. difficile encodes the anaerobic 
pathway for B12 synthesis, suggesting it is capable of de novo synthesis. Therefore, it was hypothesised 
that inactivation of the CbiMNQO transporter, the only putative cobalt transporter identified in C. 
difficile to date, would impact on B12 synthesis in C. difficile. The requirements for cobalt and B12 in C. 






inactivation of cobT, a gene within the anaerobic synthesis pathway resulted in loss of colonisation in 
mice, suggesting this is an essential pathway for C. difficile survival in the gut [498].  
The loss of CbiN was hypothesised to result in loss of function of the transporter as as previous work 
in Salmonella typhimurium demonstrated loss of CbiN results in abolishment of transporter activity in 
vitro [491].  
To achieve this, CDR20291_0330 was deleted from the C. difficile chromosome using allele exchange 
mutagenesis, a technique to generate in-frame deletion mutants in C. difficile, which reduce the risk 
of polar effects resulting from insertional inactivation [439]. This utilises two homology arms (>1000 
bp) flanking the gene for deletion, which enable the homologous recombination events to occur 
(Figure 4.4). These were introduced into R20291 using pMTL82151, a replication defective “pseudo-
suicide” plasmid, which is only stable once integrated on the chromosome. Integration results in 
improved growth on thiamphenicol so larger colonies were selected for passage on non-selective agar 
to facilitate loss of the plasmid. This resulted in reversion to wild-type or a second cross over event 
leading to a gene deletion mutant which were differentiated by PCR.  
CDR20291_0330 is only 286 bp, therefore for screening purposes, primers flanking the gene rather 
than the entire homology region were used, so the size shift would be easily visible by gel 
electrophoresis. As can be seen in Figure 4.4, clones were isolated where their corresponding 
amplicon was smaller compared to that from wild-type R20291. These potential deletion mutants 














Figure 4.4. Allele exchange mutagenesis of CDR20291_0330 in R20291. (A) Schematic of the allele 
exchange construct for generation of the CDR20291_0330 gene deletion mutant. This is annotated 
with the primers used for construction of the cassette and for screening to detect gene deletion 
mutants. (B) PCR screen of potential CDR20291_0330 gene deletion mutants using primers 
R20291_0330_MUT_f and R20291_0330_MUT_r. 1 to 7- individual clones from R20291, 8- wild-type 
R20291 gDNA, 9-dH2O.  The predicted size of amplicons with and without CDR20291_0330 are 610 bp 


















 Growth kinetics in rich media 
To determine whether R20291Δ0330 had any growth impairments, OD595 readings were taken for 
R20291 wild-type and R20291Δ0330 when growing in rich media, BHI (Figure 4.5). There was no 






Figure 4.5. Growth kinetics of R20291 and R20291Δ0330 in BHIS. R20291 and R20291Δ0330 were 
grown overnight in BHI then diluted into fresh BHI media to a starting OD595 0.05. OD readings were 
taken every hour for the first 8 hours then at 24 hours. Black- R20291 and grey- R20291Δ0330. Each 
culture was set up in duplicate and three independent replicates were performed. Error bars represent 
standard deviation.  
 Growth kinetics in minimal media  
It may be that in rich media, B12-dependent mechanisms are non-essential or that cobalt and B12 are 
freely available and the cell is capable of their uptake. To try and dissect this, the exact growth 
conditions were specified using C. difficile minimal media. Originally outlined by Karasawa et al. [32] 
and further modified to remove surplus ingredients by Cartman et al. [499], this media comprises the 
minimal components required for C. difficile growth and enables manipulation of the growth 
environment. Cobalt is provided in the form of cobalt chloride, but B12 was removed by Cartman et 
al., suggesting it is non-essential in this setting. However, the effect of removing both B12 and cobalt 
has not been examined. We hypothesised that in the wild-type, absence of B12 in the media would 
result in no growth, but this would be compensated by providing cobalt to enable C. difficile to 
synthesise its own B12. Furthermore, we hypothesised that in the mutant, the addition of cobalt would 




directly from plate cultures into minimal media containing either cobalt and B12, cobalt or B12 or 
neither. These were grown for 24 hours then diluted into fresh minimal media matching the overnight 
conditions, and growth rate measured every hour at OD595. Neither strain exhibited any differences in 















Figure 4.6. Growth kinetics of R20291 and R20291Δ0330 in minimal media. R20291 and 
R20291Δ0330 were grown for 24 hours in minimal media containing either cobalt and B12, cobalt or 
B12 or neither then diluted into fresh minimal media matching the overnight conditions to a starting 
OD595 0.05. OD readings were taken every hour for the first 8 hours then at 24 hours. Each culture was 





4.4. Cobalt and B12 requirements in C. difficile  
In both rich and minimal media, where cobalt and B12 availability was controlled, no growth 
impairments were detected in either strain. Therefore, we aimed to identify conditions where B12 was 
essential, for example for a particular metabolic pathway. Once established, this could be used to 
assess cobalt and B12 dependency and any impact of inactivating CDR20291_0330. Previous work has 
identified genes in C. difficile that are predicted to encode for B12-dependent enzymes [483, 500], 
including MetH and EutBC. These genes in 630 and R20291 were assessed for co-localisation with a 
B12 riboswitch or B12/cobalt transporter and presence of a B12-independent isomer of the enzyme, 
which bacteria can utilise during B12 deficiency and are often coupled to B12 riboswitches [483, 492]. 
Genes involved in the synthesis of B12 were excluded.  
The putative enzyme required for the final stage of methionine synthesis, MetH 
(CD3596/CDR20291_3434) is not co-localised with a B12 transporter or riboswitch. However, C. difficile 
also encodes the B12-independent isomer of this enzyme- MetE (CD0130/CDR20291_0129), which we 
hypothesised would compensate for the lack of B12 if investigated in growth assays, resulting in no 
observable phenotype. The EutBC (CD1913-1914/CDR20291_1834-1835) enzyme is also not found 
with a B12 riboswitch or uptake system but no B12-independent isomer has been identified in C. difficile 
or other species [483]. The lack of a B12 independent isomer as well information on EutBC’s 
requirement for B12 in other species made this an interesting candidate for further work. EutBC 
encodes ethanolamine ammonia lyase, the enzyme responsible for breakdown of ethanolamine which 
can be used as a carbon and nitrogen source [501]. Ethanolamine utilisation was therefore selected 
for further work using investigations in minimal media growth assays, which can be manipulated to 
generate the desired conditions [32, 431].  
 Ethanolamine Utilisation 
Phosphotidylethanolamine is the principal bacterial phospholipid and a key component of the cell 




ethanolamine into the intestinal environment. Consequently, a number of enteric bacteria use 
ethanolamine as a carbon source, including Salmonella and Enterococcus [502]. 
C. difficile harbours a 20 gene locus predicted to encode the ethanolamine utilisation pathway [36, 
111, 502] (Figure 4.7), which is upregulated in the presence of ethanolamine [36]. C. difficile 630 can 
use ethanolamine as a carbon source in vitro, although current evidence is less conclusive for R20291. 
In Enterococcus, the eut operon is positively regulated following detection of ethanolamine by a two-
[503, 504] EutW, which have also been identified within the C. difficile eut operon- CD1910 and 
CD1911, respectively [36].  
The central enzyme for ethanolamine breakdown is the ethanolamine ammonia lyase (EutBC), which 
is B12-dependent. The eut locus is therefore often found downstream of a B12 riboswitch, but no 
putative riboswitch could be identified in C. difficile in this study or others [111].  The locus encodes a 
number of other genes, which includes those that form the bacterial microcompartment, within which 
ethanolamine is utilised [505].  
 
 
Figure 4.7. The ethanolamine utilisation (eut) locus in C. difficile. Schematic of the putative 
ethanolamine utilisation locus in C. difficile based on annotation and diagram by Nawrocki et al. [36] 
(2018 Society for Applied Microbiology and John Wiley & Sons Ltd). There are three predicted 
promoters, upstream of eutG, eutS, and eutA and a transcriptional terminator following eutW. Genes 
encoded within the locus vary in their predicted function and include; metabolic enzymes (blue), 
regulatory proteins (green), bacterial microcompartment units (yellow), ethanolamine transporter 
(purple) and a protein of unknown function (white).  
 
Due to the requirement for cobalt in B12 synthesis and the association between B12 and ethanolamine 
utilisation, this was selected as a suitable assay for screening cobalt/B12 dependent conditions in C. 
difficile. We hypothesised that absence of B12 would result in C. difficile being unable to utilise 
ethanolamine. Consequently, it was predicted that ethanolamine utilisation would be abolished for 




preventing B12 synthesis. To begin with, growth kinetics were performed using R20291 and 
R20291Δ0330 with either glucose, ethanolamine or water as a no carbon control. Although no 
difference in OD between ethanolamine and water was identified by Nawrocki et al. when 
investigating R20291, the number of colony forming units (CFUs) was higher in ethanolamine, 
therefore both were measured here [36]. Cultures were grown overnight in BHIS broth, then diluted 
1:10 into fresh BHIS broth and grown until OD595 0.6. These were then diluted to OD595 0.1 in minimal 
media matching the final growth conditions and diluted 1:10 into the test flasks to obtain a starting 
OD595 0.01.  
Unlike Nawrocki et al. who observed differences in growth between glucose and ethanolamine within 
the first 12 hours [36], our study observed limited growth and therefore the total growth time was 
extended up to 72 hours, taking readings at 16, 20, 24, 40, 44, 48, 64, 68 and 72 hours. This enabled 
determination as to whether the time delay was due to C. difficile adapting to the change between 
rich and minimal media and/or using other preferred carbon sources before switching to the 
ethanolamine-dependent pathway. CFUs were taken at 16, 44 and 72 hours.   
Both R20291 and R20291Δ0330 had grown in glucose to a comparable level after 16 hours, but there 
was no increased growth in ethanolamine compared to the water only control at any time point 
(Figure 5.8). After 72 hours, the vegetative cell count was significantly higher in ethanolamine 
compared to the no carbon control for R20291, with the same comparison not significant in 
R20291Δ0330. However, in both strains the total number of CFUs appeared to be either steady or 
decreasing in ethanolamine and no carbon across the three time points, suggesting this may be a 
result of a faster reduction in viable C. difficile in the no carbon compared to ethanolamine, rather 
than growth in ethanolamine. Due to the lack of growth of the wild-type R20291 strain in 



















Figure 4.8. Growth kinetics of R20291 and R20291Δ0330 in ethanolamine. Strains were grown to OD 0.6 in rich media before inoculation into minimal media 
containing glucose, ethanolamine or water (no carbon control). OD595 readings were taken at 16, 20, 24, 40, 44, 48, 64, 68 and 72 hours. Colony forming units 
for the total cell and spore counts were also taken at 16, 44 and 72 hours.  Spore counts were incubated at 65oC for 20 mins before plating to remove 
vegetative cells then vegetative cell count was calculated by subtracting the spore count from the total cell count. (A) R20291 and (B) R20291Δ0330. 
Differences in CFU counts between strains was analysed for significance using a linear regression. * p>0.05, p>0.005, p>0.0005, NS- not significant.  Each 




The same assay was repeated using 630Δerm, 630Δerm_1910::CT and 630Δerm_1911::CT. The latter 
strains harbour ClosTron insertions within EutV and EutW, respectively, which form the ethanolamine 
sensor (these strains were constructed by Dr Alexandra Faulds-Pain). Firstly, the growth of all strains 
was compared in BHI and found to be comparable, demonstrating these mutations do not impair 







Figure 4.9. Growth kinetics of 630Δerm, 630Δerm_1910::CT and 630Δerm_1911::CT in BHIS. All 
strains were grown overnight in BHI then diluted into fresh BHI media to a starting OD595 0.05. OD 
readings were taken every hour for the first 8 hours then at 24 hours. Each culture was set up in 
duplicate and three independent replicates were performed. Error bars represent standard deviation. 
 
In the minimal media (Figure 4.10), all strains grew in glucose after 16 hours. There was no significant 
difference in total cell counts between strains in the glucose or no carbon conditions at any time point 
(Figure 4.11). At 16, 20 and 24 hours, growth in ethanolamine was comparable to that in no carbon 
for all strains. Following this, the OD and vegetative cell count slowly decreased until reaching a 
plateau, in glucose and the no carbon control.  
Interestingly, by 44 hours, the spore counts in ethanolamine were significantly higher than the no 
carbon control for 630Δerm and 630Δerm_1910::CT. By 72 hours, both the vegetative cell and spore 
count were significantly higher in ethanolamine compared to no carbon and this difference was also 


















Figure 4.10. Growth kinetics of 630Δerm, 630Δerm_1910::CT and 630Δerm_1911::CT in ethanolamine. Strains were grown to OD 0.6 in rich media before 
inoculation into minimal media containing glucose, ethanolamine or water (no carbon control). OD595 readings were taken at 16, 20, 24, 40, 44, 48, 64, 68 and 
72 hours. Colony forming units for the total cell and spore counts were also taken at 16, 44 and 72 hours.  Spore counts were incubated at 65oC for 20 mins 
before plating to remove vegetative cells then vegetative cell count was calculated by subtracting the spore count from the total cell count. (A) 630Δerm, (B) 
630Δerm_1910::CT and (C) 630Δerm_1911::CT. Differences in CFU counts between strains was analysed for significance using a linear regression. * p>0.05, 




increase in OD, vegetative cell or spore count for 630Δerm_1911::CT in ethanolamine compared to no 
carbon. At 44 and 72 hours, growth in ethanolamine was significantly higher in 630Δerm and 630Δerm-
_1910::CT compared to 630Δerm_1911::CT (Figure 4.11). Collectively, this demonstrates that 
630Δerm can use ethanolamine as an energy source for growth and inactivation of 630Δerm_1911::CT 





















Figure 4.11. Colony forming units of 630Δerm, 630Δerm_1910::CT and 630Δerm_1911::CT when 
grown in glucose, ethanolamine and no carbon. Total cell counts of 630Δerm, 630Δerm_1910::CT and 
630Δerm_1911::CT when grown in glucose, ethanolamine or water (no carbon) at (A) 16 hours, (B) 44 
hours, (C) 72 hours. Differences in CFU counts between strains was analysed for significance using a 
linear regression. * p>0.05, p>0.005, p>0.0005, NS- not significant. Each culture was set up in duplicate 




 Cobalt requirements in ethanolamine utilisation  
To evaluate the B12 requirements of ethanolamine utilisation, the 630Δerm growth kinetics were 
repeated, with and without cobalt. As cobalt is only required at trace level by the cell, it was important 
to reduce the chance of carryover of cobalt already present within the cell or rich media. Therefore, 
the assay was performed as before, but for the steps using rich media, this was replaced with minimal 


















Figure 4.12. Growth kinetics of 630Δerm in glucose, ethanolamine or water, with and without 
cobalt. 630Δerm grown overnight in minimal media with glucose but no cobalt was subbed into fresh 
media and grown to OD 0.6 before inoculation into test minimal media containing glucose, 
ethanolamine or water (no carbon control), with and without cobalt. OD595 readings were taken at 16, 
20, 24, 40, 44, 48, 64, 68 and 72 hours. (A) 16 hours (B) 44 hours and (C) 72 hours. Differences in CFU 
counts between strains was analysed for significance using a Student’s t-test, NS- not significant. Each 





We hypothesised, that in the absence of cobalt and B12, C. difficile would not be able to utilise 
ethanolamine. However, there was no difference in growth in glucose between the plus and minus 
cobalt cultures. Interestingly, even by 72 hours, there was no growth in ethanolamine for strains 
growing with or without cobalt. This suggests that minimal carryover from the rich media in the 
previous experiments may have provided an essential factor that supported ethanolamine utilisation. 
Overall, due to the lack of growth in ethanolamine in both conditions, it was not possible to determine 



















This chapter aimed to investigate the role of CDR20291_0330, a putative cobalt transport protein 
(CbiN) [483], from the CbiMNQO ECF transporter, which mediates high affinity uptake of cobalt [490, 
491]. In pursuit of this, CDR20291_0330 was deleted from the chromosome using allele exchange 
mutagenesis, which enables removal of the target with minimal disruption to neighbouring genes 
[439]. It was also aimed to investigate cobalt and B12 requirements in C. difficile, an understudied area 
especially considering the importance of B12 in many cellular processes. C. difficile encodes a complete 
anaerobic B12 biosynthesis pathway, for which cobalt is an essential component [111, 481, 482]. 
Transcriptomics data suggests genes within the cbiMNQO operon are involved in the central 
metabolism pathways in C. difficile as they are downregulated in a Spo0A mutant (cbiM and cbiO) and 
under predicted negative regulation by CodY (cbiM), two major regulators of C. difficile [506, 507]. 
In both rich and minimal media, no growth defect was observed in R20291 wild-type or R20291∆0330 
when cobalt and/or B12 was removed, suggesting in these conditions it is non-essential. However, C. 
difficile encodes putative mechanisms for both B12 uptake and de novo synthesis, the latter of which 
constitutes a large locus that is likely to pose a metabolic burden so maintenance of this suggests B12 
is required by the bacteria [111, 483, 484]. To further examine this, the expression profiles of these 
transporters and synthesis enzymes could be monitored to determine when they are required and 
under what conditions. For those genes downstream of a B12 riboswitch, including the cbiMNQO 
operon and cbiP within the B12 synthesis pathway [111], these are likely to be regulated at the 
translational level, meaning transcriptomics would be less informative. Instead, a translational fusion 
could be employed, such as a chromosomal SNAP-tag or LOV domain, which will be translated with 
the gene product and provide a detectable marker [508-510]. Upon identification of expression 
conditions, spent growth media from C. difficile which lacked exogenous B12, but was cultured with 
and without cobalt could be assessed for the presence of C. difficile-synthesised B12, using high 
performance liquid chromatography or by using the growth of Lactobacillus leichmannii in the spent 
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culture media which is auxotrophic for B12 [511]. When testing R20291∆0330 in these conditions, it 
would be necessary to consider the activity of other putative cobalt transporters (Table 5.2), but this 
would only be relevant once a cobalt/B12 dependent condition had been defined. Alternatively, to 
investigate the activity of CDR20291_0330 more directly, ligand binding assays could be performed, 
using fluorescence spectrometry to measure binding affinity of the purified protein with cobalt and 
other such as nickel or iron [512].  
With an aim to provide a growth environment where cobalt/B12 is essential, ethanolamine utilisation 
was assayed. Ethanolamine breakdown is mediated by the B12-dependent ethanolamine ammonia 
lyase (EutBC) which is encoded within the putative ethanolamine utilisation operon (eut) in C. difficile. 
There are only two publications previously dedicated to ethanolamine utilisation in C. difficile. The 
first characterises the ethanolamine microcompartment within which it is hypothesised it is 
metabolised whereas the second focuses on growth of C. difficile in ethanolamine, the genes involved, 
and how this impacts virulence [36, 505]. Therefore, the latter publication was used as a starting point 
for our own growth assays.  
Nawrocki et al. demonstrated a biphasic growth curve for strain 630Δerm in minimal media, which 
they attributed to the differences in carbon utilisation- amino acid metabolism in the first instance 
followed by an additional growth phase relying on glucose or ethanolamine after ~ 4 and 10 hours, 
respectively [36]. No substantial growth was obtained in any condition within the standard 8 hour 
time period (data not shown) therefore the growth kinetics were extended with a final reading at 72 
hours. There was a ten-fold increase in OD (0.01 to 0.1) in the first 16 hours of growth in the no carbon 
control, which is likely a combination of carry-over from rich media and amino acid metabolism. By 16 
hours, the OD for growth in glucose was comparable to the maximum absorbency readings obtained 
in the previous publication.  
Regarding ethanolamine, growth was not detected by OD in 630∆erm until the 64-hour time point. 
Although this lag time is substantial, diauxic growth is not unusual in bacteria and can be related to 
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preferential metabolism of more available energy sources [513, 514]. Therefore, C. difficile may be 
depleting the different substrates available before switching to the ethanolamine-dependent lifestyle. 
This response is reflected by in vivo transcriptomic data, where increased expression of the eut 
operon, encoding ethanolamine utilisation, is not reported until 38 hours post infection, whereas 
glucose utilisation is believed to occur at ~14 hours [35]. The differences between our data and the 
previous study are surprising, as the assay set up was based on their published methods.  It may be 
that the cas-amino acid composition used here was richer and took longer to deplete, which delayed 
the switch to ethanolamine utilisation. Alternatively, it may be an outcome of differences in 
ethanolamine, as our study used liquid ethanolamine compared to ethanolamine hydrochloride in the 
previous study, which may be easier to metabolise.  
Growth of R20291 was not detected in ethanolamine by OD or CFU, therefore it was not possible to 
determine the impact of deleting CDR20291_0330 in this assay. Nawrocki et al. found the increased 
expression of the eut operon from basal level in the presence of ethanolamine was more pronounced 
in 630 compared to R20291 [36]. Therefore in this study, the eutVW genes encoding a two-component 
response regulator for detection of ethanolamine were compared for 630 and R20291, to see whether 
sequence differences could be impairing detection of ethanolamine, but the sequences were highly 
conserved across the two strains (data not shown).  
No ethanolamine utilisation was observed when 630Δerm was sub-cultured in minimal as opposed to 
rich media before inoculation of the test flasks, which prevented analysis of cobalt requirements in 
this process. This was interesting, as it suggests lack of a component required for ethanolamine 
utilisation that is carried over in sufficient amounts when inoculating from rich media. This could be 
further investigated by comparing the minimal media at inoculation, 44 and 72 hours between the 
rich and minimal inoculants using nuclear magnetic resonance, to compare the metabolite profile, 
including B12. B12 could also be spiked into the media to try and promote ethanolamine utilisation.  
146 
 
Two distinct mechanisms of regulating ethanolamine utilisation have been identified. 
Enterobacteriaceae, such as Salmonella Typhimurium, encode EutR, a constitutively expressed 
positive transcriptional regulator. This upregulates expression of the entire eut operon by binding a 
single promoter, but only in the presence of two ligands- ethanolamine and B12 [515]. Firmicutes (like 
C. difficile) lack the EutR regulator and instead encode the EutVW two-component regulatory system, 
as demonstrated in Enterococcus faecalis and Listeria monocytogenes, which encode very similar eut 
operons to C. difficile [503, 504, 516]. In the presence of ethanolamine, EutW autophosphorylates 
then goes onto phosphorylate the response regulator EutV. EutV binds RNA to interrupt 
transcriptional terminators and enable expression of the operon (Figure 4.13) [503, 504]. Unlike EutR, 
B12 does not directly interact with EutVW, but does maintain regulation over the eut operon, via a 
riboswitch. Although B12 riboswitches usually result in the termination of expression upon B12 binding, 
presence of B12 actually facilitates expression of the eut operon. This is through interaction with a non-
coding RNA, EutX, which binds and sequesters EutV, preventing induction of the operon. EutX 
harbours a B12 binding domain which when bound, results in transcriptional termination of EutX, 
producing a shorter fragment that can no longer bind EutV, allowing induction of the ethanolamine 
utilisation pathway (Figure 4.13) [504, 517, 518].  
As no B12 riboswitch has been identified within the C. difficile eut operon, it is possible B12 is not 
required for ethanolamine utilisation in C. difficile. This seems unlikely, as no B12-independent isomer 
has been identified for ethanolamine breakdown in C. difficile or other species, the locus still encodes 
EutT, which is required for processing of B12 into the active co-factor and very early research using 
Clostridial (species not specified) cell free extracts found a cobinamide co-enzyme was necessary for 
ethanolamine breakdown [111, 483, 492, 519]. 
Furthermore, the authors of a recent review into ethanolamine note how the riboswitch within the 
EutX RNA is dissimilar to other B12 riboswitches and therefore may not be identified using standard 
riboswitch identification techniques [504]. This also acts in trans, meaning it could be located 
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elsewhere on the genome [501]. Future work should look at identifying an ortholog of EutX in C. 
difficile in addition to monitoring expression of the eut operon in the presence of ethanolamine, plus 







Figure 4.13. Regulation of ethanolamine utilisation in Enterococcus faecalis. Regulation of the eut 
operon for ethanolamine utilisation in E. faecalis which requires both ethanolamine and B12. The 
histidine kinase sensor, EutW, autophosphorylates in the presence of ethanolamine and 
phosphorylates the response regulator, EutV. EutV has an RNA-binding domain which enables binding 
and disruption of transcriptional terminators, resulting in induction of the operon. However, in the 
absence of B12, EutV is sequestered by the small RNA, EutX (not shown), and is only released upon B12 
binding, which interrupts the EutV binding site. Image taken from Kaval and Garsin [501].  
 
Separate to the requirement for B12, inactivation of EutW (CD1911), but not EutV (CD1910) abolishes 
ethanolamine utilisation in C. difficile, suggesting EutV is dispensable in this process. El Papa and 
Perego noted that both EutV and EutW had RNA binding activity in vitro. RNA binding is the method 
of anti-termination used to enable expression of the eut operon [503]. In E. faecalis, inactivation of 
EutV abolished ethanolamine utilisation, although it is noteworthy that this is an insertional mutant 
and therefore may have influenced the activity of downstream genes [503]. The mutants used in our 
study were also generated using insertional inactivation and although not confirmed using 
complementation, the results suggests there were no polar effects on downstream genes. As the 
mutation in EutW, which is encoded downstream of EutV, displayed no growth with ethanolamine, 
this would also be expected in the EutV mutant, if its inactivation influenced expression of EutW. 
However, this is not the case, as the EutV mutant shows no difference from wild-type in ethanolamine 
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utilisation. Regarding EutW, Nawrocki et al., demonstrated two transcriptional units in the presence 
of ethanolamine in C. difficile, one of which ends after eutW [36]. Therefore, the genes downstream 
of this are under the control of a separate promoter and unlikely to be susceptible to polar effects.  
Alternatively, it may be that an orphan response regulator encoded elsewhere on the genome is able 
to compensate for the loss of EutV. Orphan response regulators are encoded without a histidine kinase 
partner and can regulate genes elsewhere on the genome. C. difficile encodes 51 response regulators 
and 5 of these are considered orphan kinases (a 6th has been identified as regulating lantibiotic 
resistance) [252]. To investigate whether these could be involved in ethanolamine regulation, the 
sequence of EutV could be compared to the sequences of these different orphan response regulators 
to see if they may also be involved. 
Limitations to this study which should be addressed with future work include the lack of 
complementation for CDR20291Δ0330, 630Δerm_eutV::CT and in particular, 630Δerm_eutW::CT, as 
this is the mutant where a different phenotype from the wild-type was observed. For the reasons 
previously discussed, polar effects on neighbouring genes were not predicted to have influenced the 
results described here, but it is still important to reintroduce the gene into the cell to confirm that the 
altered phenotype is a result of loss of the target gene, only. Another limitation regarding 
ethanolamine utilisation is the difficulty in recreating the in vivo gut environment within the 
laboratory. This includes the challenges of culturing C. difficile in minimal media, in replicating the 
dynamic environment of the gut within the laboratory and the possibility of carryover of compounds 
from starting cultures. There is media available designed to mimic the gut niche which could be an 
improvement on standard minimal media. A recent study investigating ethanolamine utilisation in 
uropathogenic E. coli did so using an artificial urine medium supplemented with ethanolamine [520]. 
However, here it is important to note that urine is usually a sterile environment, whereas the 
microbiome in the gut is constantly using and releasing many different metabolites.  
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There has been significant development in the use of substrate binding proteins as vaccine candidates. 
Antibodies raised against the methionine binding protein MetQ, from Neisseria gonorrhoeae are 
bactericidal and prevent gonococcal binding to epithelial cells in vitro [521] and immunisation of mice 
with recombinant SBP2 from Moraxella catarrhalis increased clearance of infection from the lung 
[522]. Immunising mice with PiuA and PiaA from Streptococcus pneumoniae increased survival upon 
challenge [523]. Interestingly, this was not a result of impairing the activity of these essential iron 
uptake components, but was in fact due to the elicited opsonophagocytic response, demonstrating 
how essentiality in the host is not necessarily a requirement for a good vaccine target [524]. PiuA has 
been included within PnuBioVax, an anti-S. pneumoniae vaccine which was recently demonstrated to 
be safe and immunogenic in Phase I clinical trials (NCT02572635) [525]. Also in clinical trials is the 
manganese binding protein, MntC from Staphylococcus aureus, which is currently in Phase II 
(NCT02388165) [526]. In relation to use of CDR20291_0330 in a vaccine, additional studies are 
required to confirm this proteins suitability for inclusion within a vaccine. Production of antibodies 
against this protein would enable probing of intact C. difficile cells to ensure the protein is expressed 









5. Characterisation of CDR20291_3343, a putative pilin protein  
5.1. Introduction 
Motility is a key process for many bacterial species. It can facilitate movement towards nutrient 
sources or away from noxious agents and environmental stressors, interactions between cells to 
aggregate and form biofilms and is an important virulence factor, particularly for colonisation of the 
host [184, 189, 527, 528].   
Bacteria employ a number of different mechanisms for motility. Although use and definition of the 
different motility terminology can vary, swimming and swarming are typically considered a product of 
the flagella, a whip-like surface structure that propels bacteria through their environment, via a motor 
rotating the flagella filament  [529]. The two mechanisms are differentiated depending on if the 
motility is through a medium (swimming) or on the surface (swarming) [530]. Flagella-independent 
motility is often attributed to the action of the type IV pili (T4P), hair-like appendages on the cell 
surface [204]. Rather than forceful propulsion of the bacteria through or on a medium, pili drag the 
bacteria across a surface by continuous assembly and disassembly of the polymerised filament, in a 
grappling hook mechanism known as twitching motility [531-533].  Gliding motility is also used to 
describe T4P-mediated motility, for example in Clostridium perfringens [534], but is also linked to non-
T4P actions such as focal adhesions or sliding due to bacterial division [530, 531].  
C. difficile motility is primarily dictated by the action of the peritrichous flagella decorating the cell 
surface [184, 187]. These are essential for movement through semi-solid agar, as movement is 
abolished upon inactivation of the flagella filament gene fliC, or removal of the whole flagella glycan 
(some mutants of this are still motile) [184, 185, 187]. C. difficile also encodes the hypothetical major 
(CDR20291_3340-3350) and minor (CDR20291_3153-3158) T4P locus which are thought to be core 
components of its genome [111, 205, 206]. These loci are predicted to encode major and minor pilins 
that form the pilus filament and the accessory components required for pilus assembly or retraction. 
Using microscopy, predicted T4P structures have been identified on the surface of wild-type C. difficile 
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in vitro [209, 211] which have been differentiated from flagella based on size and use of a flagella 
mutant as well as through use of immunogold staining to PilA1 and PilJ [195, 209, 211]. Furthermore, 
pili like structures have been identified by microscopy in hamster infection models [210].  
CDR20291_3343 is encoded within the predicted major T4P locus of C. difficile, and has been 
previously identified as a putative minor pilin protein (Figure 3.1a) [204, 207, 534]. At a predicted 57.7 
KDa, CDR20291_3343 is larger than most other pilins but still possesses the conserved N-terminal 








Figure 5.1. The C. difficile type 4 pili locus. (A) Schematic of the major type 4 pili locus in C. difficile 
strain R20291 [195]. The locus is preceded by a c-di-GMP dependent type II riboswitch (Cdi2_4) which 
controls its expression. Putative functions have been assigned to each gene within the locus including 
the major structural pilin proteins; pilA1, the ATPase, pilB1 and the predicted tip of the pilus, pilK. (B) 
Comparison of the N-terminal amino acid sequences from different C. difficile R20291 pilin proteins 
[207]. Conserved regions are shaded in grey, including the N-terminal hydrophobic region. The glycine 
residue in black is the pre-pilin peptidase cleavage site. At position +5 after this site, PilK lacks the 
conserved glutamic acid residue, predicted to be required for interaction with neighbouring pilins via 
salt bond formation. Images from a) Bordeleau et al. and b) adapted from Maldarelli et al. [195, 207] 
(by permission of Oxford University Press). 
 
Pilus assembly in C. difficile has not been characterised and T4P assembly is less well understood 
compared to Gram-negative systems. Based on the amino acid similarity to other T4P locus, it is 
predicted that the C. difficile putative T4P assembly follow the ATPase mediated route, wherein each 
pilin protein is actively secreted from the cell, in a tip to base manner, to form the polymerised 
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filament [535-537]. Pilins are suspected to interact via salt bridge formation between a conserved 
glutamic acid residue at +5 after the prepilin peptidase cleavage site and an N-terminal phenylalanine 
on a neighbouring pilin (Figure 5.1) [207]. Interestingly, this glutamic acid residue is absent in 
CDR20291_3343, replaced instead with a hydrophobic leucine residue, which presumably abolishes 
this interaction. This has resulted in CDR20291_3343 being assigned into the GspK family of proteins. 
GspK from the Enterotoxigenic E. coli type 2 secretion system (T2SS), which share amino acid similarity 
with T4P, is also large, lacks the conserved glutamic acid residue and forms the tip of the pseudopilin 
[207, 538, 539]. CDR20291_3343 has therefore been annotated as PilK, hypothesised to form the tip 
of the pilus. [204, 207].  
As a member of the major pili locus (Figure 5.1), pilK expression is upregulated by the secondary 
messenger cyclic diguanosine monophosphate (c-di-GMP), via a positive transcriptional type II 
riboswitch, Cdi2_4. Riboswitches are RNA elements within the 5’ untranslated region (UTR) of their 
target genes which, when bound by their effector, can promote or inhibit expression at the 
transcriptional or translational level. Cyclic-di-GMP is a central regulator of a number of key bacterial 
processes and in elevated concentrations is associated with promoting cell entry into the sessile 
lifestyle [196]. As such, elevated levels of c-di-GMP are associated with repression of the flagella and 
a reduction in related motility, whereas biofilm formation and pili production are upregulated [198]. 
Expression of pilK in strain 630 is higher in the presence of elevated levels of c-di-GMP and CDR20291-
_3343 expression is higher in plate and biofilm cultures compared to planktonic growth as well as in 
biofilm cultures [195, 212].  
Previous characterisation of the role of the C. difficile pili has identified a number of associated 
phenotypes, including mediating surface motility, auto-aggregation and biofilm formation and binding 
to human cells lines and colonisation [195, 208, 212, 213]. These investigations have primarily been 
conducted in strains 630 and R20291, using wild-type strains as well as those with inactivation of PilA1, 
the major structural subunit forming the polymerised filament and PilB1, the ATPase driving pilus 
153 
 
formation. Neither of these mutant strains produce T4P, as shown by transmission electron 
microscopy [195].  
CDR20291_3343 was found to be immunogenic in patients with CDI on a pilot study using a C. difficile 
specific pan-protein array (Chapter 3). A number of bacteria encode immunogenic pili, some of which 
have since been investigated as vaccine candidates [462, 463]. Therefore, this chapter aimed to 
further investigate the role of pili in C. difficile, specifically in relation to the role of CDR20291_3343 
within pili-attributed motility, by comparing individual contributions of flagella and pili within C. 
difficile motility.  
5.2. Bioinformatics 
The amino acid sequence of CDR20291_3343 was highly conserved across a diverse selection of C. 
difficile strains (Table 5.1). The comparison tool pBLAST revealed no putative conserved domains 
within the amino acid sequence of this gene, but as already discussed, CDR20291_3343 harbours the 







Table 5.1. Conservation of CDR20291_3343 amino acid sequence across C. difficile strains.  The 
conservation of the CDR20291_3343 amino acid sequence across a number of C. difficile strains from 





Strain Ribotype Percentage Identity (%) 
R20291 027 100 
CD196 Historic 027 99.8 
630 012 99 
M120 078 94 
M68 017 97.6 
CD305 023 98 
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5.3. Construction of a CDR20291_3343 gene deletion mutant in R20291 and 
R20291_fliC::CT  
 
Previous work characterising the C. difficile pili-associated phenotype has been conducted in strains 
still harbouring their flagella [208]. Although increasing c-di-GMP levels required for pili expression 
should result in suppression of the flagella, there may be some residual activity, and removing the 
flagella altogether would aid in precise identification and be a more robust means of investigating 
pili and pili-associated phenotypes. To further dissect the contributions of each of these surface 
appendages on motility and other functions within the cell, in frame deletion mutants were 
constructed in this study, which lack flagella, pili or both (Table 5.2). It was hypothesised that loss of 
PilK could result in one of two phenotypes: either that PilK is required for pili length regulation and 
that a knockout would result in a hyper-extended pili without PilK present to act as a pilin cap [540]; 
or that PilK is essential for pilus assembly and knockout results in the loss of the pilus altogether. It 
was found that in a pilK mutant, the major structural pilin PilA1 can be detected in the cell but is no 
longer secreted as it is in the wild-type,  suggesting that the pilus isn’t assembled [541] (Neil 
Fairweather, personal communication). Therefore, throughout this study the PilK mutant has been 









Strain High level c-di-GMP Low level c-di-GMP 
 Flagella Pili Flagella Pili 
R20291 x 
✓  ✓  x 
R20291Δ3343 x x ✓  x 
R20291_fliC::CT x ✓  x x 
R20291Δ3343_fliC::CT x x x x 
 
Table 5.2. Predicted phenotype of flagella and pili inactivated strains, in the presence and absence 
of c-di-GMP. The influence of high or low-level c-di-GMP on expression of flagella and pili in four 
strains; wild-type R20291, R20291Δ3343 where no pili are expected to be assembled, R20291_fliC::CT 
where no flagella are produced and R20291Δ3343_fliC::CT, lacking both pili and flagella. 
 
To generate the desired strains, an allele exchange cassette was built targeting CDR20291_3343 
(Figure 5.2), to delete this gene from R20291 wild-type and R20291_fliC::CT. The latter strain does not 
produce flagella due to a ClosTron insertion within the flagellin gene, fliC [187]. The generation of the 
allele exchange mutants was performed as described in 4.3.2, including construction of the 3870 bp 
allele exchange cassette. Following transformation of R20291 and passage on selective and non-
selective media, the homology region from thiamphenicol sensitive colonies was amplified to screen 
for the loss of the 1539 bp region of CDR20291_3343 from both R20291 and R20291_fliC::CT (Figure 
5.2). It was not possible to amplify the entire homology region (2144 bp), in the potential mutants or 
wild-type control gDNA from R20291, therefore two products were generated instead, using one 
primer outside of the homology region (R20291_3343_MUTSEQ_f or R20291_3343_MUTSEQ_r) and 
a reverse primer adjacent to the deletion of CDR20291_3343 (R20291_3343_MUT_f and 
R20291_3343_MUT_r). Potential double crossovers and therefore gene deletion mutants were 
identified for both backgrounds and the PCR products were sequenced to confirm CDR20291_3343 
had been successfully deleted from the chromosome and no single nucleotide polymorphisms had 










Figure 5.2. Allele exchange mutagenesis of CDR20291_3343 in R20291 and R20291_fliC::CT. (A) 
Schematic of the allele exchange construct for generation of the CDR20291_3343 gene deletion 
mutants. This is annotated with the primers used for screening to detect gene deletion mutants. (B) 
PCR screen of potential CDR20291_3343 gene deletion mutants using primers 
R20291_3343_MUTSEQ_f and R20291_3343_MUT_r. 1 to 6- individual clones from R20291, 7-11- 
individual clones from R20291_fliC::CT, 12- wild-type R20291 gDNA, 13-dH2O control.  The predicted 
size of amplicons with and without CDR20291_3343 are 3683 bp and 2184 bp, respectively. Clones 
from lanes 2, 3, 9 and 10 clones are predicted wild-type revertants with the remaining representing 
gene deletion mutants, which were confirmed with DNA sequencing.  
 
5.4. Selection of an expression system for c-di-GMP 
Pili expression is upregulated in the presence of c-di-GMP, therefore it is necessary to elevate the 
cellular levels of this secondary messenger for study. This was achieved using the dccA gene, which 
encodes a cyclic diguanylase, the enzyme responsible for synthesis of c-di-GMP. Although 15 genes 
encoding cyclic diguanylases have been predicted in C. difficile, previous work has demonstrated that 
expression of the dccA gene is sufficient to achieve high intracellular levels of c-di-GMP [198, 542]. 
Two plasmids have previously been constructed which encode dccA under control of either a 
constitutive Pcwp2 promoter (pECC12) or an anhydrotetracycline (Atc) inducible promoter, Ptet 
(pECC17). These were a kind gift from the Fairweather Laboratory [221]. Initially, the pECC12 plasmid 
for constitutive expression of c-di-GMP was preferentially used over the anhydrotetracycline (Atc) 
inducible promoter, as motility assays take a number of days and the ability to maintain induction for 
that length of time, was unknown.  
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 Swimming motility with constitutive expression of c-di-GMP 
In the presence of elevated levels of c-di-GMP, the flagella filament gene, fliC, is repressed, due to 
interaction of c-di-GMP with the type I  riboswitch upstream of fliC [198]. As the flagella are the driving 
force behind swimming motility, reduced expression of fliC results in loss of this phenotype [198]. To 
confirm expression of constitutive dccA resulted in the anticipated c-di-GMP induced effects on 
motility, assays were performed to monitor the swimming capabilities of different strains as a marker 
of flagella expression. Colonies taken from agar plates were inoculated into 0.3% minimal media agar 
using sterile cocktail sticks and incubated for 5 days (Figure 5.3).  
As previously reported, the flagella-negative strains, which harbour a ClosTron insertion within fliC did 
not move beyond the inoculation (stab) point, whereas R20291 and R20291Δ3343 demonstrated a 
halo swimming pattern. Surprisingly, constitutive c-di-GMP expression in R20291 and R20291Δ3343 
did not result in a reduction in swimming motility- in fact, both strains appeared to swim more when 
c-di-GMP was present. This experiment was terminated early due to this finding, as it was not in 
keeping with a reduction in expression of fliC that should be observed in the presence of c-di-GMP 
[198]. The swimming observed may have been due to condensation on the plates, or due to an unusual 
phenotype of the constitutively expressed c-di-GMP, which leads to artificially high levels of the 
messenger. Overall, it is clear these strains are still swimming in the presence of c-di-GMP, suggesting 















Figure 5.3. Swimming motility with and without constitutive expression of c-di-GMP. Individual 
colonies were taken from plate cultures and stab inoculated into 0.3% minimal media agar plates then 
incubated at 37oC, anaerobically. Strains either contained no plasmid or pECC12, for constitutive 
expression of the dccA gene, leading to high levels of c-di-GMP within the cell. Each culture was set 
up in duplicate and the assay performed once.  
 
 Inducible control of c-di-GMP mediated motility 
To replace constitutive expression of c-di-GMP, the pECC17 plasmid was utilised, which encodes the 
dccA gene under control of the Atc-inducible promoter, Ptet. Swimming motility was assessed in 
R20291 carrying pECC17 or the empty vector, pASF085, in 0.3% minimal media agar plates (Figure 5.4) 
with a range of Atc concentrations to test induction of c-di-GMP at; 0, 25, 50, 100 or 250 ng/ml and 
15 µg/ml thiamphenicol (for plasmid maintenance). It was hypothesised that increasing the level of 
induction would result in a reduction in swimming motility in the wild-type strains due to an increase 
in the cellular level of c-di-GMP. Plates were incubated for 5 days, and the diameter measured at 5 
days to determine whether sufficient Atc would still be present to induce c-di-GMP expression, as 
measured by a reduction in swimming, compared to the empty vector control (pASF085).  
When carrying the empty vector (pASF085), there was no significant difference in swimming motility 
when comparing +/- Atc, until the Atc concentration reached 250 ng/ml (Figure 5.4). Here, swimming 
was significantly lower compared to in the absence of Atc (p<0.05), suggesting this concentration is 
toxic to the cell, or has a deleterious effect on growth.  Swimming motility was significantly reduced 
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in the presence of c-di-GMP, even in the lowest concentrations of Atc induction (25 ng/ml) (p<0.05), 
demonstrating flagella repression in these conditions. As hypothesised, swimming was significantly 
reduced in the presence of c-di-GMP (p<0.05) (Figure 5.4), and was almost completely abolished in 
concentrations of 50 ng/ml Atc. Further experiments were undertaken in a concentration of 25 ng/ml 
to minimise the deleterious effect that Atc can have on growth at high concentrations (Figure 5.4).  
 
Figure 5.4. Swimming motility with increasing concentrations of c-di-GMP. Individual colonies of C. 
difficile were used to inoculate the centre of 0.3% minimal media agar plates, supplemented with 0, 
25, 50, 100 or 250 ng/ml Atc and 15 µg/ml thiamphenicol. R20291 either carried the empty vector 
pASF085 or pECC17, for inducible expression of c-di-GMP. Plates were photographed after 5 days 
incubation and two perpendicular measurements were taken of the diameter. A linear regression was 
performed to assess any differences in swimming motility when c-di-GMP is induced, for each 
concentration of Atc compared to the empty vector control. (A) Photo of swimming motility of C. 
difficile R20291 after 5 days incubation, (B) Average diameter of each motility halo after 5 days growth. 
NS not significant, * p<0.01, **p<0.001, ***p<0.0001. Each culture was set up in duplicate with three 
independent replicates performed. Error bars represent standard deviation. 
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 Growth kinetics with Atc and c-di-GMP 
The swimming defect of R20291 in the presence of 250 ng/ml Atc, even without induction of c-di-
GMP, warranted growth assessment of R20291 and R20291_fliC::CT in the presence of 25 ng/ml Atc, 
to ensure this concentration of Atc does not have deleterious effects on the cell. This was performed 
using R20291 and R20291_fliC::CT harbouring either pASF085 or pECC17, to also test if c-di-GMP 
expression affected the growth rate (Figure 5.5). Strains were grown in BHIS with either 0 or 25 ng/ml 
Atc and 15 µg/ml thiamphenicol and OD595 readings taken every hour for the first 8 hours then after 













Figure 5.5. Growth kinetics with anhydrotetracycline inducible c-di-GMP. R20291 and 
R20291_fliC::CT harbouring either pASF085 or pECC17 were grown overnight in BHIS then diluted to 
a starting OD595 0.05 in fresh BHIS supplemented with 0 or 25 ng/ml Atc and 15 µg/ml thiamphenicol. 
OD595 readings were taken every hour for the first 8 hours of growth then at 24 hours. (A) 0 ng/ml Atc 
and (B) 25 ng/ml Atc. Black solid line- R20291 + pASF085, grey solid line- R20291 + pECC17, black 
dashed line- R20291_fliC::CT + pASF085, R20291_fliC::CT + pECC17. Each culture was set up in 




There was no difference when comparing the same strain in each of the four growth conditions. When 
comparing R20291 to R20291_fliC::CT, the latter demonstrated a reduced growth rate during 
exponential phase with and without Atc, but at 8 hours there was no difference in OD. The aflagellate 
strains appeared to clump more in the growth flasks, which may have interfered with the accuracy of 
cell density readings.   
5.5. Swimming motility 
Once the conditions for induction of c-di-GMP were established, swimming motility was assessed in 
all strains with and without induction of c-di-GMP. As swimming motility is a flagella-driven action, we 
hypothesised that only the absence of the flagella would lead to a reduction in swimming motility and 
there would be no difference between the PilK positive and negative strains (Figure 5.6). As previously 
described, a colony of each strain carrying either pASF085 or pECC17 was inoculated into 0.3% minimal 
media agar +/- 25 ng/ml Atc and containing 15 µg/ml thiamphenicol and incubated for 5 days.  
As expected, strains without flagella did not disperse beyond the inoculation point and swimming was 
significantly reduced in flagella-positive strains in the presence of c-di-GMP (Figure 5.6) There was no 
significant difference in swimming motility between R20291 and R20291Δ3343, suggesting pili do not 
influence this phenotype (Figure 5.6), and that this motility is driven by expression of the flagella locus 





















Figure 5.6. Swimming motility in the presence of inducible c-di-GMP. Individual C. difficile colonies were inoculated into the centre of 0.3% minimal media 
agar plates, supplemented with 0 or 25 ng/ml Atc for induction of c-di-GMP and 15 µg/ml thiamphenicol. Each strain carried either the empty vector pASF085 
or pECC17, for Atc-mediated induction of c-di-GMP. Plates were photographed after 5 days incubation and two perpendicular measurements were taken of 
the diameter. A linear regression analysis was performed to assess any differences in swimming motility compared to the wild-type R20291. (A) Swimming 
motility with the empty vector pASF085, (B) swimming motility with pECC17, carrying Atc-inducible dccA for expression of c-di-GMP.  NS not significant, * 
p<0.01, **p<0.001, ***p<0.0001. Each culture was set up in duplicate with three independent replicates performed. Error bars represent standard deviation.
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5.6. Colony morphology 
 
Pili and flagella are both surface appendages and can direct movement of the cell, therefore it was 
interesting to see whether inactivation of either of these influenced colony morphologies. We 
hypothesised that in the presence of c-di-GMP, when pili expression is induced, cells would display a 
pili-mediated colony morphology which would be absent in the presumed pili-negative strain, 
R20291Δ3343. Strains carrying pASF085 or pECC17 were grown in BHIS supplemented with 15 µg/ml 
thiamphenicol to OD595 0.3 - 0.4, then diluted in PBS to ensure single colonies when plated on 1.8 % 
BHIS agar + 1 % glucose +/- 25 ng/ml Atc and 15 µg/ml thiamphenicol and incubated for 5 days (Figure 
5.7). 1.8% agar was selected as pili activity tends to increase with a harder surface [208]. The 
aflagellate strains displayed a typical C. difficile morphology in all conditions. In the presence of high-
level c-di-GMP only, R20291 and R20291Δ3343 displayed numerous fronds growing outwards from 
the centre colony (Figure 5.7). However, as this occurs in strains with and without PilK, it suggests this 
is not a pili-mediated phenotype, which may indicate that FliC plays a role in this extended colony 






















Figure 5.7. Colony morphology of C. difficile. Strains of C. difficile harbouring pili and flagella (R20291), 
either pili or flagella (R20291_fliC::CT or R20291Δ3343, respectively), or neither 
(R20291Δ3343_fliC::CT), were serially diluted then spread onto 1.8% BHIS agar plates supplemented 
with 15 µg/ml thiamphenicol and incubated for 5 days in the presence or absence of Atc for induction 
of c-di-GMP (pECC17) or with an empty vector (pASF085). Each culture was set up in duplicate with 
three independent replicates performed.  
 
5.7. Surface motility 
Both swarming and twitching motility enable bacteria to move across solid surfaces. While the former 
is attributed to the action of the flagella, twitching motility is associated with the pili, powered by their 
continuous assembly and disassembly. This has been demonstrated in many species, including C. 
difficile [208]. Surface hardness of the agar is believed to enable twitching motility, therefore 1.8% 
BHIS agar was used, based on previous work [208]. The assay was set up as outlined for colony 
morphology, but instead of plating dilutions, 5 µl of neat culture was spotted directly onto the surface 
of 1.8% agar with 15 µg/ml thiamphenicol, in quadruplicate. Two perpendicular measurements of the 
diameter of each growth spot were taken daily, for 5 days when plates were also photographed. It 
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was hypothesised that as pili are associated with surface motility, under c-di-GMP expression the 
bacteria would move outward from the centre spot of inoculation but this phenotype would be lost 
in the R20291Δ3343 mutant strain.  
Figure 5.8 presents the image of each growth spot and the total diameter reached after 5 days 
incubation. When carrying the empty vector pASF085, there was no significant difference between 
strains in the presence or absence of Atc. Upon c-di-GMP induction, the conditions under which 
flagella are down-regulated and pili are expressed, the motility radius for all strains increased in size, 
significantly (p<0.001). The flagella-positive strains dispersed significantly more than the aflagellate 
strains, and R20291 reached a larger total diameter than R20291Δ3343, although both displayed the 
frond phenotype as seen in the colony morphology assays (Figure 5.8).  
The aflagellate strains did disperse beyond the initial inoculation site more under c-di-GMP induction, 
but this is a much smaller, more uniform halo compared to the flagella positive strains. In addition, a 
similar pattern is seen in both R20291_fliC::CT and R20291Δ3343_fliC::CT, suggesting this may be a 
general cellular effect of c-di-GMP, rather than a specific effect mediated by fliC or pilK. As was 
observed with the colony morphologies (Figure 3.7), the flagella positive strains produced much larger 
and more irregular swarms under c-di-GMP induction compared to uniduced strains and induced 
strains without flagella (Figure 5.8).  
Overall, in the presence of c-di-GMP, surface motility was reduced in a PilK inactivated strain 
compared to the wild-type, but only in strains still harbouring an active flagella. Inactivation of the 













Figure 5.8. Surface motility of C. difficile. Strains of C. difficile harbouring pili and flagella (R20291), either pili or flagella (R20291_fliC::CT or R20291Δ3343, 
respectively), or neither (R20291Δ3343_fliC::CT), were spotted onto 1.8% BHIS agar plates with 15 µg/ml thiamphenicol and incubated for 5 days in the 
presence or absence of Atc for induction of c-di-GMP (pECC17) or with an empty vector (pASF085). Two measurements of the diameter of each inoculum 
spot were taken daily and plates photographed after 5 days. NS not significant, * p<0.01, **p<0.001, ***p<0.0001. Each culture was set up in duplicate with 






This chapter investigated the role of CDR20291_3343, a putative pilin protein predicted to form the 
tip of the pilus, PilK. CDR20291_3343 was investigated in relation to its role within the C. difficile T4P, 
assessed using motility assays in both flagella-positive and flagella-negative strains. To aid this, allele 
exchange mutagenesis was successfully applied to generate clean CDR20291_3343 deletion mutants 
in a R20291 wild-type and R20291_fliC::CT backbone.  
We found that in surface motility and colony morphology assays, under c-di-GMP induction, where 
flagella are downregulated and pili expression is induced, both R20291 and the pilK mutant, 
R20291Δ3343, produced frond like filaments, extending from the initial inoculation site (Figure 5.7 
and 5.8), a phenotype previously attributed to the action of the pili [208]. The diameter of the total 
growth site, including the fronds, was significantly larger compared to the same strains growing 
without c-di-GMP induction. This phenotype was previously observed in R20291 and attributed to 
pili-mediated motility due to the observation that induction of c-di-GMP leads to downregulation of 
flagella expression and induction of pili expression [198, 208]. However, the total motility on the 
surface of the agar for the flagella-negative strains did not increase significantly upon c-di-GMP 
induction, and they remained significantly smaller than the flagella-positive strains and the frond 
phenotype was absent (Figure 3.6). From these results, three potential mechanisms driving the 
surface motility phenotype were considered; i) the action of the pili, ii) the action of the flagella or 
iii) pili and flagella independent effect, of induction by c-di-GMP. 
If surface motility and frond formation in the presence of c-di-GMP were due solely to the action of 
the pili, then loss of surface motility would be expected in the pilK mutant (R20291∆3343 and 
R20291∆3343_fliC::CT), as the pilus should not be assembled in this mutant [541]. However, both 
R20291 and R20291∆3343 were able to move across the agar surface. These results indicate the 
phenotype seen here is likely to be independent of the pili. There was a small but significant reduction 





and produced the distinctive frond display. Although this suggests that the pili could still be functional 
in the absence of PilK, it may also be influenced by the variability within surface motility assays. It has 
previously been reported that the conditions for testing can influence this phenotype, as has been 
described for organisms such as Pseudomonas aeruginosa, where motility has been thoroughly 
investigated. The composition and hardness of the agar surface can influence results which therefore 
can provide room for error, particularly when measuring millimetre differences in motility [530, 543].  
It may be that PilK inactivation does not abolish pili formation in C. difficile, as this has not been 
confirmed using microscopy. This was attempted in this study by providing samples of each strain with 
and without c-di-GMP induction to Tony Fearns in the Gutierrez laboratory at the Francis Crick 
Institute for scanning electron microscopy, but no data had been obtained at the time of writing. Even 
so, the lack of secretion of the major pili structural subunit, PilA1, in a PilK mutant is highly suggestive 
of lack of pilus assembly [541]. This was demonstrated in strain 630 but the pili loci are highly 
conserved between 630 and R20291, albeit differentially responsive to c-di-GMP [208]. Furthermore, 
evidence that this is a pili-independent phenotype is provided in a recent thesis by Couchman, who 
could detect no difference in swarming motility between R20291 wild-type and a ClosTron PilB1 
mutant [541]. PilB1 is the ATPase driving assembly of the pili and in the mutant, pili cannot be detected 
on the surface of the cell via microscopy [208].  
Interestingly, both our results and those obtained by Couchman contradict the only published data on 
“pili-mediated” motility in C. difficile. Here, Purcell et al. also utilised ClosTron mutagenesis to 
inactivate PilB1 in R20291, but found in their strain, the surface motility phenotype was abolished, 
including in the presence of c-di-GMP [208]. Furthermore, where the authors demonstrate substantial 
surface motility in R20291 without c-di-GMP induction, we see very little expansion from the 
inoculation site without c-di-GMP induction (Figure 5.8). Couchman speculated that the insertional 
inactivation used to remove PilB1 activity in the published work may have inactivated other genes in 





inactivation of PilB1 has disrupted genes required for functioning of the secondary pili gene cluster, 
which may be the true mediator of motility, but this has not been tested [541].  
Alternatively, is this simply a result of high-level expression of a prolific secondary messenger with 
multiple cellular targets? Overexpression of c-di-GMP can influence cellular morphology, with 
published microscopy identifying elongation and curling of cells [221]. However, if this were purely an 
effect of c-di-GMP on the cell, independent of flagella or pili, one may hypothesise this would be 
observed in flagella and non-flagella strains, alike.  
This study is the first to test surface motility of C. difficile flagella-negative strains. Aflagellate strains 
were found to be significantly less motile than strains harbouring their flagella and did not produce 
the filamentous fronds seen in the flagellate strains. If this phenotype were truly a result of the action 
of the flagella filament, then it would be present in low-level c-di-GMP (i.e. the empty vector with and 
without Atc and c-di-GMP but without induction), when the flagella are expressed and active. 
However, it is only found upon induction of c-di-GMP, conditions which downregulate the flagella, as 
demonstrated previously [198] and in the swimming assays in this study. Future work should 
determine fliC expression in the surface motility assay without and without c-di-GMP to confirm it is 
not being expressed.  
If not a direct result of the flagella filament, could this be related to regulation? The flagella operon in 
C. difficile does not just encode for expression and assembly of the flagella, it also can also mediate 
regulation of a number of cellular processes, most notably toxin expression. Toxin expression is 
positively regulated by the alternative sigma factor, SigD, which is encoded with the early stage flagella 
genes. SigD regulates expression of the late stage flagella genes, in addition to a number of other 
genes throughout the C. difficile genome [191]. Pili formation was demonstrated in a SigD mutant 
strain, but as the motility phenotype seen here is not believed to be pili-related, its activity cannot be 
ruled out [195]. However, a previous ClosTron insertion with FliC did not inactivate SigD, as toxin 





Alternatively, is this a result specific to the inactivation of FliC? As mentioned, previous inactivation of 
FliC did not inactivate SigD, but did result in differential expression of 310 genes in vivo and 258 genes, 
in vitro, although only 36 of these were shared across the two groups. [544]. Further investigation of 
surface motility in C. difficile would also have to consider how PilB1 contributes to this, as surface 
motility was lost in a PilB1 ClosTron mutant [208]. 
Interestingly, during preparation of this discussion a publication was deposited on the pre-peer review 
site, BioRxiv, which identified a putative phosphorelay system, named the colony morphology 
regulators (cmr), involved in regulation of C. difficile motility [545]. This is composed of a histidine 
kinase (cmrS) and two response regulators (cmrT and cmrS), positively regulated by a c-di-GMP 
riboswitch and under additional control of an additional genetic switch which mediates phase 
variation. The authors related two colony morphologies to this system- rough and smooth. In the 
presence of c-di-GMP all colonies were of the rough phenotype, but in the absence of c-di-GMP, the 
genetic switch determined between the rough (ON) and smooth (OFF) morphologies. These are 
believed to be adaptations to the environment, as rough colonies were associated with the fronding 
phenotype in surface motility assays (although without induction of c-di-GMP) and the smooth 
colonies were isolated from the swimming agar [545]. This supports our findings of a difference in 
behaviour of our R20291 and R20291Δ3343 strains in swimming and surface motility assays, when 
both are under c-di-GMP induction.  
The cmr-mediated spreading of bacteria in the surface motility assays was suggested to be a result of 
bacterial chaining, as identified using scanning electron and light microscopy, although the exact 
targets of the response regulators is unknown and there may be multiple [545]. Importantly this 
appears to be a flagella and T4P independent phenotype, as rough colonies were produced upon c-di-
GMP induction in a SigD and PilB1 mutant. Furthermore, transcript levels of T4P and flagellum genes 





This is interesting as the authors demonstrate surface motility of R20291 without c-di-GMP, which is 
lost in the PilB1 mutant. It therefore brings into question the exact contribution of pili and the cmr 
response regulator in this motility. Furthermore, in our results, we see no surface motility unless c-di-
GMP is induced and as mentioned there is no different between wild-type and the pili-negative strain. 
Finally, how do flagella relate to this? Our surface motility phenotype is completely absent in FliC 
negative strains, yet flagella are not believed to be regulated by cmr. The current study did not assess 
surface motility in the SigD mutant. It would interesting to further investigate the activity of cmr in the 
FliC mutant to see if rough and smooth colonies can be isolated, and the effect of over expression of 
the two response regulators on colony morphology and surface motility phenotypes.  
Irrespective of the mechanism(s) behind surface motility, it appears this is not a reliable or definitive 
measure of pili activity. A number of other C. difficile phenotypes have been associated with the pili, 
including aggregation, biofilm formation, adhesion to host cells, and in vivo colonisation [195, 208, 
212, 213]. Assessment of these mechanisms may provide further insight into the relationship between 
flagella and pili and any associated regulation in these phenotypes. The recent finding relating to a 
role for them in in vivo colonisation was interesting and is one of the strongest publications to date to 
link the C. difficile pili to an active role in virulence and colonisation of the host, rather than exclusively 
in vitro phenotypes [213].  
The lack of a reliable method of measuring motility was a limitation to this study as was the use of c-
di-GMP as a means of studying flagella and pili expression and their associated motility phenotypes. 
Although this is the standard means of such assessments of motility and is one of the regulatory 
mechanisms for these surface appendages in vivo, it is difficult to tease apart specific influence of the 
flagella and pili on motility when c-di-GMP has so many targets within the cell [202, 203]. Additionally, 
despite some preliminary evidence from other groups and ongoing work with a collaborator [541], it 
has not yet been possible to confirm CDR20291Δ3343 is a pili-negative strain. It would be interesting 





surface motility phenotype is the same as seen here. Finally, as with the CDR20291Δ0330 work, these 
phenotypes have not been complemented. As there is a lack of resistance markers available for 
plasmid maintenance in C. difficile and a plasmid is already in use for expression of c-di-GMP, there 
are two options for construction of these complements. R20291_3343 could be reintroduced onto the 
genome using allele exchange mutagenesis and watermarked by changing the stop codon so the 
complement could be differentiated from the wild-type by sequencing. This would not be applicable 
for R20291_fliC::CT as this is a ClosTron mutant so instead the fliC gene could be cloned into the same 
plasmid as the dccA gene for c-di-GMP expression, under its native promoter. 
The whole pilus or different pilin components have been demonstrated to induce an immune response 
in mice for Neisseria meningitidis and P. aeruginosa, and an anti-pili vaccine is licensed for the animal 
pathogen Moraxella bovis [207]. As pili tend to be assembled with the hydrophobic N-terminal buried 
within the central helix, the exposed C-terminal domain is predicted to be the immunogenic portion 
[546].  
In the pan-protein array described in Chapter 3, CDR20291_3343 was found to be immunogenic in a 
pilot study. The follow up array found a higher response to the protein in healthy controls compared 
to those with CDI, although this was not significantly different. Individual pilins from C. difficile (PilK 
not tested) induced an immune response in the mouse model of CDI [207], and in a follow up study, 
three pilin proteins, PilA, PilJ and PilW were taken forward for challenge experiments to determine 
protective efficacy. However, in these experiments, only weak antibody responses were raised to 
these pili and no protection was demonstrated. As the authors were unable to replicate their own 
results in relation to antibody generation against the pilins, they suggest these results may be a result 
of the mouse model differing between the first and second studies. Furthermore, even the dmLT 
adjuvant didn’t induce an immune response in these experiments, which had been used successfully 
in previous mouse studies [546]. Therefore, the true immunogenic properties and vaccine potential 





vaccines have noted the likely need for a multi subunit approach, covering many surface antigens in 





















6. Characterisation of CDR20291_0342, a putative permease protein 
6.1. Introduction 
ATP-binding cassette (ABC) transporters are ubiquitous integral membrane proteins in prokaryotes. 
Through hydrolysis of ATP, they transport a variety of substrates across the lipid bilayer, both in and 
out of the cell. Their preferred substrates are diverse, as is their function, which includes but is not 
limited to; nutrient acquisition, antimicrobial resistance, export of virulence factors and trafficking of 
cell surface components [547]. The number of ABC transporters a bacterial genome encodes appears 
to correlate with both genome size and the environmental niche within which the bacteria resides 
[548].  
CDR20291_0342 has been annotated as the putative permease component of an ABC transporter 
[111], but information regarding this protein in the literature is limited. Forgetta et al. found 
CDR20291_0342 was one of the genes identified with a high SNP prevalence, which differentiated 
hypervirulent 027 isolates from other C. difficile strains, although the impact of this on the activity or 
putative function of the transporter was not determined [549]. Transcriptomic analysis of C. difficile 
identified that CDR20291_0342 was significantly downregulated during germination [506].   
This chapter aimed to characterise the role of CDR20291_0342 and its associated ABC transporter 
within C. difficile, using allele exchange mutagenesis to inactive the gene and a series of phenotyping 










6.2. Bioinformatic analysis of CDR20291_0342 
CDR20291_0342 is a predicted 212 KDa protein, conserved across a diverse range of C. difficile strains 
(Table 6.1). Amino acid sequence similarity analysis across a diverse selection of C. difficile strains was 
86%, slightly reduced compared to the level of conservation reported for CD20291_3343 and 
CDR20291_0330, where amino acid similarity was over 90% for all strains. This is likely a result of the 
high SNP prevalence within this gene, as discussed above [549]. Following on from this, the amino acid 
sequence of CDR20291_0342 from strains 630 and R20291 were aligned which showed the high SNP 
prevalence did introduce non-synonymous mutations, but none resulted in a stop codon and 
therefore these SNPs do not affect expression of the full protein (Appendix E). The CD305 genome was 
unavailable for the first analysis but when investigated at a later date, it was found CDR20291_0342 









Table 6.1 Conservation of CDR20291_0342 amino acid sequence across C. difficile strains. The 
conservation of the CDR20291_0342 amino acid sequence across a number of C. difficile strains from 
diverse ribotypes was compared using pBLAST searches with the R20291 amino acid sequence as the 
comparator sequence. CDR20291_0342 and the two genes it is encoded with are absent from the 
ribotype 023 strain CD305.  
 
Phyre2 analysis identified 8 putative transmembrane domains within the protein, and it is encoded in 
the genome alongside a putative ATPase (CDR20291_0341), supporting its annotation as the 
permease component of an ABC transporter (Figure 6.1a and b). A third, hypothetical protein is 
Strain Ribotype Percentage identity (%) 
R20291 027 100 
CD196 Historic 027 100 
630 012 86 
M120 078 86 
M68 017 86 





encoded alongside these (CDR20291_0340), but analysis of the protein provided no indication as to 
its function or the potential role of the transporter.   
Analysing the amino acid sequence using pFam and Phyre2 corroborated the annotation of 
CDR20291_0342 as a permease. 21% of the whole protein was modelled with 99.2% confidence 
against the N-terminus of the LolE protein from Acinetobacter baumannii, with high amino acid 
similarity also found when modelled against MacB. LolE is the transmembrane component of the 
lipoprotein releasing system LolCDE, which traffics lipoproteins to the outer membrane in E. coli [550]. 
Bioinformatic analysis can help identify putative lipoproteins by screening for the consensus lipobox 
sequence within 40 residues of the N-terminus of the protein [551]. The amino acid sequence of 
theCDR20291_0340 hypothetical protein neighbouring CDR20291_0342 was analysed using The 
Database of Bacterial Lipoproteins (https://www.mrc-
lmb.cam.ac.uk/genomes/cgi/dolop/newlipo.cgi), but was not a predicted lipoprotein. 
The MacB transporter has been identified as a means of resistance to macrolides and antimicrobial 
peptides in a number of species, although it can export a range of compounds from the cell, including 
virulence factors [552, 553]. In addition to the MacB and LolE domains, pFam also highlighted a SalY 
domain, related to antimicrobial peptide (AMP) transport (Figure 6.1 c). Taken together, these results 
indicate the transporter may be involved in mediating efflux from the cell, for either lipoproteins, 




















Figure 6.1. Bioinformatic analysis of CDR20291_0342. (A) The position of the putative permease 
CDR20291_0342 in the R20291 genome, encoded with the other components of a predicted ABC 
transporter, including the putative ATPase, CDR20291_0341 and a hypothetical protein, 
CDR20291_0340. (B) A schematic of the organisation of CDR20291_0342 within the cell membrane, 
produced from Phyre analysis of the CDR20291_0342 amino acid sequence, revealing 8 putative 
transmembrane domains. (C) Analysis of CDR20291_0342 amino acid sequence using the pFam 
database, revealing regions of homology with domains of efflux transporters LolE and MacB.  
 
6.3. Construction of a CDR20291_0342 gene deletion mutant  
Deletion of CDR20291_0342 from the chromosome could aid understanding as removal of the 
permease component is hypothesised to inactivate the entire transporter. Allele exchange 
mutagenesis was used to delete CDR20291_0342 from the chromosome, as described in 4.3.2 and 
5.4.1 (Appendix B). Potential double cross over mutants were screened using primers flanking both 
the entire homology region (MUTSEQ_F and R) and the gene only (SEQ_F and R) (Figure 6.2). Four 
colonies generated amplicons matching wild-type R20291, suggesting wild-type revertants. Two 
amplicons were ~1.2 Kb smaller than the wild-type amplicon, indicating a gene deletion mutant, which 














Figure 6.2. Allele exchange mutagenesis of CDR20291_0342 in R20291. (A) Schematic of the allele 
exchange construct for generation of the CDR20291_0342 gene deletion mutant. This is annotated 
with the primers used for screening to detect gene deletion mutants. (B) PCR screen of potential 
CDR20291_0342 gene deletion mutants. Lanes 1 to 6- individual clones from R20291, 7- R20291 wild-
type, 8- water only, all screened using primers R20291_0342_MUTSEQ_f and 
R20291_0342_MUTSEQ_r. Lanes 9-16- individual clones from R20291, 15- R20291 wild-type, 16- 
water only, all screened using primers R20291_0342_SEQ_f and R20291_0342_SEQ_r (grey arrows). 
The predicted size of amplicons with and without CDR20291_0342 are 4800 bp and 2262 bp, 
respectively for the MUTSEQ primers and 3288 bp and 750 bp, respectively, for the SEQ primers. 
Clones from lanes 5 and 6 and 13 and 14 were suspected gene deletion mutants, which were 
confirmed by sequencing.  
 
6.4. Antimicrobial susceptibility 
 As the bioinformatic analysis identified domains relating to antimicrobial efflux, presumably for the 
purposes of resistance, it was hypothesised that CDR20291_0342 and its associated transporter could 
be an antimicrobial efflux pump. To investigate this, the sensitivity of R20291 and R20291Δ0342 
against the macrolide erythromycin, the lincosamide lincomycin and the cyclic peptide bacitracin were 
all investigated. These were chosen as the amino acid sequence CDR20291_0342 harboured amino 
acid similarity to the antimicrobial efflux pump MacB, which can export macrolides from the cell in 
other species [552]. Macrolide efflux pumps can often also transport lincosamides and therefore 
lincomycin was investigated. Finally, as a cyclic peptide bacitracin is sometimes classed as an 
antimicrobial peptide and was therefore investigated as CDR20291_0342 harbours a SalY domain 





broth dilution method was used to determine the MIC of both strains against the three compounds, 
but no difference in MIC was found for any of the antimicrobials (Table 6.2) in either strain.   
 
Table 6.2. Antimicrobial susceptibility of R20291Δ0342. R20291 and R20291Δ0342 were tested for 
susceptibility to erythromycin, bacitracin and lincomycin using the broth dilution method. Strains were 
incubated in 24-well tissue culture plates containing 1 ml BHI broth supplemented with bacitracin and 
erythromycin at 512, 256 and 128 µg/ml and lincomycin at 40, 20 and 10 µg/ml. Pre-equilibrated 
plates were inoculated with a day culture of each strain to a starting OD595 0.003 and incubated for 16 
hours before the OD595 was taken for each well using a plate reader. Each concentration was tested in 
duplicate and three independent replicates were performed. 
 
6.5. Growth kinetics  
To determine whether loss of CDR20291_0342 influenced growth, both the mutant and wild-type 
were grown in BHI media and OD595 taken every hour for 8 hours then a final reading at 24 hours. 








Figure 6.3. Growth rate of R20291Δ0342 in rich media. R20291 and R20291Δ0342 were grown 
overnight in BHI broth then diluted to a starting OD595 0.05 in fresh media. Absorbance readings were 
taken every hour for the first 8 hours followed by a final 24 hour reading. Cultures were set up in 
duplicate and three independent replicates were performed. Error bars represent standard deviation. 
Strain Bacitracin Erythromycin Lincomycin 
R20291 >512 µg/ml > 512 µg/ml 20 µg/ml 





6.6. Carbon utilisation 
 
 Phenotypic microarrays 
 
Where the role of a particular protein within the cell is not easily decipherable from bioinformatics 
analysis alone, large-scale screening methodologies can be of use, enabling rapid identification or 
exclusion of potential functions. Biolog Phenotypic Microarrays assays are an established 
methodology for high-throughput screening of a number of different growth conditions in a plate 
format, a much simpler set up than traditional growth kinetics [554], and have recently been 
optimised for the study of anaerobes.  
The Biolog assays were performed and analysed at The Wellcome Trust Sanger Institute by Dr Hilary 
Browne and Dr Kevin Vervier, respectively. Strains R20291 and R20291Δ0342 were grown with 95 
different carbon sources, broadly grouped into acids, amino acids and carbohydrates. Two other, 
unrelated strains were screened simultaneously- R20291∆0330 and R20291_2436::CT. Plates were 
inoculated with C. difficile overnight culture and incubated in sealed anaerobic bags within an 
OminoLog for automated cell density readings. A minimum of seven replicates were performed per 
strain and analysis by Dr Vervier allocated a growth/no growth outcome for each strain in every tested 
growth condition, based on OD readings. Tables 6.3, 6.4 and 6.5 detail growth outcomes in amino 
acids, acids and carbohydrates, respectively. Any carbon source where no growth was recorded for 
any strain was excluded.  
Although two versions of the wild-type R20291 strain were tested, these performed poorly in the 
assay, with strains failing to grow in the majority of tested carbon sources, including well established 
sugars such as glucose. Therefore, to try and extract any potential phenotypes for R20291Δ0342, all 
strains were compared to one another. It was noted that R20291Δ0342 did not grow with L-valine, 
aspartic acid plus L-valine or alpha-ketovaleric acid. Both R20291_2436::CT and R20291∆0330 grew 





acid and alpha-ketovaleric acid. As valine was central to all these compounds, growth of R20291 and 
R20291Δ0342 in L-valine was taken forward for further investigation. 
 Amino acids 
Carbon Source R20291 (1) R20291 (2) R20291_2436::CT R20291Δ0330 R20291Δ0342 No. strains 
Alaninamide - - + - - 1 
L-Alanine - + + + - 3 
L-Alanyl-L-glutamine - - + - - 1 
L-Alanyl-L-Histidine - - + - - 1 
L-Alanyl-L-Threonine - - + + - 2 
Glycyl-L-Aspartic Acid - - + - - 1 
Glycyl-L-Glutamine - + + - - 2 
Glycyl-L-Proline - - + - - 1 
L-Phenylalanine - - + - + 2 
L-Serine - - + + - 2 
L-Threonine - - + - - 1 
L-Valine - - + + - 2 
L-Valine plus L-
aspartic acid 
+ - + + - 3 
Deoxyadenosine - - + - - 1 
Inosine - - + - - 1 
Thymidine - - + - - 1 
Uridine - - + - - 1 
Thymidine 
monophosphate 
- - + - - 1 
Uridine-
Monophosphate 
- - + - - 1 
No. growth 
conditions (n=19) 
1 2 19 5 1  
 
Table 6.3. Amino acids utilisation in R20291 and R20291∆0342. Growth of R20291 and R20291∆0342 
compared to each other and two other strains; R20291∆0330 and R20291_2436::CT in the presence 
of different amino acids as carbon sources. This was performed using a Biolog Phenotypic Assay on an 
AN microplate. Green and plus indicates growth and red and minus indicates no growth. The last 
column indicates the total number of strains growing in each condition and the last row displays the 










Table 6.4. Acid utilisation in R20291 and R20291∆0342. Growth of R20291 and R20291∆0342 
compared to each other and two other strains; R20291∆0330 and R20291_2436::CT in the presence 
of different acids as carbon sources. This was performed using a Biolog Phenotypic Assay on an AN 
microplate. Green and plus indicates growth and red and minus indicates no growth. The last column 
indicates the total number of strains growing in each condition and the last row displays the number 

















Carbon source R20291 (1) R20291 (2) R20291_2436::CT R20291Δ0330 R20291Δ0342 
No. 
strains 
Acetic Acid - - + - - 1 
Glyoxylic Acid - - + - - 1 
Itaconic Acid - - - + - 1 
alpha-Ketobutyric 
Acid 
- - + + - 2 
alpha-Ketovaleric 
Acid 
- + + + - 3 
DL-Lactic acid - - - + - 1 
L-Lactic Acid - + + + - 3 
Pyruvic Acid - - + - + 2 
Pyruvic Acid Methyl 
Ester 
- - + - - 1 
Succinic Acid - - + - - 1 
Succinic Acid Mono-
Methyl Ester 
- - + - + 2 
m-Tartaric Acid - - - + - 1 
No. growth 
conditions (n=12) 






  R20291 (1) R20291 (2) R20291_2436::CT R20291Δ0330 R20291Δ0342 No. strains 
D-Cellobiose - - + - - 1 
beta-Cyclodextrin - - - + - 1 
Dextrin - - + - - 1 
Dulcitol - + + - - 2 
D-Gluconic Acid - - + - - 1 
alpha-D-Glucose - - + - - 1 
D-Glucose6-Phosphate - + + + - 3 
Maltotriose - - + - - 1 
D-Mannose - - + - - 1 
3-Methyl-D-Glucose - - + + + 3 
alpha-Methyl-D-
Galactoside 
- - + - - 1 
beta-Methyl-D-
Glucoside 
- - + - - 1 
D-Trehalose - - + - - 1 
Turanose - - + - - 1 
No. growth conditions 
(n=14) 
0 2 13 3 1  
Table 6.5. Carbohydrate utilisation in R20291 and R20291∆0342. Growth of R20291 and 
R20291∆0342 compared to each other and two other strains; R20291∆0330 and R20291_2436::CT in 
the presence of different amino acids as carbon sources. This was performed using a Biolog Phenotypic 
Assay on an AN microplate. Green and plus indicates growth and red and minus indicates no growth. 
The last column indicates the total number of strains growing in each condition and the last row 
displays the number of growth conditions each strain grew in. Each strain was tested in seven 
independent assays.  
 
 Valine utilisation 
To further investigate the importance of valine in the growth of R20291 and any differences in 
R20291∆0342, a series of growth kinetics were conducted using the defined minimal media as 
described in 2.7.1.2. Both strains were grown with and without glucose with one of three amino acid 
preparations. In the strains tested, Karasawa et al. identified 11 amino acids required for optimal 
growth of C. difficile and 6 amino acids essential for growth; valine, proline, tryptophan, leucine, 
isoleucine and cysteine. Both of these amino acid preparations were tested in addition to the basic 6 
but with valine removed to confirm this was essential in R20291. Furthermore, it was hypothesised 
that if R20291 were able to grow in the 6 amino acid composition without glucose, i.e. using the amino 
acids as carbon sources only, that this growth would be impaired in the R20291∆0342 strain if valine 





Strains were inoculated directly from plate cultures into individual defined minimal media overnights, 
which matched the final growth conditions and incubated for 24 hours. Only the growth obtained in 
11 amino acids with glucose was sufficient for inoculation of the final growth assays, therefore this 
was used as the inoculant for all conditions. It is likely the drastic change in environment from a rich 
plate culture to very minimal nutrient broth did not facilitate growth in the other conditions in the 
overnight set up. OD595 readings were taken using a plate reader every hour for 8 hours then a final 
reading at 24 hours by removing 100 µl of culture for measurement. The results obtained from growth 
of both strains in all three amino acid set ups are detailed in Figure 6.4.  
Unsurprisingly, the maximum OD595 achieved decreased as the number of amino acids was reduced, 
and both strains exhibited poor growth without glucose. Interestingly, both strains appeared to be 
capable of growing without valine, suggesting this is not essential for growth of R20291. Finally, there 
was no difference in growth between the strains in any of the conditions, suggesting inactivation of 








































Figure 6.4. Growth kinetics of R20291 and R20291∆0342 with differing amino acid compositions. 
Three growth conditions were tested, with and without glucose, using 11, 6 or 5 amino acids, as 
described in the table next to each growth curve. Strains were incubated for 24 hours in defined media 
supplemented with the 11 amino acid composition and glucose, which was then used to inoculate the 
final growth conditions. 100 l of culture was removed every hour for 8 hours and at 24 hours to take 
an OD595 readings using a plate reader. Cultures were set up in quadruplicate and two independent 








This study aimed to characterise the role of the putative permease protein, CDR20291_0342, within 
C. difficile. This was identified in Chapter 3 as a potential vaccine candidate, as the protein array results 
revealed antibody responses to the protein were higher in healthy people compared to those with 
CDI. To investigate its function, the gene was successfully deleted from the chromosome of R20291 
using allele exchange mutagenesis. As this removed the permease component within a putative ABC 
transporter, it was hypothesised the activity of the transporter would also be abolished.  
The N-terminal portion of CDR20291_0342 was found to share high similarity with the N-terminal 
domains of LolE and MacB, components of export ABC transporters. The LolCDE transporter from E. 
coli is involved in sorting of lipoproteins to the outer membrane [550]. Lipoproteins can have a variety 
of potential roles in virulence, including mediating attachment to host cells. Indeed, the C. difficile 
lipoprotein CD0873 was found to be important for binding to Caco-2 cells in vitro [223, 555]. 
Lipoproteins harbour an N-terminal motif known as the lipobox [551]. No lipobox was identified for 
CDR20291_0340, therefore this line of enquiry was not pursued. 
MacB transporters have a number of functions, but were first identified as efflux transporters of 
macrolide antibiotics [553]. They have since been shown to pump out a variety of antimicrobials, 
including colisitin and bacitracin [556, 557]. Antimicrobial resistance (AMR) rates within C. difficile can 
vary depending on geographical location and ribotype prevalence [249]. For example, hypervirulent 
strains within the 027 ribotype harbour a mutation in DNA gyrase, which confers high-level 
fluoroquinolone resistance [123]. Strain 630 is highly resistance to erythromycin via the presence of 
two ermB genes on the Tn5398 transposon inserted on the chromosome [558-560]. These encode for 
methylases, which modify the macrolide binding site within the 23S rRNA, conferring resistance [561]. 
Interestingly, there are some high-level erythromycin resistance strains of C. difficile, such as R20291, 





suggests there are unidentified mechanisms of resistance mediating this phenotype [205]. As 
R20291_0342 shared similarity with the MacB transporter, the mutant and wild-type strains were 
investigated for sensitivity to the macrolide erythromycin and lincosamide lincomycin, however, no 
difference was found in MIC for either antibiotic. It is not uncommon for efflux pumps to increase the 
MIC to a particular antimicrobial rather than be the critical switch between susceptibility and 
resistance [562], and as erythromycin was resistant to the highest concentration tested (512 µg/ml) 
any smaller changes above that would not have been identified.  
No difference was found in susceptibility of R20291 and R20291∆0342 to the common antimicrobial 
peptide bacitracin. AMPs are abundant within the gut and can interrupt the integrity of the cell 
membrane, therefore bacteria require defence mechanisms for survival [563]. ABC transporters are a 
very common mechanism of AMP resistance in Gram-positive species and C. difficile encodes the cpr 
and cln operons for resistance to nisin and galidermin, and cathelicidin, respectively [253, 564]. 
However, it is unlikely this is an exhaustive list of AMP resistance mechanisms within C. difficile, as 
inactivation of the cpr operon did not completely abolish resistance to its associated AMPs. 
R20291∆0342 is a putative efflux transporter and has potential links to efflux of antimicrobials. 
Although there was no difference in bacitracin sensitivity between the wild-type and mutant strains, 
some AMP-resistance mechanisms require pre-conditioning with their related AMP before their 
activity can be detected in vitro, as was the case for the Cpr transporter [564]. This would be an 
interestingly line of investigation, where gene expression could also be monitored and the repertoire 
of AMPs screened expanded to include other AMPs common to the gut environment.  
Despite identification of conserved domains within CDR20291_0342, it may be that the orthologue is 
a product of similar physical functions i.e. efflux, and unrelated to the purpose of the transporter on 
which the protein was modelled. For example, Phyre2 modelled CDR20291_0342 against LolE with 





protein function are limited, high-throughput screening assays can be a valuable source of potential 
candidates for transport.  
Biolog Phenotypic Microarrays have been employed for many bacterial and fungal species and have 
enabled elucidation of nutritional and chemical phenomes [565-567]. Conditions required for 
different cellular pathways can also be screened, as was demonstrated for C. difficile toxin production 
[568]. Disappointingly, our R20291 strain performed poorly in this assay and didn’t grow in the 
majority of conditions tested. Previous work using the Biology Phenotypic Arrays to assess the growth 
of R20291 found this strain in fact had an expanded nutrient utilisation profile compared to other 
strains of C. difficile. This and other studies identified numerous conditions where R20291 was able to 
grow, which was not identified within our assays [38, 565]. The reason behind this poor growth is 
unknown. The other strains (mutants) also appeared to be growing weakly in these biological runs, 
with the exception of R20291_2436::CT which grew well in most conditions. On a technical note, it is 
my experience and others that the organism does not grow well in a 96-well plate format even in rich 
media, so this may have also influenced the Biolog results.  
Despite this, there were some compounds worth following up on, including  L-valine, L-valine plus 
aspartic acid and alpha-keto valeric acid which were unable to support growth of R20291∆0342. As 
these all had the common component of L-valine, the growth of R20291 and R20291∆0342 with and 
without valine was assessed to determine whether the Biolog results were a true phenotype. Previous 
studies have found C. difficile is auxotrophic for valine, along with five other amino acids (proline, 
cysteine, leucine, isoleucine and tryptophan) [32]. However, until now, this hasn’t been assessed for 
R20291. C. difficile strain R20291 was able to grow in minimal media with the 5 amino acids and the 
biggest impact on growth resulted from resulting from removal of glucose, rather than L-valine. 
Furthermore, no difference between the mutant and wild-type strain was found in any of the 
conditions tested. This indicates that the results from the Biolog were most likely due to inter-plate 





Valine is a branched chain amino acid (BCAA) that is an important donor for Stickland fermentation, 
the major source of energy production within C. difficile. Both the valine synthesis pathway and BCAA 
transporter, BrnQ are regulated by CodY, a global regulator within C. difficile, which can bind valine 
directly to suppress transcription of the CodY regulon [507]. Considering the synthesis pathways 
available for valine in C. difficile and the multiple BCAAs that can be used in Stickland fermentation, it 
is slightly surprising that valine is an essential requirement in minimal media. Our results suggest valine 
is in fact not essential for growth of R20291. It may be that carry over from the overnight conditions 
provided adequate valine to support growth, although this is likely to only sustain initial growth (i.e. 
0-2 hours) and be insufficient for the full growth curve obtained. Even so, future work could look at 
removal of any residual media with washing of the pellet or further dilution of the primary cultures 
before inoculation of the test media. Pellet washing was not attempted in these experiments, as when 
trialled previously with minimal media experiments, growth was very slow and the bacteria did not 
demonstrate the typical lag, exponential and stationary growth phases, even in conditions that could 
support normal growth.  
As with the other proteins undergoing phenotypic characterisation, no complements were 
constructed for CDR20291_0342, although here there was less of a requirement as the phenotype of 
the mutant did not differ from wild-type in the conditions tested. The difficulties in working with 
minimal media and carryover were similar to those faced with the CDR20291_0330 growth 
experiments. The contribution of media carryover is important to identify in these experiments to see 
whether valine is truly unnecessary for growth or if the bacteria were relying on the small 
concentration likely to still be in the media. It could also be interesting to extend the growth time to 
see if there are any downstream differences in growth rate, as was seen for 630 when grown in 
ethanolamine. If it were possible to obtain gut filtrate, the growth and antimicrobial sensitivity assays 
could be repeated in these conditions to determine whether an environment more similar to the in 
vivo conditions highlights any differences. In relation to further characterisation of CDR20291_0342, 





experiments should focus on large scale screening methodologies. For example, transcriptomics 
comparing the mutant to wild-type R20291 could determine whether gene expression is altered when 
CDR20291_0342 is inactivated. Any patterns of differential expression obtained could then inform 
functions related to CDR20291_0342. Alternatively, adaptive transcriptomics could be used to 
monitor the gene expression of CDR20291_0342 under different conditions and/or over a period of 
time. For example, adaptive transcriptomics in a mouse model was used to investigate the virulence 
of an epidemic ribotype 027 strain [35].  
CDR20291_0342 was highlighted as a potential vaccine candidate as a higher sera IgG response in 
healthy controls compared to CDI patients was found in both the pan-protein array and using the 
purified protein in an ELISA (albeit not significantly higher for the ELISA). CDR20291_0342 was 
conserved across a number of clinically relevant strains except the ribotype 023 CD305. Although this 
could reduce vaccine coverage, it is unlikely that C. difficile vaccines of the future will be single 
component vaccines and instead will constitute multiple immunogenic components include anti-
colonisation factors and Toxins A and B. From a basic accessibility perspective, ABC transporters are 
encoded within the cell membrane, often with large extra cellular portions or exposed substrate 
binding components, which are therefore available for recognition by the immune system. 
Furthermore, a number of ABC transporters have been identified as immunogenic and assessed in 
vaccine trials [547]. This includes vaccines against Streptococcus pneumoniae, Mycobacterium 
tuberculosis, Moraxella catarrhalis and Yersinia pestis [547, 569, 570]. In relation to C. difficile, a study 
of immunoreactive cell surface proteins included an ABC transporter that was recognised by human 
sera [571], but no ABC transporter antigens have been evaluated in clinical trials, suggesting this is a 








7. Expressing the C. difficile flagella glycan in E. coli  
7.1. Introduction 
C. difficile vaccine development to date has primarily relied on the immunogenic properties of Toxins 
A and B, with all vaccines currently in clinical trials based on these components [375]. However, these 
trials have not led to the production of a licenced vaccine, therefore alternative approaches to C. 
difficile vaccine design is a current imperative. As described in Chapter 1 (section 1.6.3), a number of 
C. difficile antigens have been investigated as vaccine candidates, including spore coat proteins CdeM 
and CdeC, cell surface proteins SlpA and Cwp84 and the surface polysaccharides PS-I, PS-II and PS-III 
[235, 419, 421, 425]. The latter have been tested as glycoconjugates, a very effective vaccine design 
whereby polysaccharides are conjugated to proteins to stimulate a T-cell dependent immune 
response. leading to immunological memory, a process not possible with polysaccharide alone [324]. 
C. difficile PS-II has been chemically conjugated to the diphtheria toxin CRM197, the enterotoxigenic E. 
coli enterotoxin B subunit, and portions of Toxins A and B from C. difficile. Antibodies specific to PS-II 
are raised in mice, but the protective efficacy of this construct is yet to be demonstrated in challenge 
studies [234, 235, 238].  
The glycoconjugates described above were synthesised chemically, a multistep process requiring 
production and purification of the protein and glycan components separately, before they can be 
coupled together and then purified [572]. In more recent years, the development of bioconjugation 
has provided an alternative and in some ways, superior means of synthesising glycoconjugates, by 
exploiting the innate capacity of bacteria to build and conjugate complex glycans [341, 365, 367, 368]. 
Bacterial glycosylation systems can differ in a number of ways, including by which residues within the 
acceptor protein the glycan is attached to, either asparagine (N-linked) or serine/threonine (O-linked). 
Furthermore, these differ by where the glycan is synthesised, which can be directly on to the acceptor 
protein or first built on a lipid linker (e.g. UndPP) within the inner membrane before transfer to the 





systems into E. coli cells can result in an in vivo “vaccine factory”, as demonstrated at the basic 
research level, but also advanced to such a stage that vaccines prepared using this method are now in 
clinical trials [332, 370-372]. Bioconjugation offers a number of advantages over chemical conjugation, 
including ease and safety of working with E. coli cells over the native organism, improved isolation of 
fully synthesised, intact conjugates and fewer rounds of purification, meaning reduced cost of 
manufacture [333]. 
Although the term bioconjugation covers a number of methodologies, arguably the best 
characterised is the use of the OST PglB from the Campylobacter jejuni N-linked glycosylation 
pathway, in E. coli. The N-linked glycan from C. jejuni is first synthesised onto the UndPP lipid linker, 
on the cytoplasmic leaflet of the inner membrane. This is then translocated by a flippase enzyme to 
the periplasm. Here, it is recognised by the OST PglB, which attaches the glycan to the D-X-N-Y-S/T 
recognition sequence within a given acceptor protein [341, 348]. PglB can be expressed in E. coli and 
used to transfer a diverse range of glycan substrates to acceptor proteins [430]. In its simplest form, 
this can be achieved with co-expression of the acceptor protein, OST PglB and biosynthesis locus of 
the desired glycan in a suitable host cell, such as E. coli (Figure 7.1).  
Use of bioconjugation to build a C. difficile specific glycoconjugate offers many advantages over 
chemical conjugation [332, 333]. For example, a multi-component vaccine could be designed using an 
immunogenic surface antigen, such as one or more of those identified by the protein array, fused to 
domains of Toxins A and B conjugated to a C. difficile specific glycan. Previous work has demonstrated 
that recombinant Toxin B fragments chemically conjugated to C. difficile PS-II result in a Toxin B and 





















Figure 7.1. Assembly of glycosylation machinery in E. coli. The OST PglB from C. jejuni can be 
expressed in E. coli and used to attach a broad range of glycans onto a specific acceptor protein. This 
can be achieved by plasmid-mediated expression of each of the three required components; PglB, 
the acceptor protein and the machinery for bulding the glycan, in a suitable host cell such as E. coli.  
 
The aim of this work was to develop the use of bioconjugation, namely the C. jejuni OST PglB in E. coli, 
to build a C. difficile-specific glycoconjugate.This would provide a novel mechanism for the synthesis 
of glycoconjugate vaccines for C. difficile. Furthermore, this would represent the first example of the 
functional transfer of C. difficile glycosylation enzymes into E. coli by combining O-linked and N-linked 
glycosylation systems to build glycan structures, which represents an important contribution to the 











7.2. Using bioconjugation to express the C. difficile flagella glycan  
 Glycan selection 
Interest in the C. difficile glycome has increased in recent years and consequently so has 
understanding of the different sugars within and on the cell surface (Introduction, section 1.3.4.2). 
This review was used to inform glycan selection for inclusion within the C. difficile-specific 
glycoconjugate in this study. It was essential that the native locus encoding glycan synthesis had 
been identified in C. difficile and ideally, characterised, in order to inform the role of enzyme(s) 
required for glycan synthesis. This then informed which genes were required for transfer into E. coli. 
Structural information about the C. difficile glycan was also essential to know what to screen for.  
The glycans decorating the C. difficile flagella have been resolved by mass spectrometry (MS) and 
nucleic magnetic resonance (NMR) and their glycosylation loci characterised in detail for ribotype 
012 (strain 630) and ribotype 027 (strain R20291) [184, 185, 187, 190]. A flagella glycan was 
therefore deemed the most appropriate substrate for this proof of concept study. The flagella 
glycans are O-linked, meaning they are attached to serine and threonine residues within FliC. The 
glycan structures have been resolved by NMR, and are shown in Figure 7.2. The flagella from strain 
630 is decorated with a N-acetyl-glucosamine (GlcNac) joined to a methylated threonine via a 
phosphodiester bond [184]. The flagella glycan from ribotype 027 is more intricate, with a GlcNac 
starting sugar followed by a methylated di-rhamnose and a terminal sulfonated peptidylamido 
glycan moiety [190]. As proof of principle, the first three sugars of the 027 strain glycan (Rha-2-α-
Rha3OMe-3-β-GlcNac-) were selected for transfer into E. coli and glycosylation of an acceptor 
protein. These precursor sugars (GlcNac and rhamnose) should all be readily available in E. coli and 
the glycan harbours an acetoamide group at the C2 position of the reducing end sugar (GlcNac), a 
structural requirement of PglB [364]. It was decided that to begin with the whole glycan wouldn’t be 





addition of individual enzymes rather than the whole flagella glycosylation locus from C. difficile 









Figure 7.2. The structure of C. difficile flagella glycans. The flagella glycan structure as resolved by 
nuclear magnetic resonance (NMR) imaging for (A) strain 630, from Faulds-Pain et al. [184] and (B) 
strain R20291, from Bouche et al. [190]. Above each glycan structure is a simplified schematic of the 
glycan organisation, modified from an image by Dr Alexandra Faulds-Pain; grey box- GlcNac, green 
triangle- rhamnose, red hexagon- peptidylamido glycan moiety, blue circle- phosphate group, purple 
diamond- threonine, black dot- methyl group.  
 
The flagella glycosylation locus begins with fliC, encoding the structural unit of the flagella filament, 
followed immediately downstream by the enzymes required for glycosylation [113, 184, 185] (Figure 
7.3). Glycosyltransferase 1 (GT1) adds the starting GlcNac sugar directly onto serine and threonine 
residues within FliC, followed by addition and methylation of the di-rhamnose by glycosyltransferase 
2 (GT2), encoded by CDR20291_0242. This enzyme is thought to be responsible for both glycosylation 
and methylation of the rhamnose sugars and harbours putative active sites for both functions present 
within its structure [187]. Only GT2 was transferred into E. coli for expression of the glycan, as 














Figure 7.3. The flagella glycosylation locus from R20291. The organisation of the flagella glycosylation 
locus including; the flagella filament gene fliC, the glycosyltransferases GT1 and GT2, responsible for 
addition of the GlcNac and di-rhamnose onto FliC, respectively, an additional glycosyltransferase (GT3) 
and two open reading frames (ORF 5 and ORF 6) required for synthesis of the full glycan structure and 
flgB, which encodes the putative flagella basal body rod gene. Below is the numbering of the genes in 
C. difficile R20291 [113, 184, 187].  
 
 Adaptation of C. jejuni N-linked glycosylation 
The production of glycosylated protein using PglB involves the following three stages:  
1. Synthesis of the glycan in the cytoplasm on an undecaprenol pyrophosphate (UndPP) linker 
within the inner membrane 
2. Transfer of the synthesised glycan into the periplasm by a membrane bound flippase 
3. Periplasmic transfer of the glycan onto an acceptor protein by PglB 
Glycoconjugates previously synthesised using PglB and its associated N-linked glycosylation pathway 
tend to include glycans originating from organisms with complementary pathways of synthesis, 
facilitating their transfer into E. coli. For example, Francisella tularensis already encodes enzymes for 
synthesis of the glycan onto UndPP and for its transfer into the periplasm, enabling successful 
recombinant glycoconjugate vaccine synthesis [365, 573]. C. difficile is a Gram-positive organism, 
which lacks a periplasm, and therefore encodes neither of the enzymes described above (those 
mediating synthesis of the glycan onto UndPP and its transfer into the periplasm). Instead it is 
proposed to follow other mechanisms of flagella glycosylation and synthesise the glycan in the 
cytoplasm directly onto serine/threonine residues (O-linked) within FliC.  
In this proof of concept study, elements of the E. coli O-antigen locus were hijacked for synthesis of 
the C. difficile flagella glycan. The E. coli strain CLM24 does not build its native O-antigen (O16) (Figure 
7.4) due to insertional inactivation of wbbL (a gene necessary for synthesis) with an IS5 element [574]. 
  fliC                  GT1                             GT2                           GT3                   ORF 4       ORF 5       ORF 6          ORF 7               flgB                      





However, as the other genes in the loci are still present, they could be reappropriated. The first step 
requires the synthesis of the glycan onto UndPP in the inner membrane. As the O16 antigen and 
flagella glycan share the same starting sugar, GlcNac, the enzyme responsible for its placement on 
UndPP in E. coli, WecA, was selected as the starting enzyme for C. difficile flagella glycan synthesis. 
This replaces the native C. difficile enzyme, CDR20291_0241 (GT1), which adds GlcNac directly onto 
the flagellin subunit, FliC. Once UndPP-linked GlcNac was available, GT2 from C. difficile could be 
expressed for addition of the di-rhamnose. In relation to the transfer of the flagella glycan into the 
periplasm, E. coli encodes its own flippase, Wzx. The promiscuity of this flippase is under debate, but 
as both the E. coli O16 antigen and C. difficile flagella glycan begin with a GlcNac linked to L-rhamnose, 










Figure 7.4. Biosynthesis pathway of the E. coli O16 antigen. Pathway for synthesis of the E. coli O16 
antigen. This pathway is harboured by K-12 strains of E. coli (standard laboratory strains) but these do 
not produce their O-antigen due to a mutation in wbbL. Glycosyltransferases sequentially add 
individual sugars to UndPP within the inner membrane. The glycan is then transferred into the 
periplasm (Wzx), polymerised (Wzy), then ligated to Lipid A on the surface of the cell (WaaL). Image 
from Hong et al. [575]. 
 
Finally, the C. difficile flagella glycan is O-linked, meaning it is built directly onto serine and threonine 
residues within FliC, whereas PglB is an N-linked system and attaches glycans to asparagine residues 
within a D-X-N-Y-S/T recognition sequon. The C. difficile flagella glycan contains a GlcNac starting sugar 





acceptable protein with a D-X-N-Y-S/T recognition site is provided (section 7.2.3).  The concept of 
different enzymes working cooperatively to synthesise a glycan structure has been reported 
previously, as when the C. jejuni heptasaccahride was expressed in a WecA-positive E. coli, structures 
were identified beginning with both bacillosamine, the native starting sugar, and GlcNac, due to the 


















Figure 7.5. Proposed pathway for the expression of the C. difficile flagella glycan in E. coli. The E. coli 
enzyme, WecA, adds GlcNac onto UndPP then the C. difficile GT2 (CDR20291_0242) builds the 
methylated di-rhamnose structure onto this. The E. coli flippase transfers the glycan into the periplasm 
where it can be recognised by C. jejuni PglB and conjugated to the D-X-N-Y-S/T recognition sequon 








 Acceptor protein design  
Once the desired glycan for synthesis was identified, it was necessary to select a suitable acceptor 
protein to receive the flagella glycan. The estimated size of the glycan when fully synthesised (Rha-2-
α-Rha3OMe-3-β-GlcNac-) is approximately 0.4 KDa, which would result in a minor change to the 
protein molecular weight and therefore difficult to resolve by SDS-PAGE. Gel-based assessment of 
changes to protein molecular weight is a useful indicator of whether glycosylation has occurred, 
providing a quick and easy screening method during optimisation. This is especially important 
considering the lack of antibodies and lectins to this structure and the more time consuming and 
expensive process of MS, using which isn’t feasible for assessing many different strains and growth 
conditions.   
To account for the anticipated minor change to protein mass upon glycosylation, a short reporter 
protein with multiple glycosylation sequons was deemed the ideal candidate for glycosylation. Minor 
size changes are easier to distinguish on smaller proteins and increasing the number of potential 
glycosylation sites, which should increase the number of glycans occupying the protein and therefore 
increase the total shift molecular weight (i.e. if all 7 potential sites were occupied with the 0.4 KDa 
glycan this would equate to a total 2.8 KDa size difference). At this stage the immunogenic properties 
of the protein were not a priority, as the aim of the work was to demonstrate functional transfer of C. 
difficile GT2 into E. coli and synthesis of the Rha-2-α-Rha3OMe-3-β-GlcNac- structure.  
The C. jejuni periplasmic lipoprotein, AcrA, is a well-studied and routinely utilised carrier protein in 
bioconjugation, with multiple glycosylation sequons [341, 430, 577]. At ~40 KDa, its size made it 
unsuitable for this work, as very small changes to protein mass by glycosylation with the flagella glycan 
would not be visible by SDS-PAGE. Therefore a truncated ~13 KDa fragment of the protein harbouring 
a single native glycosylation site was designed for use in this study. This fragment was derived from a 
publication identifying the smallest domain of AcrA that could be glycosylated by PglB, using different 





glycosylation site, the  authors engineered two more glycosylation sequons into the coiled coil domain, 
by changing one residue per sequon at F115D and T145D. All three sites were demonstrated to be 
glycosylated with the C. jejuni heptasaccharide by PglB.  Therefore the region containing all these and 
the flanking lipoyl domain was selected as the acceptor. A fourth native glycosylation sequon also 
present in the sequence was excluded as its distance from other sequons meant accommodating it 
would result in a significant increase in protein size (Figure 7.6a). To further improve the opportunities 
for glycosylation, a “glycotag” was added to the C-terminus consisting of 4 glycosylation sites, 
including the optimal sequon DQNAT, separated by glycine-arginine-glycine linkers [578]. Glycotags 
are commonly employed in bioconjugation to improve glycosylation of the protein, particularly in the 
absence of native or easily engineered internal glycosylation sequons [576]. Finally, an N-terminal 
signal sequence from the E. coli DsbA protein was included for localisation to the periplasm where 










































Figure 7.6. Design and sequence of the acceptor protein, AcrAtag. A short acceptor protein was 
designed for use in the glycosylation experiments, comprising a fragment of the C. jejuni periplasmic 
lipoprotein, AcrA with a four sequon glycotag. (A) Sequence alignment of full length AcrA and AcrAtag. 
The coloured regions represent the different protein domains; β barrel sandwich hybrid (grey), lipoyl 
domain (pink) and coiled coil domain (green) [348]. Arrows denote N-glycosylation sequons, either 
native (filled black), native but not used for AcrAtag (filled red) or engineered (empty). : defines 
residues mutated to reduce proteolytic cleavage. (B) Schematic of AcrAtag with N-terminal DsbA signal 
sequence for localisation to the periplasm, where PglB functions, the peptide sequence containing 
one native and two engineered glycosylation sequons (asterisks), the glycotag comprising four 
glycosylation sequons and a C-terminal 6xHis tag for nickel affinity purification. (C) Full sequence of 
AcrAtag; DsbA signal sequence (double underlined), N-glycosylation sequon (single underlined), 
glycosylated asparagine residue (arrow), mutated residue to generate another glycosylation sequon 







7.3. Glycosylation trials using a multi-vector system  
 System design  
Initial glycosylation trials utilised a multi plasmid system for expression of the different components 
of the glycosylation pathway, including: the acceptor protein AcrAtag, the glycosyltransferase GT2, 
and the OST, PglB (Figure 7.1). This approach has previously been used to build glycoconjugates for C. 
jejuni, F. tularensis, Staphylococcus aureus and Burkholderia pseudomallei [365, 368, 369, 576].  E. coli 
strain CLM24 was selected as the expression host and is derived from the K-12 strain W3110, but lacks 
a functional WaaL ligase. WaaL traffics glycans from the periplasmic UndPP to Lipid A on the cell 
surface. Deletion of waaL  results in accumulation of UndPP-linked glycan in the periplasm [430]. The 
CLM24 strain used also harboured transposon-integrated pglB on the chromosome (CLM24 
cedA::pglB, referred to here as CLM24pglB, kindly provided by Dr Jon Cuccui, LSHTM, London, UK), 
under IPTG inducible expression. Chromosomal integration of pglB removes the need for a third 
plasmid in the system which reduces the burden of plasmid incompatibility when expressing multiple 
constructs within one cell and enables a wider variety of plasmids to be trialled for expression of GT2 
and AcrAtag.  
The pEXT series of plasmids were selected for expression of GT2 and AcrAtag (Figure 7.7). pEXT20, 21 
and 22 all express from a Ptac promoter, but differ in origin of replication and resistance cassette, 
meaning they can be stably maintained within the same cell [581]. They range in copy number from 
high (pEXT20) to low (pEXT21 and pEXT22), so plasmid selection can influence the concentration of 
the desired construct within the cell. As the ideal ratio of glycan to protein was not yet known, AcrAtag 
and GT2 were cloned into both pEXT20 and pEXT21, offering maximum flexibility during optimisation 
of protein expression and glycosylation. pEXT22 was not taken forward as both this plasmid and the 























Figure 7.7. Maps of the pEXT series of plasmids. Plasmids pEXT20 and pEXT21 were used for 
expression of the glycosyltransferase GT2 and acceptor protein AcrAtag. Expression is driven from a 
Ptac promoter in all plasmids but they differ by origin of replication and antibiotic resistance cassette, 
meaning they can co-express within the same cell. Image taken from Dykxhoorn et al. [581].  
 
 Confirming glycosylation of IPTG-inducible AcrAtag  
The gene encoding GT2, CDR20291_0242, was amplified from C. difficile genomic DNA and ligated into 
pEXT20 and pEXT21. The acceptor protein, AcrAtag, was synthesised as a G-block gene fragment 
(section 7.2.3) and  ligated into pEXT20 and pEXT21. Correct construction of all plasmids was 
confirmed with test digestion and sequencing.  
The AcrAtag protein harbours a C-terminal 6xHistag, which was used to confirm protein expression. 
GT2 was not constructed with a 6xHistag due to concerns of the tag interfering with enzyme function. 
CLM24pglB cells harbouring the pEXT20_AcrAtag construct were induced overnight at 37oC with 1 mM 





resin and visualised on an anti-His immunoblot (Figure 7.8). The predicted molecular weight of AcrAtag 
with a 6xHistag, but without the DsbA signal sequence (which is cleaved once the protein is localised 
to the periplasm) is ~17.27 KDa. The anti-His immunoblot detected a protein in the induced strain 
carrying pEXT20_AcrAtag, which was within the expected size range and absent from both the 

















Figure 7.8. Expression of the acceptor protein, AcrAtag. CLM24pglB cells harbouring pEXT20_AcrAtag 
or empty pEXT20 only were incubated overnight at 37oC with 1 mM IPTG and the nickel affinity purified 
soluble fraction was probed for the ~17.27 KDa AcrAtag on an anti-His immunoblot (red). I, induced, 
UI, uninduced.  
 
The functional transfer of the pgl locus encoding the C. jejuni heptasaccharide synthesis machinery, 
into E. coli and glycosylation of a chosen acceptor protein has been demonstrated previously [341]. 
This can be utilised as a useful indicator as to whether the protein of interest can be glycosylated and 
how many sequons are occupied, which in turn indicates the maximum size change to be expected 





where glycosylation occurs and is a permissible substrate for PglB. The pgl glycosylation locus encoded 
on pACYC (pACYCpglΔpglB) contains the complete machinery required for synthesis of the C. jejuni 
heptasaccharide (pglB is chromosomally integrated), including glycosyltransferases to build the glycan 
onto UndPP and a flippase for transport across the inner membrane.  
To confirm AcrAtag could be glycosylated, CLM24pglB or CLM24 cells carrying pEXT20_AcrAtag and 
the constitutively expressed pACYCpglΔpglB was induced overnight at 37oC or 30oC with 1 mM IPTG. 
Cells were harvested and lysed and proteins purified by nickel affinity chromatography then resolved 
by SDS-PAGE and probed by Western blot with anti-His antibody and SBA lectin. The 6XHistagged 
AcrAtag and galactose residues within the C. jejuni heptasaccharide were detected by anti-His 
antibody and the soy bean agglutinin (SBA) lectin, respectively (Figure 7.9 panel 1 and 2). It was 
hypothesised that when expressing AcrAtag in the presence of PglB and the C. jejuni heptsaccharide, 
a ladder of bands would be produced relating to occupation of each glycosylation site with glycan. 
Indeed, when expressed together, a laddering pattern of bands is produced, corresponding to 
unglycosylated material at the bottom, followed by an increasing number of glycosylation sites 
occupied by the ~1.2 KDa heptasaccharide, up to a maximum of 6, one fewer than the total number 
available. Only unglycosylated protein is present when the same constructs are expressed in CLM24 
cells without pglB on the chromosome and glycosylation appears to be more pronounced at 30oC over 
37oC (Figure 7.9).  
The uninduced control only relates to AcrAtag, as the C. jejuni glycosylation locus is under constitutive 
expression. Here, the banding pattern of glycosylation can still be detected, which is attributed to 
leaky expression of the acceptor protein, AcrAtag, as expression of the C. jejuni glycan locus alone 
does not result in any banding pattern (Figure 7.9, panel 3, lane 5). In the uninduced control, no 
unglycosylated protein was detectable by the anti-His antibody, suggesting less protein is favourable 
for glycosylation and results in a more efficient reaction, as the higher bands of glycosylation are 





compared to the anti-His antibody (Figure 7.9). On a repeat expression test of the C. jejuni glycan and 
AcrAtag (Figure 7.9, panel 4), a banding pattern was produced which corresponds to all seven 
glycosylation sites being occupied, confirming all are available for occupancy and AcrAtag is an 


















Figure 7.9. Glycosylation of IPTG-inducible AcrAtag with the C. jejuni heptasaccharide. To confirm AcrAtag could be glycosylated, the constitutive 
pACYCpglΔpglB construct, encoding the C. jejuni heptasaccharide locus was co-expressed with pEXT20_AcrAtag in CLM24pglB and CLM24 (no pglB) cells. 
These were incubated overnight at 37oC and 30oC, then induced with 1 mM IPTG: I, induced, UI, uninduced. AcrAtag was extracted and nickel affinity purified 
then detected by immunoblot using anti-His antibody to AcrAtag and soy bean agglutinin (SBA) lectin to the C. jejuni glycan. The first three panels present the 





 Screening for glycosylation with GT2 
After confirming AcrAtag is a functional acceptor protein for glycosylation by PglB, AcrAtag was co-
expressed with GT2 from C. difficle, from the pEXT21, to screen for glycosylation with the truncated 
C. difficile flagella glycan. CLM24pglB or CLM24 cells expressing AcrAtag (pEXT20) and the C. difficile 
GT2 (pEXT21) were induced overnight with 1 mM IPTG at 37oC or 30oC then processed as described 
above. Purified protein was probed with anti-His antibody only, there is no specific antibody against 
the C. difficle glycan (Rha-2-α-Rha3OMe-3-β-GlcNac). As can be seen in Figure 7.10, there is no 
discernible difference between the molecular weight of AcrAtag when expressed with GT2 in the 
presence or absence of PglB, suggesting glycosylation had not occurred. Indeed it is possible that the 
size shift is too slight to be visible on a gel (maximum 2.8 KDa), as even though the C. jejuni 
heptasaccharide occupied all potential sites, this was to varying degrees and the same phenotype may 
not be achieved across different glycans.  
In case this was an issue with the ratio of acceptor protein to glycan, the glycosylation trial was 
repeated, but with AcrAtag expressing from pEXT21 and GT2 from pEXT20. Although less AcrAtag 
protein would be expected from expression in pEXT21, due to a much lower copy number, no protein 
could be detected by anti-His immunoblot, indicating lack of AcrAtag expression. As this is the same 
backbone (pEXT21) expressing GT2 in the first experiments, it suggests GT2 was also not being 































Figure 7.10. Expression of AcrAtag with C. difficile GT2. pEXT21_GT2, encoding the second 
glycosyltransferase from the R20291 flagella glycosylation locus was co-expressed with 
pEXT20_AcrAtag in CLM24pglB and CLM24 cells (no pglB). These were incubated overnight at 37oC 
and 30oC and induced with 1 mM IPTG; I, induced, UI, uninduced. AcrAtag was extracted and nickel 
affinity purified then detected by immunoblot using anti-His antibody to AcrAtag.  
 
7.4. Glycosylation trials using a single plasmid system  
 System design  
To overcome the difficulties in working with pEXT21, and the lack of protein/glycan expression an 
alternative system was adopted where AcrAtag and GT2 could be expressed from the same plasmid. 
This is advantageous as the acceptor protein and glycosyltransferase would be under the induction of 
different inducible promoters (IPTG and L-arabinose), meaning their expression could be 
independently controlled. Furthermore, expression from the L-arabinose promoter is easier to titrate,  
meaning the expression of its downstream gene(s) can be more tightly controlled. The dual expression 
plasmids, namely the pCH series, were constructed by Gibson assembly (Methods, section 2.4.6) using 






cassette [582]. Dr Ian Passmore designed the system of incorporating pEC415 and pEXT20 to build a 
dual expression plasmid, which I then adapted for incorporation of my constructs.  
All plasmids were constructed using Gibson assembly, amplifying the plasmid and insert fragments 
with complimentary overhangs to permit joining of the two constructs. This was firstly used to build 
pEXT20 and pEC415 harbouring either AcrAtag or GT2 which were then used in synthesis of the dual 
expression plasmids. The backbone of the pCH series of plasmids was a 3485 bp fragment of the 
backbone of pEXT20 (3913 bp), containing the pBR322 origin of replication, the lacI repressor gene, 
the ampicillin resistance cassette, the IPTG-inducible Ptac promoter for expression of AcrAtag or GT2 
but without tet gene, as tetracycline resistance was not required. In place of the tet gene, a 4176 bp 
fragment of pEC415 was inserted, containing the L-arabinose inducible PBad promoter, again 
controlling AcrAtag or GT2 and the araC gene, for activation of expression. Plasmids were built with 
L-arabinose inducible GT2 and IPTG inducible AcrAtag (pCH01) or in the opposite arrangement 
(pCH05) (Figure 7.11).  
In addition to building these plasmids with the standard GT2 construct used previously, a codon 
optimised version of GT2 was designed using the IDT Codon Optimisation tool and ordered for 
synthesis as a G-block. Codon usage differs between species and therefore some may be less well 
translated when expressed in the non-native strain, depending on the pool of tRNA available. By codon 
optimising the sequence for E. coli, protein expression can be improved. Multiple attempts were made 
to insert codon optimised GT2 into pEXT20 or pEC415 and many clones were obtained following 
ligation and transformation of Top10 cells. However, all clones harboured multiple SNPs or deletions 
within the coding region of GT2, suggesting codon optimised GT2 may be toxic to the cell, so this was 






















Figure 7.11. Plasmid maps of pCH01 and pCH05. Schematic of the plasmid design for dual expression 
of GT2 (CDR20291_0242) and AcrAtag. The pBR322 origin of replication, ampicillin resistance cassette, 
lacI gene and IPTG inducible promoter all originate from pEXT20, whereas the L-arabinose inducible 
promoter and araC gene originate from pEC415. The table describes the inducer for each construct in 
plasmids pCH01 and pCH05.  
 
 Confirming glycosylation of L-arabinose-inducible AcrAtag  
Before testing of the dual plasmids was undertaken, it was first necessary to confirm expression and 
glycosylation of the L-arabinose inducible AcrAtag. pEC415_AcrAtag, which was constructed as an 
intermediate plasmid during generation of pCH05, was transformed into CLM24pglB and CLM24 cells 
harbouring pACYCpglΔpglB (Figure 7.12) then induced overnight at 37oC or 30o with 1 mM IPTG for 
induction of PglB and a range of L-arabinose concentrations (0.05, 0.1, 0.2, 0.4, 1%), to determine 
whether varying the amount of acceptor protein available could improve efficiency of the 
glycosylation reaction.  
As seen with pEXT20_AcrAtag, a ladder of eight bands corresponding to occupation of all seven 





an increase in AcrAtag and at 37oC over 30oC, the latter being the opposite finding compared to using 
pEXT20_AcrAtag (Figure 7.9). It is noteworthy that in this test, more protein appears to be available 
for glycosylation at 37oC, which could explain the improved glycosylation (Figure 7.12). In summary, 
AcrAtag expressing from a L-arabinose inducible promoter can be glycosylated and remains a suitable 































































Figure 7.12. Glycosylation of L-arabinose-inducible AcrAtag with the C. jejuni heptasaccharide. To 
confirm AcrAtag could be glycosylated when expressed from an L-arabinose inducible promoter, the 
constitutive pACYCpglΔpglB construct, encoding the C. jejuni heptasaccharide locus was co-expressed 
with pEC415_AcrAtag in CLM24pglB and CLM24 cells. These were incubated overnight at 37oC and 
30oC and induced with 1 mM IPTG and a range of L-arabinose concentrations. AcrAtag was extracted 
and nickel affinity purified then detected by immunoblot using anti-His antibody to AcrAtag and SBA 
lectin to the glycan. The three panels present the immunoblot images with anti-His only (red), anti-
glycan only (green) then the two overlaid. When both AcrAtag and the C. jejuni heptasaccharide are 






 Screening for glycosylation with dual expression pCH01 and pCH05 plasmids  
Following detection of AcrAtag glycosylated with the C. jejuni heptasaccharide using pEC415_AcrAtag, 
glycosylation was tested for using pCH01 and pCH05. Either pCH01 or pCH05 was transformed into 
CLM24pglB and CLM24 cells, which were induced overnight with 1 mM IPTG for PglB and GT2/AcrAtag 
induction and a range of L-arabinose concentrations (0.05, 0.1, 0.2, 0.4, 1%) for GT2/AcrAtag 
induction, at 37oC or 30oC. Cells were lysed and the soluble fraction nickel affinity purified then 
visualised on an anti-His immunoblot. This revealed no obvious shift in molecular weight of AcrAtag 
under any condition, suggesting glycosylation had not occurred (Figure 7.13).  
Additional His-reactive bands were detected above the band corresponding to AcrAtag alone, which 
can be indicative of glycosylation as seen with the C. jejuni heptasaccharide Figures 7.9 and 7.12). The 
shift in size of these bands is larger than the predicted size of the glycan, but this could be a result of 
polymerisation of the glycan by the native E. coli O-antigen polymerase, Wzy. However, after 
increasing the intensity of the green channel, the same banding pattern was identified in the PglB-




















Figure 7.13. Expression of the pCH01 and pCH05 dual expression plasmids in the presence of PglB. To screen for glycosylation of AcrAtag when expressing 
from pCH01 or pCH05, plasmids were transformed into CLM24pglB or CLM24 cells and induced overnight at 37oC or 30oC with 1 mM IPTG and a range of L-
arabinose concentrations. AcrAtag was nickel affinity purified then detected by anti-His immunoblot (green). (A) Nickel affinity purified protein isolated after 





To confirm the absence of detectable glycosylation so far was not the result of lack of GT2 expression, 
the GT2 construct was built with an additional C-terminal 6XHistag. This was inserted into pEC415 
using Gibson assembly, transformed into CLM24pglB and CLM24 cells and induced overnight with 
0.05, 0.1, 0.2, 0.4 or 1% L-arabinose at 37oC and 30oC, with or without induction of PglB (1 mM IPTG) 
(Figure 7.14). Purified protein was visualised using an anti-His immunoblot which revealed a protein 
approximately 72 KDa in size, corresponding to the estimated size of GT2-His, confirming it is 
expressing in the presence and absence of PglB. Expression appears to be improved at 37oC compared 
with 30oC, although higher levels of the glycosyltransferase doesn’t necessarily equate to improved 
glycosylation. Expression is also increased in the absence of PglB, an unsurprising result considering 












Figure 7.14. Confirming the expression of GT2. pEC415_GT2-His harbouring a C-terminal 6XHistag 
was expressed overnight at 37oC and 30 oC with a range of L-arabinose concentrations. Protein was 
extracted and the soluble fraction nickel affinity purified before probing on an anti-His immunoblot.  
 
GT2 in the dual expression plasmids was replaced with the 6XHis-tagged construct to produce pCH03 
and pCH07, allowing the monitoring of GT2 expression throughout the different screening conditions. 
(Figure 7.15). As before, these were synthesised using Gibson assembly, amplifying GT2-His and the 




















Figure 7.15. Plasmid maps of pCH03 and pCH07. Schematic of the plasmid design for dual expression 
of GT2-His (CDR20291_0242) and AcrAtag. The pBR322 origin of replication, ampicillin resistance 
cassette, lacI gene and IPTG inducible promoter all originate from pEXT20, whereas the L-arabinose 
inducible promoter and araC gene originate from pEC415. The table describes the inducer for each 
construct in plasmids pCH03 and pCH07.  
 
Testing conditions mirrored those used for pCH01 and pCH05 (Figure 7.13), using both CLM24pglB 
and CLM24 strains with induction at 37oC and 30oC and a titration of L-arabinose for AcrAtag induction. 
In order to improve purification of AcrAtag and only isolate protein available for glycosylation, 
periplasmic extractions were performed prior to nickel affinity purification. Here, periplasmic protein 
is released using a sucrose buffer with lysozyme while the inner membrane is left intact, meaning the 
cytoplasmic protein is not released. Following removal of the periplasmic fraction, the cytoplasmic 
protein was also extracted using freeze thaw cycles, which should contain GT2-His.   
No glycosylation was visible when GT2-His and AcrAtag were expressed from pCH03 or pCH07 (Figure 
7.16). Again, the additional bands above AcrAtag only were present in both CLM24pglB and CLM24 
lanes. There was some contamination of cytoplasmic protein, as demonstrated by the presence of an 
anti-His reactive band at ~ 70 KDa, the size of GT2. When the cytoplasmic fractions were probed on 





suggesting expression of the glycosyltransferase was not the reason for lack of detectable 
glycosylation. Cytoplasmic fractions were not tested for pCH03 as GT2-His was clearly visible in the 



























Figure 7.16. Expression of the pCH03 and pCH07 dual expression plasmids in the presence of PglB. To screen for glycosylation of AcrAtag when expressing 
from pCH03 or pCH07, plasmids were transformed into CLM24pglB or CLM24 cells and induced overnight at 37oC and 30oC with 1 mM IPTG and a range of L-
arabinose concentrations. AcrAtag was isolated in periplasmic extractions and GT2-His in a cytoplasmic extraction (pCH07 only), then both nickel affinity 
purified and detected by anti-His immunoblot (green). (A) Nickel affinity purified protein isolated after induction of pCH03 and (B) Nickel affinity purified 





7.5. Glycosylation trials using an in vitro glycosylation system   
A recently published study demonstrated a method for in vitro protein glycosylation using a “one pot” 
system [583]. The system uses individual culture lysates harvested from an E. coli expressing the 
acceptor protein, E. coli expressing the glycan (which is built onto the lipid linker in the membrane) 
and E. coli expressing the OST (i.e. PglB). These are incubated together overnight before nickel affinity 
purifying the protein from the reaction and screening for glycosylation. By preparing the components 
for glycosylation separately, the ratio of glycan, acceptor protein and PglB can be more easily 
manipulated. This system also offered the possibility to overcome one of the major potential barriers 
of PglB-mediated production of the C. difficile glycan, the transfer of the glycan from the cytoplasm to 
the periplasm, as the promiscuity of the E. coli Wzx flippase is still not defined. It is assumed that PglB 
requires glycan built on UndPP but that this is not restricted by which leaflet of the inner membrane 
this is presented on, therefore removing the need for transfer to the periplasm. We therefore 
hypothesised that in vitro glycosylation could avoid the step of transferring the glycan into the 
periplasm, enabling glycosylation of AcrAtag with the truncated C. difficile flagella glycan. 
 Testing GT2 using in vitro glycosylation   
To confirm correct set up of the in vitro assay and glycosylation of AcrAtag in this system, both this 
protein and the Exotoxin A (ExoA) acceptor protein from Pseudomonas aeruginosa, containing nine 
glycosylation sequons, were incubated with lysate harbouring UndPP-linked C. jejuni heptasaccharide. 
Individual cell lysates containing PglB, C. heptasaccharide built onto UndPP and ExoA were provided 
by Dr Elizabeth Atkins. A 1 L culture of the acceptor protein (pEXT20_AcrAtag) in CLM24 cells was 
induced overnight with 1 mM IPTG at 37oC then washed with S30 buffer before lysing on the cell 
homogeniser. Lysates of the acceptor protein, C. jejuni heptsaccharide and PglB were incubated in S30 
buffer overnight at 30oC, then the protein nickel affinity purified before probing on an anti-His, SBA 





heptasaccharide were incubated without PglB, with a strong anti-galactose signal produced when PglB 





















Figure 7.17. In vitro glycosylation of ExoA and AcrAtag with the C. jejuni heptasaccharide. Lysates of 
the C. jejuni heptasaccharide, PglB, and acceptor proteins ExoA or AcrAtag were incubated together 
overnight at 30oC, then the nickel affinity purified protein probed on an anti-His (red), anti-galactose 
(green) immunoblot. (A) standard exposure, (B) increased exposure for the green channel.  
 
A single band at ~ 20 KDa was detected representing AcrAtag only, which increased to multiple bands 
when PglB was added. Glycosylation had occurred, demonstrated by the increased size of AcrAtag, 





in vitro (Figure 7.17). This may be a result of insufficient glycan availability, as in the in vivo system the 

















Figure 7.18. In vitro glycosylation trials of AcrAtag with the C. difficile GT2. Lysates of CLM24 
harbouring GT2-His, PglB, and AcrAtag were incubated together overnight at 30oC, then the nickel 
affinity purified protein probed on an anti-His (green) immunoblot.  
Once the conditions for glycosylation had been established, the C. jejuni heptasaccharide was replaced 
with GT2-His. Between 200 and 300 µl of GT2-His donor was incubated with either 25, 50 or 100 µl of 
AcrAtag. As before, reactions were incubated overnight at 30oC, then the protein was nickel affinity 
purified and probed on an anti-His immunoblot (Figure 7.18). There was no difference in 
electrophoretic mobility of AcrAtag under any condition, suggesting glycosylation had not occurred. 
Only a faint band was detectable corresponding to GT2-His.  
Previous investigations with AcrAtag have detected additional His-reactive bands below the size of 





detected here, more pronounced than previous assays which is assumedly also a result of proteolytic 
cleavage which have been enhanced in the upscaled set up and further incubation steps. Inclusion of 
a protease inhibitor in further experiments may limit this effect, although this would first have to be 
tested within the control assay to ensure protease inhibitor did not interfere with the in vitro 
glycosylation reaction using the C. jejuni glycan.  
7.6. The E. coli O13 antigen  
The lack of glycosylation detected so far necessitated the investigation of alternative mechanisms of 
expressing the truncated flagella glycan. One such option was the use of a glycan from a different 
species that shared structural similarity with the glycan of interest. Depending on similarity, this could 
then be expressed directly or further modified to achieve the desired structure. Furthermore, use of 
a complementary glycan with a native synthesis pathway, more compatible with PglB could also 
increase the chance of glycosylation.  
In the search for a suitable glycan, it was important to identify a structure with the correct linkage 
between the monosaccharides, as this stereochemistry can dictate antibody binding and reactivity. A 
number of L-rhamnose rich glycans were identified, such as from the Group A Streptococcus surface 
polysaccharide, but this lacked the required linkage [584]. Interestingly, the O-antigen of Shigella 
flexneri 2a harbours a GlcNac starting sugar followed by an L-rhamnose, attached via a β1-3 linkage, 
identical to the starting sugars of the R20291 flagella glycan (Figure 7.19). Although the next L-
rhamnose is attached by a second β1-3 linkage, this is attached to the subsequent L-rhamnose by a 
β1-2 linkage, also found in the R20291 glycan. Modification of the O-antigen synthesis locus, may 
enable production of the desired structure, including removal of the glucose moiety on the first L-
rhamnose, but first it was necessary to determine whether the acceptor protein (AcrAtag) could be 

























Figure 7.19. Glycan structures that share similarity with the truncated C. difficile flagella glycan. (A) 
NMR resolved structure of the structure of full length flagella glycan from C. difficile R20291, adapted 
from Bouche et al. [190], (B) organisation of the O-antigen from Shigella flexnerii serotype 2a, adapted 
from Perepelov et al. [585], (C) organisation of the E. coli O13-antigen [585] and (D) comparison of the 
loci encoding the S. flexnerii 2a O-antigen (F2a) and E. coli O13-antigen (O13), adapted from Liu et al. 
[586] (by permission of Oxford University Press).  
 
As a serious cause of diarrheal disease, S. flexnerii is a Category 2, Schedule 5 pathogen, requiring 
increased security measures in the laboratory. Fortunately, the E. coli O13 antigen harbours an 
identical O-antigen, in structure and synthesis locus and antibodies cross react against both O-antigens 
[587]. As this strain does not require the same security precautions, it was selected for glycosylation 





 Glycosylation with the E. coli O13 antigen in vivo  
E. coli strain O13 was acquired from the Public Health England Culture Collection and transformed 
with pEXT21_pglB or pGVXN115, encoding a copy of PglB harbouring two amino acid alterations [588], 
rendering it inactive. Both pEXT20_AcrAtag and pEC415_AcrAtag (IPTG induced or L-arabinose 
induced, respectively) were trialled as the acceptor for glycosylation, for IPTG or L-arabinose induction 
of AcrAtag, respectively. Strains were induced overnight at 37oC or 30oC with 1 mM IPTG and 0.2% L-
arabinose, or a titration of L-arabinose for pEC415_AcrAtag. Cells were harvested and lysed, protein 
purified using nickel affinity chromatography then resolved using SDS-PAGE and probed on an anti-
His immunoblot (Figure 7.20). Using pEXT20_AcrAtag, it was not possible to detect glycosylation in 
any condition. At ~ 1.05 KDa, a single copy of the O13 antigen is much larger than the truncated flagella 
glycan (~0.4 KDa), meaning unglycoyslated and glycosylated species would be more easily 
distinguished by gel electrophoresis. Furthermore, if all seven glycosylation sequons were occupied, 
this could result in a total 7.399 KDa shift, in addition to potential polymerisation by the E. coli Wzy 
polymerase.  
In a second trial, using L-arabinose induced AcrAtag, a ladder of bands was produced above the 
unglycosylated AcrAtag when induced at 37oC with pEXT21_pglB. This was absent in the CLM24 trial 
and therefore indicates glycosylation had occurred. Furthermore, the 15 bands detectable above the 
unglycosylated AcrAtag, exceed the seven glycosylation sites available, suggesting polymerisation of 
the glycan. In relation to the trials performed at 30oC, the same laddering effect is absent, and again 
the suspected oligomerisation of AcrAtag was demonstrated in the presence and absence of PglB. 
There is a single band immediately above the unglycosylated AcrAtag, which potentially could be 




















Figure 7.20. Glycosylation of AcrAtag with the E. coli O13-antigen. AcrAtag was expressed in a strain of E. coli O13 with PglB or inactivated PglB at 37oC and 
30oC then the soluble protein fraction nickel affinity purified. Protein samples were probed on an anti-his immunoblot (green). (A) Expression of IPTG inducible 





As demonstrated with the C. jejuni glycosylation trials, anti-glycan antibodies and lectin offer an 
additional means of confirming glycosylation and are often more sensitive to detecting glycosylated 
protein than anti-his antibody alone. An antibody specific for the S. flexnerii O-antigen, and 
consequently the E. coli O13 antigen was purchased, but unfortunately no reactivity was detected. 
This is likely due to low antibody concentrations as the antibody purchased was not optimised for use 
in immunoblotting. In summary, incubation of AcrAtag with PglB and the E. coli O13 antigen results in 
glycosylation and polymerisation.  
Although not possible within the time constraints of this work, the next steps would be to investigate 
mutagenesis of the O13-antigen synthesis loci from E. coli to generate a modified glycan to fully match 





7.7. Discussion   
The work in this chapter aimed to utilise the recombinant PglB glycosylation pathway in E. coli to 
engineer a C. difficile specific glycoconjugate, the first example of bioconjugation with a C. difficile 
glycosyltransferase. Despite multiple attempts using a number of approaches, it was not possible to 
detect glycosylation of our targeted acceptor protein with the truncated C. difficile flagella glycan, via 
a recombinant C. difficile glycosyltransferase (GT2). This may be due to issues with detection of such 
a small glycan (only 0.4 KDa) or the lack of transfer of the glycan onto the AcrAtag carrier protein. To 
account for this, AcrAtag from the glycosylation trials using the dual expression system and in vitro 
glycosylation are being analysed by NMR, which is a much more sensitive means of glycan detection.  
The aims of this work were not only novel in relation to C. difficile, but also within the field of 
bioconjugation, in terms of building an O-linked glycan from a Gram-positive organism using an N-
linked system in a Gram-negative bacteria. These aims feed into ongoing research developing the 
bioconjugation “toolbox”, identifying novel enzymes and pathways and using unrelated enzymes 
together to expand the bioconjugation repertoire. For example, Hug et al. demonstrated the synthesis 
and conjugation of a human Lewis antigen in E. coli, using enzymes from Haemophilus influenzae and 
Helicobacter pylori [589]. Despite these successes, this remains a challenging research area, requiring 
optimisation and modification of glycosylation pathways and identification of new glycoengineering 
tools. Glycoengineering in E. coli is a technology in its infancy and all new attempts to couple and 
express different protein/glycan combinations add to the knowledge bank. This study designed, 
expressed and glycosylated a novel acceptor protein, AcrAtag, for use in glycosylation trials. Many 
common acceptors are between 40 and 70 KDa. Therefore, AcrAtag represented an alternative short 
reporter peptide that could be glycosylated at all seven sites and enable detection of modification 
with smaller glycans.  
In relation to production of the flagella glycan using bioconjugation, if it is confirmed by NMR that 





Firstly, is the glycan being synthesised onto UndPP within the inner membrane? As C. difficile doesn’t 
encode the enzyme for this step, WecA from E. coli was used which transfers GlcNac to UndPP [575]. 
As GlcNac is also the starting sugar for the flagella glycan it was hypothesised that C. difficile GT2 would 
then build the rhamnose residues onto this GlcNac.  However, this requires GT2 to interact with a 
membrane-associated GlcNac residue, differing from its proposed native function of building the L-
rhamnose residues onto GlcNac conjugated to the flagella filament [335]. Glycan synthesis can require 
cooperative action of glycosyltransferases, meaning GT2 function may have been impaired without its 
native accompanying glycosyltransferases, or in the presence of the unfamiliar WecA. For example, 
the streptococcal virulence-associated protein, Fap1, is only decorated with its O-linked glycan upon 
interaction of two of the required glycosyltransferases [590]. In the absence of suitable methods to 
isolate UndPP-linked glycan still attached to the inner membrane, it is difficult to determine whether 
the glycan is being synthesised. However, no glycosylation was detected in the in vitro system either. 
This system is hypothesised to only require glycan built onto UndP, irrespective of its position in the 
cytoplasm or periplasm. Therefore, if glycosylation is not occurring, this suggests the glycan is not 
being built. It it also possible that glycan synthesis was inefficient and the levels of UndPP-linked glycan 
were too low to be available as a substrate for PglB. It was possible to glycosylate both AcrAtag and 
ExoA with the C. jejuni heptasaccharide, therefore it is possible that currently, the assay requires 
plenty of optimised acceptor protein and glycan for high-level glycosylation.  
The next step is whether the glycan is being translocated across the membrane. This is normally 
performed by a dedicated flippase enzyme, but as this is not required by the native pathway of glycan 
synthesis in C. difficile, it was necessary to reappropriate the E. coli O16-antigen flippase, Wzx, present 
in the strains of E.coli used in this study (CLM24). As the flagella glycan and O16 antigen share the 
same two starting sugars, albeit with different linkages, it was proposed that this would be a sufficient 
level of similarity for translocation. However, the promiscuity of Wzx in E. coli and other species is 
subject to debate. Early research demonstrated full complementation of WzxO16 with a variety of E. 





[591]. However, further work found this transfer from the cytoplasm to the periplasm was only 
possible when Wzx was overexpressed from a plasmid. This was compensating for inefficient 
translocation compared to the native Wzx, as confirmed through chromosomal integration of the 
flippases [575]. The translocation rate was also improved if the target antigen starting sugars were 
shared between Wzx homologs.  
From a methodological stand point, overexpression of Wzx could be exploited to improve 
translocation and accordingly glycosylation, although the consequences of overexpression of a large 
membrane bound transporter on a cell already expressing an OST, glycosyltransferase and acceptor 
protein would have to be considered. Furthermore, understanding of the activity and specificity of 
Wzx is still limited and does not explain the activity of all Wzx homologs. For example, diverse antigens 
from Pseudomonas aeruginosa and Yersinia pseudotuberculosis all share the same Wzx [592, 593] and 
recent work building a human-like glycan (Man3GlcNAc2) in E. coli O16 did so without the provision 
of a specific flippase, suggesting this relied on WzxO16 [594]. A non-Wzx based mechanism of 
translocation could also be explored, such as the ABC transporter PglK from C. jejuni. This was 
demonstrated to almost fully complement the activity of two different E. coli Wzx flippases and 
transfer their corresponding glycans, suggesting promiscuity [359].  
 Glycosylation of AcrAtagwith the flagella glycan was also attempted using in vitro glycosylation but 
no glycosylation was detected. As discussed, it was hypothesised that this system could overcome the 
need for translocation of the glycan to the periplasm if PglB only requires UndPP-bound glycan, 
regardless of membrane orientation. However, the PglB-glycan interaction and the in vitro 
glycosylation method is not yet well enough understood to confirm this, meaning the translocation 
step could be essential for PglB recognition in the in vitro system. A way of evaluating this would be 
to set up an in vitro glycosylation reaction whereby ExoA is incubated with either C. jejuni 





is inactivated so UndPP-linked glycan would be locked in the cytoplasmic leaflet of the inner 
membrane. 
Use of an E. coli O13-antigen, which shares structural similarity with the truncated flagella glycan 
offered a promising alternative approach of producing a C. difficile- specific glycoconjugate. 
Glycosylation of AcrAtag with the full O13-antigen structure was demonstrated, which provided a 
strong starting position for further modification of the locus to obtain the desired composition. The 
O-antigen locus of E. coli O13 has been identified and annotated, but the function of the individual 
glycosyltransferases have not yet been characterised. The number of sugars and linkages exceed the 
number of identified glycosyltransferases (two), suggesting these enzymes may perform multiple 
roles. Use of non-native glycans has been discussed previously, particularly using the pre-existing pool 
of diverse E. coli O-antigens. A combination of PglB with different E. coli O-antigens have been used 
to build glycoconjugates specific for the human blood group B antigen and the Vi antigen from 
Salmonella enterica serovar Typhi [595, 596]. The latter included manipulation of the encoding 
synthesis loci to obtain a structure that cross reacted with antibodies raised against the native glycan. 
On the other hand, Nishiuichi et al. demonstrated cross reactivity between the O-antigens of E. coli 
O157 and Citrobacter freundii and suggested use of the latter in production of an anti-O157 
glycoconjugate vaccine, which would avoid working directly with the pathogenic strain [597].  
The C. difficile flagella glycan was selected for use as a well characterised glycan for the purposes of 
proof of principle experiments rather than as a strong immunogenic candidate. The immunogenic 
properties of the glycan are unknown and flagella glycans can be associated with immune evasion, 
masking immunogenic epitopes on the flagella filament [339]. The exact immunogenic properties 
remain to be determined but it may be that the whole or a shorter fragment of the glycan is 
immunogenic, indeed L-rhamnose is typically immunogenic as it is not found in human glycans, which 





The surface polysaccharide PS-II has already received attention for inclusion with an anti-C. difficile 
vaccine, and antibodies have been raised to the structure in vivo [234-237]. This anionic polymer has 
been found in all C. difficile strains investigated to date, and the structure has been solved [231, 233]. 
However, the enzymes responsible for each step of synthesis remain rather elusive, partially due to 
the detrimental effects on the cell when genes within the synthesis loci were deleted or knocked 
down, as is the case for PS-II [218]. Therefore, although interesting, this was an unsuitable target for 
study, based on current knowledge. Based on partial annotation of the putative synthesis locus, genes 
encoding homologs of UndPP and for translocation across the membrane have been identified [218], 
suggesting similarity with the N-linked glycosylation pathway using PglB. If it were possible to transfer 
this locus into E. coli for use with PglB, one stalling point could be the presence of a mannose at the 
reducing end of the glycan, a non-permissible substrate for PglB. However, specificity of this 
interaction is subject to debate, and the utilisation of modified PglB by structure guided directed 
evolution or use of PglB orthologs from different species may be able to overcome this in the future 
[332].   
The absence of a screening method for the glycan, such as a specific antibody was a limitation of this 
study. Although protein samples are currently under analysis by NMR, this is not a suitable method 
for screening for glycosylation for multiple different candidates from many different conditions. 
Regarding synthesis of the truncated flagella glycan from C. difficile, although it was possible to 
confirm C. difficile GT2 was being expressed in E. coli by anti-His Western blot, it was not possible to 
confirm whether the enzyme was active in the conditions for testing, either in the E. coli cell or the 
cell-free system. A means of answering this would be to use the native components from C. difficile 
within the cell-free system. As a panel of flagella mutants are already available for R20291, the lysate 
of a C. difficile strain expressing GT1 and GT2 but not FliC could be incubated in the cell-free system 
with recombinant FliC. If the native components are able to glycosylate the flagella protein then this 





There remains no licensed vaccine for C. difficile and the current toxin-based formulations have not 
yielded any success. A vaccine offers an effective control strategy for CDI, especially for at risk groups 
and glycoconjugate vaccines in particular have been highly successful in the control of a number of 
very problematic infections with over a billion doses used each year [332].  Despite the challenges 
described here, the rapid advances being made in the relatively new field of bioconjugation means 
future progress may enable the development of C. difficile- specific bioconjugation. It may be that 
identification of new technologies or enzymes allow this, such as the use of O-linking rather than N-


















C. difficile can cause severe infections that are fatal for those at risk. Patterns of CDI have seen distinct 
changes over the past 40 years, including the emergence of hypervirulence and the associated 
epidemic in the mid-2000s through to the increase in community infections still seen today [69, 112, 
129, 131]. As a prominent nosocomial infection, CDI poses a significant financial burden on healthcare 
systems, and although this is difficult to quantify, one study reported CDI cost over $4.8 billion to US 
acute care facilities in 2008 [600]. Current treatment options are hampered by the high rates of 
recurrent infections and their inability to provide long-term protection from CDI [61, 62]. There are 
significant benefits to be gained from an effective C. difficile vaccine, particularly one that is able to 
prevent both infection and colonisation simultaneously. The colonisation aspect is very important as 
those who are asymptomatically colonised with C. difficile have been identified as a major source of 
C. difficile transmission, therefore targeting these people could result in a steep decrease in 
transmission [47, 51]. 
Vaccine development is complex and challenging. A prime example of this is the lack of a currently 
marketed C. difficile vaccine, despite a number of high-profile clinical trials [408-410]. Furthermore, 
no colonisation specific antigens are yet to reach Phase II or III clinical trials. This study aimed to use a 
large-scale protein array to identify immunogenic C. difficile proteins, that could be useful anti-
colonisation factors for a vaccine, then characterise a subset of these to further understand their role 
in the bacteria. Additionally, this study aimed to explore the development of glycoconjugate vaccines 
for C. difficile, which have received limited attention. Specifically, this focused on developing 
bioconjugation technology for the synthesis of a C. difficile specific glycoconjugate.  
8.1. Identifying novel immunogenic candidates from C. difficile  
A C. difficile specific pan-protein array was the starting point for identification of novel immunogenic 
protein candidates in C. difficile. A protein array of this scale is the first of its kind for C. difficile and 





controls. In Chapter 3, the results from this array were utilised to identify protein candidates where a 
higher response was recorded in the healthy control group compared to those with CDI, which 
suggested a response to these proteins provided protection from infection. These antigens 
constituted a range of mainly surface proteins that were conserved across important clinical strains of 
C. difficile. 
Non-toxin antigens investigated so far tend to be well characterised surface proteins of C. difficile such 
as flagella or surface layer proteins [395, 417, 424, 425]. We identified seven potential vaccine 
candidates on the pan-protein array where a higher IgG response was found in the healthy control 
group compared to the CDI patients, suggesting that prior exposure had resulted in circulating 
protective antibodies. These proteins have not yet been investigated in C. difficile either in terms of 
their immunogenicity or function within the pathogen, which demonstrates the utility of the pan-
protein array in the identification of novel candidates. The reactivity of these antigens was confirmed 
using a specifically designed ELISA to minimise the cross reactivity to E. coli, which is also present in 
the human gut therefore there is likely to be substantial reactivity to this bacteria, especially 
considering the array proteins are printed within E. coli lysate [380]. Although samples are exposed to 
E. coli lysate prior to screening on the array, this is unlikely to remove all background. Therefore, by 
purifying these proteins it made it easier to detect any specific antibody responses without the 
interference of E. coli background. Of the three array proteins purified and analysed by ELISA, the 
mean signal intensity was higher in the CDH group for proteins CDR20291_0342 and CDR20291_2697 
compared to the CDI, albeit not significantly so. This is most likely due to the small sample size tested 
in the ELISA. As discussed in Chapter 3, the inclusion of these purified proteins in a down selected 
array will help further analyse their immunogenicity.  
Furthermore, previous studies have used ELISAs to analyse antibody content in sera from those 
convalescing from CDI [275, 470]. This could be explored further here, as the advantages with this 





combination with the available metadata, will enable comparison of antibody responses in recovered 
patients compared to those with continuous colonisation or those with recurrent CDI infections. 
Analysis of mucosal humoral immunity to CDI is limited [270, 274, 276, 427], which may in part be due 
to the ease in isolating blood samples as opposed to biopsies or intestinal lavage [399, 475, 476]. 
Faecal samples are a non-invasive means of analysing this response, but as seen with the protein array 
screening, cross-reactivity and high background of these samples can be problematic. Furthermore, 
concentration of antibody in the stool can be influenced by the size of sample and number of bowel 
movements [601]. ELISA based screening of stool samples has been previously achieved, using purified 
toxin antigens [274]. Using purified proteins like those produced in this study could be a means of 
analysing these stool samples, either in an ELISA or by printing the purified protein on an array, with 
reduced background due to the purification process removing most if not all of the E. coli 
contaminants.  
The antigens selected for investigation were found in different clinically relevant strains of C. difficile, 
which is important for vaccine coverage. Due to time constraints it wasn’t possible to take this further, 
but future work should focus on the safety and suitability of these potential vaccine candidates as well 
as their efficacy in vivo. Firstly, antibiotic use is a major risk factor for CDI, due to their devastating 
effects on the gut microbiome, so if CDI can be prevented when patients have been treated with 
antibiotics for an unrelated condition, this would improve clinical outcomes, prevent CDI and 
therefore prevent further antibiotic use. It would need to be determined whether there is any cross 
reactivity between these potential vaccine candidates and the healthy microbiota, including other 
Clostridial species, which could it could lead to unintended effects on the microbiome. To answer this, 
work in ongoing with the WTSI, to look for orthologs of the protein antigens discussed here within 
their database of sequenced strains of the gut microbiome. Furthermore, only one strain from each 
clade was available for analysis of protein conservation throughout C. difficile. Although the standard 
reference strains were used, there is still variation seen within clades and therefore future work should 





The second consideration is the interaction between the protein antigens and the antibodies that 
recognise them. Direct antibody/antigen interactions can be assessed using an immunofluorescence 
test [602]. However, it is not sufficient for the antigen to simply bind the protein, this must either 
prevent growth or result in an opsonophagocytic response, to clear the infection from the host [603]. 
The genes encoding the three proteins selected for in vitro characterisation, CDR20291_0330, 
CDR20291_3343 and CDR20291_0342 were all successfully deleted from the R20291 genome, 
suggesting these are not essential for survival of C. difficile, in the in vitro conditions tested. Instead, 
an opsonophagocytosis assay can be used to monitor antibody activity, an assay used routinely for 
evaluation of responses to pneumococcal vaccines, among others [604-606]. They could also be tested 
in a mouse model to determine whether they clear CDI or reduce the infective titre.  
Finally, and most importantly for any vaccine candidate, is analysis of the antigens of interest in vivo, 
which was not possible in this study due to time, funds and absence of testing facilities. Use of a 
hamster or mouse model offer their own individual benefits and can elucidate immune response to 
these antigens. A standard approach to begin with would test each antigen individually, starting with 
intra-peritoneal administration with an adjuvant, of which many are available including Alum or 
inactivated cholera toxin [395, 396, 420, 422, 425-427]. Following initial inoculation, two booster 
doses would be administered before antibiotic-induced gut dysbiosis and challenge with CDI. CDI 
results in acute infection in hamster models, therefore animal survival can be taken as a measure of 
protection. As hamsters are very sensitive to the C. difficile toxins, inactivated copies of Toxins A and 
B which have been previously utilised as vaccine candidates these should be co-administered with the 
antigens of interest. Alternatively, a number of mouse models are available that can enable the 
exploration of other measures of protection such as colonisation. This method of assessing in vivo 
immunogenicity and protection for antigens of interest has been widely used for the study of C. 
difficile antigens [238, 267, 390, 396]. Following on from this, for promising candidates, oral routes of 





systems have been investigated such as pectin beads and expression on the surface of B. subtilis 
spores, the latter of which was particularly successful [268, 276, 422]. 
8.2. In vitro characterisation of novel candidates 
Three immunogenic array candidates were selected for further characterisation of their role within 
the cell; CDR20291_3343, the putative tip of the T4P, CDR20291_0330, a putative cobalt transport 
protein and CDR20291_0342, a putative ABC transporter. Characterisation and understanding of the 
role of a vaccine or drug target is an important aspect of its development. Other non-toxin C. difficile 
antigens investigated in previous studies have been functionally characterised, including in C. difficile 
FliC and SlpA [273, 447].  
Deletion of pilK (R20291Δ3343) was deemed to result in a pili-negative strain, as previous work  found 
PilA1 (the major pilin subunit) was not secreted in this mutant, suggesting lack of pilus assembly (Neil 
Fairweather, personal communication) [541]. In order to confirm this, work is ongoing with a 
collaborator at the Francis Crick Institute, using scanning electron microscopy to identify the pili on 
the surface of C. difficile. In future assays, ideally a pilA1 mutant would also be used as no pili are 
observed on the surface of C. difficile by microscopy in a pilA1 mutant [195].   
In this study, a panel of pili and/or flagella negative strains were constructed in R20291 to assess C. 
difficile motility in the presence and absence of c-di-GMP. In high c-di-GMP, fliC expression is 
repressed whereas pili expression is induced, via the action of c-di-GMP on riboswitches upstream of 
these loci [198]. This study found the pilK mutant was still capable of surface motility and in fact it was 
inactivation of the flagella that almost abolished this motility. A previous study found inactivation of 
the putative pili ATPase, pilB1, abolishes surface motility on agar, but this was conducted in a flagellate 
strain [208]. This suggests a role for FliC in surface motility, even though fliC is down-regulated in the 
presence of high-level c-di-GMP [198]. 
One issue in the assessment of pili phenotypes in C. difficile is the need for c-di-GMP to induce 





overwhelming effect on the cell, and the levels of c-di-GMP can influence the observed phenotypes 
[203]. Therefore, future work could investigate introducing an inducible promoter onto the 
chromosome before fliC and the pili locus to improve control and measure the effects of each in a 
more defined manner, without the need for c-di-GMP. Alternatively, pilK could be overexpressed in 
the the flic/pilK mutant strain constructed in this study. These approaches could also be expanded to 
include analysis of other pili and flagella related phenotypes, such as cell aggregation and biofilm 
formation [189, 195, 198, 212].  
The putative transporters CDR20291_0330 and CDR20291_0342 were also investigated for their role 
in C. difficile. In the conditions tested, it was not possible to determine a cobalt or B12 related 
phenotype in vitro for R20291Δ0330. In many bacterial species ethanolamine is used as a carbon 
source and is regulated by a B12 dependent riboswitch [501, 502]. Although we were unable to identify 
a B12 riboswitch upstream of or within the ethanolamine utilisation operon, to our knowledge, no B12 
independent ethanolamine utilisation pathways have been identified in bacteria [504].  Herein, 
studies with ethanolamine found regulation of this pathway may differ from that previously reported 
for another enteric Gram-positive pathogen, E. faecalis, as only the histidine kinase (EutW, CD1911) 
part of the two-component regulatory system was required for ethanolamine utilisation [503]. It was 
also found that growth in ethanolamine could not be detected until 64 hours into the growth kinetics, 
as opposed to 10 hours in a previous study of C. difficile [36].  
Regarding characterisation of CDR20291_0342, a Biolog assay found this strain did not grow on L-
valine, L-valine and aspartic acid and alpha-ketovaleric acid, but the wild-type did. To further 
investigate this, R20291 and R20291Δ0342 were grown in minimal media including six amino acids 
previously documented to be essential for C. difficile growth (valine, isoleucine, leucine, proline, 
cysteine and tryptophan) [32]. There was no difference in growth between the strains, but both strains 





used to inoculate the growth assays were also in minimal media, these contained valine to support 
the sufficient growth required to use this as an inoculant, therefore there is a chance for carry over.  
It would be prudent to investigate these mutants in a mouse model of CDI, to determine whether 
inactivation of these transporters impairs colonisation. Furthermore, this would also be beneficial 
from a nutritional requirement stand point, as it is very challenging to recreate the niche environment 
of the gut in vitro, particularly as culturing C. difficile in minimal media can be difficult. This would be 
particularly interesting for the CDR20291_0330 mutant, as previous work found a mutant of cobT, a 
component of the B12 biosynthesis pathway, was unable to colonise mice, suggesting it is essential for 
survival within the host [498]. B12 is also believed to be a very important vitamin for the gut 
microbiome, and 80% of sequenced species within this community utilise corrinoids (compound group 
including B12) [607, 608].  
8.3. Bioconjugation of a C. difficile-specific glycoconjugate 
Chapter 7 describes the investigation of bioconjugation technology as a means of producing a C. 
difficile specific glycoconjugate, using a truncated form of the flagella glycan from strain R20291. This 
involved a novel approach of combining enzymes from Gram-positive and Gram-negative bacteria to 
create a hybrid system to synthesise a native O-linked glycan using an N-linked glycosylation system.  
A short, novel acceptor protein, AcrAtag, was designed and shown to be glycosylated at all seven sites 
with the positive control, C. jejuni heptasaccharide in vitro. However, despite multiple attempts using 
a range of techniques, it was not possible to identify glycosylation of this acceptor protein with the 
desired trisaccharide from the C. difficile flagella glycan. Indeed, each trisaccharide would only result 
in a 0.4 KDa change in size to the protein, and therefore successful glycosylation of all seven sites 
would result in a 2.8 KDa size shift which may not be visible by SDS-PAGE and subsequent immunoblot. 
Furthermore, there was still a distinct band of unglycosylated AcrAtag in the glycosylation experiments 
with the C. jejuni heptsaccharide. Therefore, if only a small percentage of the total protein is being 





ongoing with a collaborator at Leiden University, to screen for the glycan addition using the much 
more sensitive method of nuclear magnetic resonance (NMR) imaging.  
Different techniques were applied to try and identify potential barriers to glycosylation such as 
transfer of the glycan from the cytoplasm to the periplasm using the E. coli flippase enzyme Wzx, the 
specificity of which is debatable [575, 591]. This transfer was not an issue for the C. jejuni glycan as it 
encodes its own specific flippase. The in vitro glycosylation approach was used as this is hypothesised 
to not require the translocation step and instead just needs glycan presented on a lipid-linked glycan 
(i.e. bound to UndPP) [583]. Again, glycosylation was not detected by SDS-PAGE and immunoblot, but 
herein we still have the issue of minimal size change, so this will also be screened by NMR as above. If 
glycosylation has not occurred, it is possible the glycan is not being synthesised. In vitro glycosylation 
is a relatively crude method so an alternative way to study glycan synthesis and glycosyltransferase 
interaction would be to purify the individual components required for glycosylation (PglB and each 
glycosyltransferase) then incubate these together in vitro [609, 610]. This would however require 
substantial optimisation to purify functional enzymes and identify appropriate buffers for their 
activity.  
The R20291 flagella glycan was selected for reconstitution in E. coli as it has been characterised in 
detail, meaning this understanding could inform selection of the enzymes to be used for 
bioconjugation [187]. These were proof of principle experiments to determine whether this hybrid 
glycosylation system could be developed. Glycosylation of bacterial flagella has been linked to immune 
evasion, by masking important immunogenic epitopes [339], suggesting this might not be useful as a 
vaccine candidate. However, Valiente et al. found no difference between TLR5 recognition of the 
flagella protein in the absence and presence of the glycan, suggesting it does not mask this epitope 
[187, 611]. Alternatively, Bouche et al. suggested immune evasion could be achieved by the terminal 
peptidylamido sugar moiety which is taurine-like, an amino sulfonic acid associated with immune 





absent or truncated flagella glycan has not been studied in animal models, therefore although it is 
possible the flagella glycan is involved in immune evasion in C. difficile, this remains hypothetical [187, 
190]. Antibodies to the flagella filament proteins FliC and FliD were identified in 15/17 patients with 
CDI [612] while another study found antibody responses to FliC and FliD were higher in a control group 
compared to those with C. difficile associated disease [273].  
It may be that a portion of this glycan is immunogenic. For example, removal of the peptidylamido 
sugar terminus, would expose the GlcNac di-Rhamnose targeted in this study. Rhamnose is often 
immunogenic as it is a non-human glycan [598]. Mutants in the R20291 glycosylation pathway, leading 
to truncated glycans have already been constructed [187], but not tested in an animal model, 
therefore this is a promising next step. Use of a mouse model could aid understanding of virulence 
and colonisation of R20291 strains with truncated or absent glycans. Furthermore, Martin et al. used 
glycan arrays to screen sera from mice immunised with the full repeating unit from surface 
polysaccharide PS-I against different portions of this repeat unit, to identify the epitopes within this 
that are immunogenic and recognised in vivo [419]. A similar study could be conducted for the flagella 
glycan to determine, which portions if any, are recognised by the immune system. Regarding glycan 
arrays, this approach could be expanded for analysis of the C. difficile glycome, screening both full and 
truncated glycans and polysaccharides to identify immunogenic structures and epitopes. Combining 
this with the existing bank of patient samples already collected for the protein array could produce 
informative results.  
Although in this study it has not been possible to conclusively determine whether transfer of the 
glycan was successful, this does not mean it is an unachievable approach, especially considering this 
study was the first attempt at using bioconjugation with C. difficile. Bioconjugation is a large and 
rapidly advancing discipline, meaning new glycoengineering enzymes and techniques are continually 
being explored and developed. It would be interesting to use the results of a C. difficile glycan array 





vaccine. Although OST (the enzyme that transfers the glycan to the acceptor protein) substrate 
specificity can be a stalling point in glycan transfer, this is the subject of ongoing investigation. Recent 
research has expanded the repertoire of glycans it is possible to transfer, through modification of 
existing OSTs to reduce specificity as well as identification of new OSTs with different specificities, 
such as those from deep sea vent bacteria [349, 350, 362, 613].  
8.4. Future work and final conclusions 
In addition to those described above, there are a number of areas for future work. For the protein 
array, the next steps should address those points raised in Chapter 3, including assessment of antibody 
functionality and characterisation of patient groups. As discussed, there are many factors influencing 
susceptibility to CDI other than antibody response. Over the course of this study, additional metadata 
has become available which is currently being processed, and will hopefully aid in understanding of 
co-morbidities and immune status of the patient. As anti-Toxin antibodies are correlated with 
exposure to C. difficile, anti-toxin response in each patient could be used as a marker of prior exposure 
to the pathogen. Regarding quality of the microbiome and its role in protection from CDI, the WTSI 
has sequenced the gut microbiome for a subset of patients using their faecal samples, so using this 
data can hopefully provide a picture of microbiome quality of the patient, which can then be linked 
back to the antibody response of the patient and their experience of CDI. Furthermore, as discussed, 
protein arrays use recombinantly expressed protein which may not fold to match the structure 
presented in vivo. As conformational epitopes are an important part of antigen recognition, flow 
cytometry could be used to monitor antibody binding to whole bacterial cells [614, 615]. 
Regarding those proteins taken forward for phenotypic characterisation in C. difficile, there are a 
number of avenues to pursue. Firstly, it would be prudent to whole genome sequence the three gene 
deletion mutants to ensure no other single nucleotide polymorphisms have been accrued during the 
mutagenesis process which may be influencing the phenotypes seen. For CDR20291_0330, it would 





cytometry has previously been used to study the activity of bacterial multidrug efflux transporters in 
E. coli, Francisella tularensis and Burkholderia pseudomallei, [616, 617] so a similar approach could be 
applied for C. difficile, using labelled cobalt and B12. As discussed in Chapter 4, the environment of the 
gut is difficult to replicate in vitro and is subject to a whole host of other factors, particularly 
metabolism of nutrients by the microbiome. It would therefore be interesting to look at the 
metagenomics and metabolomics of ethanolamine utilisation by the gut microbiome, but data related 
to this is currently limited [618]. One recent study in weaned rats found administration of 
ethanolamine resulted in a shift in microbiome metabolism towards lipid and sugar biosynthesis and 
metabolism and altered the composition of the predominant species composing the microbiome 
[619]. For CDR20291_0342, inactivation of the gene encoding this protein did not appear to impact 
valine utilisation, therefore CDR20291_0342 and its associated transporter may have an alternative 
target. It would be interesting to assess the protein composition of the cell membrane in the mutant 
compared to the wild-type to determine whether another transporter is compensating for the loss of 
CDR20291_0342. This could also give an indication as to the function of CDR20291_0342. Bacterial 
transporters have a wide array of functions, meaning there are a lot of possible phenotypes that could 
be screened for. For example, Edwards et al. identified two permease proteins in C. difficile which 
inhibit sporulation [620]. There are a number of areas for future work regarding CDR20291_3343 and 
the role of the pili and flagella in surface motility, particularly as both the flagella and c-di-GMP are 
within complex regulatory networks. This could be further investigated by looking at RNA seq data 
with and without c-di-GMP induction, ideally using colonies from the surface motility plates, 
comparing those within the original spot of inoculant to those on the outer edge. This could aid in 
identifying which proteins are contributing to the surface motility phenotypes in the different 
conditions reported here. For example, it may be that flagella proteins are required for function of the 
pili but these are not expressed in the fliC mutant. To follow up on this, it would be interesting to 
investigating C. difficile strain M120, which lacks the F3 region of the flagella operon, including the 





The longer-term objective of this work, would be to take the promising candidates from the pan-
protein array and fuse these to appropriate glycotag for bioconjugation with the desired glycan. This 
could use the binding protein CDR20291_0330, as a recent study demonstrated glycosylation of the 
streptococcal binding protein PiuA with the capsule 4 polysaccharide using bioconjugation resulted in 
protection in mice that was comparable to the commercially available vaccine [367]. Another 
alternative formula would be use of the binding domain of Toxin B, which can retain immunogenicity 
when fused [238, 578]. Further validation of the potential bioconjugation techniques evaluated here, 
provide an exciting concept for future vaccine designs.  
This study has used a combination of approaches to both expand our understanding of C. difficile 
biology and contribute to the ongoing development of a C. difficile vaccine. The results of a large-scale 
screen of the C. difficile proteome were used to identify immunogenic proteins for potential inclusion 
within a C. difficile vaccine. Characterisation of these in vitro has led to further understanding of both 
motility and nutritional metabolism of C. difficile. Finally, the use of bioconjugation was explored for 
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Table A1. Plasmids used in this study 
Plasmid Description Source 
pETM11 
Protein expression vector with T7 promoter and kanamycin 
resistance cassette and N-terminal 6XHistag with TEV 
cleavage site.  
[1] 
pETM11_0342 S1 pETM11 with residues 41-242 from CDR20291_0342 This study 
pETM11_0342 S3 pETM11 with residues 439-728 from CDR20291_0342 This study 
pETM11_3343 pETM11 with residues 34-479 from CDR20291_3343 This study 
pETM11_0330 pETM11 with residues 22-95 from CDR20291_0330 This study 
pETM11_3155 pETM11 with residues 34-56 from CDR20291_3155 This study 
pETM11_2253 pETM11 with residues 1-132 from CDR20291_2253 This study 
pETM11_2697 pETM11 with residues 43-209 from CDR20291_2697 This study 
pETM11_2640 pETM11 with residues 1-191 from CDR20291_2640 This study 
pMTL82151 
Replication-defective C. difficile vector with chloramphenicol 
resistance cassette and multiple cloning site (MCS).  
[2] 
pMTL82151_0342 
pMTL82151 vector harbouring allele exchange mutagenesis 
cassette for CDR20291_0330 between BamHI and HindIII  
This study 
pMTL82151_3343 
pMTL82151 vector harbouring allele exchange mutagenesis 
cassette for CDR20291_3343 between EcoRI and BamHI  
This study 
pMTL82151_0330 
pMTL82151 vector harbouring allele exchange mutagenesis 
cassette for CDR20291_0342 between EcoRI and XmaI  
This study  
pEXT20 
High copy number protein expression vector with ampicillin 
resistance cassette and Ptac promoter.  
[3] 
pEXT21 
Low copy number protein expression vector with 
spectinomycin resistance cassette and Ptac promoter. 
[3] 
pEXT21_pglB pEXT21 carrying full length PglB  [4] 
pGVXN115 pEXT21 carrying inactivated PglB GlycoVaxyn 
pACYCpglΔpglB  
pACYC carrying pgl glycosylation locus from Campylobacter 
jejuni with inactivated PglB 
[5] 
pEXT20_AcrAtag pEXT20 harbouring the acceptor protein AcrAtag This study 
pEXT20_GT2 pEXT20 harbouring CDR20291_0242 (GT2)  This study 
pEXT21_AcrAtag pEXT21 harbouring the acceptor protein AcrAtag This study 
pEXT21_GT2 pEXT21 harbouring CDR20291_0242 (GT2)  This study 
pEXT20_GT2-His 




Ampicillin resistant with PBAD promoter and araC gene for L-
arabinose induction 
[6] 
pEC415_AcrAtag pEC415 harbouring the acceptor protein AcrAtag This study 
pEC415_GT2 pEC415 harbouring CDR20291_0242 (GT2) This study 
pEC415_GT2-His 








Backbone of pEXT20 with PBAD promoter and araC gene from 
pEC415, enabling dual expression of constructs under IPTG 
and L-arabinose induction 
This study 
pCH01 AcrAtag under Ptac promoter and GT2 under PBAD promoter  This study 
pCH03 
AcrAtag under Ptac promoter and GT2-his under PBAD 
promoter  
This study 
pCH05 GT2 under Ptac promoter and AcrAtag under PBAD promoter  This study 
pCH07 




Chloramphenicol resistant, constitutive expression of the 
diguanylate cyclase dccA 
[7] 
pECC17 
Chloramphenicol resistant, inducible expression of the 
diguanylate cyclase dccA, under control of Ptac promoter 
[7] 










































Table A2. Oligonucleotides used in this study.  
 
 Primer Name Sequence  
Construction of plasmids for expression of recombinant C. difficile proteins in E. coli 
PAC_R20291_3155_F TACGGGGTCTCCCATGTACAGCAAAGTACAGGAGTC 
PAC_R20291_3155_R TCGAAGAATTCTTACTTGGGGTAAAACTGCTTTG  
PAC_R20291_0342S1_F TACGGGGTCTCCCATGCGCAGCGCTCAACAAGCCGA 
PAC_R20291_0342S1_R TCGAAGAATTCTTAGGAGTTGTCCAACGTACCGT  
PAC_R20291_0342S3_F TACGGGGTCTCCCATGGACATCCAGAATAAGAACGG 
PAC_R20291_0342S3_R TCGAAGAATTCTTAACGAGCGGTCATTTTATCAA  

















T7_terminator  GCTAGTTATTGCTCAGCGG 


































































i. Plasmid construction for expression of C. difficile recombinant proteins in E. coli  
The DNA sequence encoding each C. difficile protein selected for recombinant expression in E. coli 
was firstly codon optimised for E. coli using the IDT Codon Optimisation Tool 
(https://www.idtdna.com/CodonOpt), then ordered for synthesis as gBlock gene fragments. Regions 
of each protein selected for expression were cloned into the pETM11 plasmid using two different 
strategies.  
pETM11_0342S1, pETM11_0342S3, pETM11_0330 and pETM11_3155 were built using 
restriction/ligation cloning. pETM11 encodes an N-terminal his-tag followed by a TEV cleavage site 
and NcoI recognition site for insertion of the coding sequence. However, inserting the coding 
sequence into this site would result in a frame shift, meaning the correct protein would not be 
expressed. To overcome this, the sequence encoding for the region of the protein to be expressed 
was amplified from the gBlocks using primers PAC_R20291_name of protein, which contained a 5’ 
restriction sites, BsaI on the forward primer and XhoI on the reverse. BsaI is a type II endonuclease 
which cuts downstream of its recognition site so the cutting site was designed to leave an overhang 
complimentary to pETM11 following digestion with NcoI but which would result in loss of the final 
guanidine nucleotide of the NcoI recognition sequence, meaning the coding sequence would be in 
frame. pETM11 was digested with NcoI and XhoI then ligated with the respective insert. Following 
ligation, transformation into electro-competent Top10 cells and plated on LB agar supplemented 
with kanamycin (to select for pETM11). Plasmids were checked by colony PCR using the T7 promoter 
and terminator primers flanking the insertion site and test digest with XbaI and XhoI, then confirmed 





pETM11_2640, pETM11_2697 and pETM11_3343 were built using Gibson assembly, as described in 
Methods, section 2.4.6. The backbone of pETM11 was amplified to include complimentary 
overhangs to 2640, 2697 or 3343, using primers pETM11_name of protein. Protein sequences were 
amplified to include complimentary overhangs to pETM11, using primers  PAC_R20291_name of 
protein_Gib. Amplified sequons were then joined as described in Methods section 2.4.6 and 
screened for insertion of the insert using PCR with the T7 primers followed by DNA sequencing with 
the T7 primers.   
ii. Plasmid construction for allele exchange mutagenesis 
pMTL82151_3343, pMTL82151_0330 and pMTL82151_0342 were constructed using restriction 
ligation. SOE PCR was used to generate DNA constructs comprising two ~1200 bp DNA regions 
homologous to those flanking the gene for deletion, with 42 bp of the original gene remaining and 
restriction sites at the 5’ and 3’. Construction of the allele exchange cassette Initially required 
amplification of the two homology arms using primers HA1_F and HA1_R or HA2_F and HA2_R (each 
of these is preceded by R20291_name of construct) with 21 bp of the beginning or the end of the 
gene for deletion incorporated, respectively. HA1_R and HA2_F primers contain overhangs 
complimentary to the other primer, so amplification of both products using HA1_F and HA2_R 
generates one construct with both regions of homology and 42 bp of the gene for deletion. These 
joined constructs were amplified with restriction digest sites for cloning into pMTL82151. 
pMTL82151 was digested with restriction enzymes matching those for digestion of the insert which 
were; EcoRI and BamHI for 3343, EcoRI and XmaI for 0342 and BamHI and XmaI for 0330. Following 
ligation, transformation and selection on Lb chloramphenicol plates and plasmid isolation all 
plasmids were screened by PCR using with MUTSEQ_f and MUTSEQ_r, which cover the whole 
construct, including homology arms, or SEQ_F or SEQ_R which flank the gene for deletion (each of 
these primers is preceded with R20291_name of construct). Potential gene deletion mutants were 
confirmed by DNA sequencing with M13_F and M13_R. Additional information about the screening 





iii. Plasmid construction for bioconjugation 
Glycosyltransferase 2. 
For expression of the C. difficile flagella glycosyltransferase 2 (GT2) in E. coli, the gene encoding this 
protein, CDR20291_0242, was amplified from C. difficile gDNA using primers R20291_0242_F and R 
These primers added EcoRI and SacI restriction sites to the 5’ and 3’ of the GT2 sequence, 
respectively so these could be cloned into the pEXT20 and pEXT21 vectors which share the same 
multiple cloning site (MCS), using restriction/ligation cloning. Plasmids were screened for the GT2 
insert using test digestion with EcoRI and SacI and sequencing with primers pEXTseq_F and 
pEXTseq_R.  
Acceptor protein.  
For expression of the acceptor protein AcrAtag, this was first ordered for synthesis as a gBlock then 
amplified with primers acrAtag_F and acrAtag_R These primers added EcoRI and HindIII restriction 
sites to the 5’ and 3’ of the GT2 sequence, respectively so these could be cloned into the pEXT20 and 
pEXT21 vectors which share the same multiple cloning site (MCS), using restriction/ligation cloning. 
Plasmids were screened for the GT2 insert using DNA sequencing with primers pEXTseq_F and 
pEXTseq_R. 
Dual expression plasmids.  
For construction of one plasmid expressing both the acceptor protein acrAtag and GT2 (pCH01, 
pCH03, pCH05 and pCH07), Gibson assembly was utilised for all plasmids (Methods, section 2.4.6). 
Codon optimised R20291_0242 was ordered for gBlock synthesis with a C-terminal 6XHistag. 0242, 
0242His and AcrAtag were inserted into pEXT20 and pEC415 before synthesis of the dual expression 
plasmid (AcrAtag and GT2 were already inserted into pEXT20, as described above). For insertion of 
0242 into pEC415, the insert was amplified with 0242_pEC415_f and 0242_pEC415_r and the 
plasmid amplified with pEC415_0242_f and pEC415_0242_r. For insertion of 0242his into pEC415, 





with pEC415_0242his_f and pEC415_0242his_r. For insertion of 0242his into pEXT20, the insert was 
amplified with 0242hisgib_f and 0242hisgib_r and the plasmid amplified with pEXT20hisgib_f and 
pEXT20hisgib_r. For insertion of AcrAtag into pEC415, the insert was amplified with 
acrAtag_pEC415_f and acrAtag_pEC415_r and the plasmid amplified with pEC415_acrAtag_f and 
pEC415_acrAtag_r. All constructed plasmids were screened using DNA sequencing with primers 
pEXTseq_f and r for pEXT and pEC415screen_f and r for pEC415. The same primers were used for 
synthesis of pCH01, pCH03, pCH05 and pCH07. For pCH01, pEXT20_acrAtag was amplified with 
pEXT20_0242tag_f and r and pEC415_GT2 was amplified with pEC415_0242his_f. For pCH03, 
pEXT20_acrAtag was amplified with pEXT20_0242tag_f and r and pEC415_GT2-His was amplified 
with pEC415_0242his_f. For pCH05, pEXT20_GT2 was amplified with pEXT20_0242tag_f and r and 
pEC415_AcrAtag was amplified with pEC415_0242his_f. For pCH07, pEXT20_GT2-His was amplified 
with pEXT20_0242tag_f and r and pEC415_AcrAtag was amplified with pEC415_0242his_f. All 
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Table D1. Results of the C. difficile specific pan-protein array pilot study. IgG responses of patients 
with severe (CDP) or mild CDI (CDN) CDI, patients with diarrhoea but presumed negative for 












Avg CDN + 
CDP all 
P CDA vs 
CDN+CDP 
all 
P CDA vs 
CDN + CDP 
plasma 
baseline 





vs CDN + 
CDP all 
CDR20291_0227 6144.904 7236.992 6444.779 8808.842 0.134563 0.8774 0.65397 1.37 e-09 
CDR20291_0253 2929.519 2061.185 2496.648 3776.027 0.628835 0.810764 0.63782 0.000107 
CDR20291_0297-s5 7514.212 5416.108 5630.54 7427.788 0.976856 0.551462 0.506568 6.83 e-06 
CDR20291_0330 458.9038 1382.569 2772.714 3655.602 4.31 e-06 0.016092 0.271572 0.22 e-10 
CDR20291_0337 2076.827 2530.531 2399.714 3292.967 0.265747 0.836679 0.850785 3.75 e-06 
CDR20291_0342 659.9808 2764.108 3076.801 3434.668 3.53 e-07 0.014683 0.024184 0.953175 
CDR20291_0351 1633.673 2923.377 2898.214 3508.464 0.065406 0.413163 0.580447 5.51 e-06 
CD0386-s3 5907.519 2197.108 4876.366 6174.393 0.913644 0.694244 0.15155 0.003545 
CDM120_0411 6452.135 6202.415 6078.844 6051.099 0.697008 0.737936 0.8369999 0.003055 
CDR20291_0424 4223.288 1355.338 2288.17 3073.255 0.326864 0.12365 0.021706 4.25 e-08 
CDR20291_0516 2917.673 1994.031 2409.388 3376.512 0.694831 0.687362 0.520863 1.8 e-05 
CDR20291_0561 3170.212 1868.492 2552.279 3181.422 0.991648 0.597553 0.270667 0.000121 
CDR20291_0575 3173.596 3245.031 3541.214 4594.399 0.539788 0.915216 0.817912 1.82 e-06 
CDR20291_0582-s5 3259.058 1317.415 2338.018 3520.512 0.830152 0.49249 0.157111 0.007659 
CDR20291_0584-s2 3080.673 1362.454 2117.083 3148.56 0.952295 0.427461 0.17608 0.001936 
CDR20291_0584-s6 4192.904 1865.608 2741.583 3513.89 0.468682 0.159364 0.33205 0.045754 
CDR20291_0671 7803.442 5364.492 5843.779 7404.087 0.880914 0.49509 0.423467 1.95 e-05 
CDR20291_0971 2889.75 152.9923 1573.257 3117.86 0.844591 0.301737 0.22826 0.635679 
CDR20291_1023 2831.981 5391.492 4488.931 4886.165 0.116289 0.3752 0.357941 0.00016 
CDR20291_1276 4511.135 2272.8 2184.54 3101.213 0.586.213 0.381.1789 0.429434 5.75 e-05 
CDR20291_1282 1863.058 1239.377 2103.714 3128.021 0.263601 0.260274 0.608231 0.007803 
CDR20291_1360 771.9038 2335.954 2186.779 3610.375 0.01167 0.318176 0.518304 0.020121 
CDR20291_1379 3532.904 2166.762 2574.844 3345.399 0.836152 0.349673 0.252066 1.31 e-07 
CDR20291_1383 3075.212 1249.108 1966.757 3479.704 0.750299 0.401788 0.187119 1.11 e-09 
CDR20291_1391 7328.596 4229.838 4721.105 6269.56 0.758529 0.47506 0.444531 3.05 e-07 
CDR20291_1409 3447.365 3263.069 3800.974 4776.315 0.145891 0.729741 0.877919 0.12296 
CDR20291_1480 3543.288 1820.723 2121.192 3241.225 0.80299 0.27311 0.215 5.21 e-08 
CDR20291_1491 7783.135 4243.877 5230.214 7022.201 0.850555 0.546081 0.434268 0.01379 
CDR20291_1529 3914.442 1434.223 2123.931 3673.027 0.853136 0.191493 0.080964 1.61 e-06 
CDR20291_1569 43011.06 40223.95 41127.87 42080.46 0.636248 0.408221 0.273375 2.00 e-13 
CDR20291_1606 4439.288 2406.838 2895.561 3543.28 0.397861 0.10936 0.109474 1.23 e-11 
CDR20291_1795-s2 1838.904 1016.915 1817.474 3141.896 0.087277 0.98245 0.370239 0.00483 
CDR20291_1795-s6 5702.058 2109.646 2619.279 4068.674 0.398846 0.134849 0.088068 4.17 e-05 
CDR20291_1802 3245.058 1508.492 2361.388 3369.626 0.934291 0.5739 0.281065 2.43 e-10 
CDR20291_1825 3255.288 4164.377 3484.431 4587.728 0.175933 0.880246 0.71088 0.000144 
CDR20291_1911 3982.058 1915.454 2622.279 3232.003 0.274367 0.077412 0.015258 0.015406 
CDR20291_1931 3499.827 3099.8 2953.757 3539.728 0.980218 0.788819 0.88748 6.62 e-07 
CDR20291_1985 6583.904 4359.915 1964.322 3656.74 0.14877 0.032321 0.016669 0.000684 
CDR20291_2034 4106.596 2666.569 3491.388 4562.985 0.765295 0.715413 0.383649 0.002388 
CDR20291_2174-s2 3335.212 1987.3 3050.779 4360.165 0.401495 0.833523 0.32286 1.21 e-05 
CDR20291_2178 4605.904 2574.069 3280.061 3378.979 0.452697 0.283085 0.140074 1.14 e-10 
CDR20291_2226 7194.519 2036.3 2512.301 4198.506 0.169586 0.046612 0.026392 0.212682 
CD2293 2598.904 4675.685 3889.214 4586.692 0.067664 0.346958 0.313845 0.001408 
CDR20291_2298 3888.981 1306.954 2407.54 3471.901 0.855278 0.531547 0.273618 0.002115 
CDR20291_2346 3103.058 2668.762 3238.061 4003.345 0.471989 0.922956 0.796855 1.36 e-10 
CDR20291_2345 4741.288 2634.377 2728.974 3419.087 0.429258 0.251236 0.258885 2.97 e-05 
CDR20291_2359 4090.288 1968.8 2709.931 3439.069 0.542547 0.235962 0.086836 0.005127 
CDR20291_2503 20811.13 19762.15 20058.26 20183.22 0.600999 0.571591 0.468663 1.1 e-05 
CDR20291_2559 5183.904 7958.492 6889.17 7913.967 0.178063 0.477314 0.375692 0.000797 
CDR20291_2653 3186.212 1511.108 1746.822 3330.105 0.920003 0.321351 0.265558 0.000113 
CDR20291_2660 2751.288 1562.415 2300.474 3185.973 0.6830392 0.704769 0.33489 7.44 e-09 
CDR20291_2671 8171.135 1630.492 4392.627 5547.075 1.571289 0.431691 0.170442 0.000565 
CDR20291_2686-s2 5702.827 2572.069 3650.996 5261.842 0.888845 0.53332 0.343185 5.83 e-08 
CDR20291_2687 4635.519 1652.992 2284.431 3294.105 0.364527 0.130176 0.066246 0.023405 





CDR20291_2744 1472.981 2868.992 3654.344 4075.393 0.010575 0.198603 0.57161 7.69 e-07 
CDR20291_2805 3266.904 1532.992 2705.496 4153.47 0.610615 0.758221 0.331671 1.85 e-11 
CDR20291_2873 4931.135 2154.146 2755.888 3221.369 0.179694 0.104482 0.048627 0.427101 
CDR20291_2903 2773.981 2059.915 2341.344 3068.434 0.782354 0.711357 0.59073 3.05 e-09 
CDR20291_2971 3595.442 2070.262 2644.409 3504.548 0.937897 0.451552 0.274288 0.000286 
CDR20291_3061 3625.058 1781.685 3191.127 4477.345 0.599553 0.806212 0.276782 2.85 e-05 
CDR20291_3081 3296.365 2960.223 2221.627 3288.285 0.997177 0.644664 0.890525 5.31 e-05 
CDR20291_3279 2315.365 3092.262 2644.148 4125.728 0.079993 0.782977 0.6503 6.96 e-09 
CDR20291_3280 5422.673 2042.608 2205.496 3188.111 0.187998 0.069511 0.065385 2.4 e-05 
CDR20291_3328 4986.288 3789.3 3462.409 4095.003 0.6715 0.516457 0.634058 5.61 e-09 
CDR20291_3334 4317.288 1884.223 2604.17 3440.213 0.375513 0.119303 0.032547 0.00015 
CDR20291_3335 3464.519 1915.877 2444.235 3220.632 0.850218 0.457725 0.298 1.16 e-06 
CDR20291_3343 1416.75 1385.108 2500.801 3287.446 0.006311 0.195467 0.964582 0.010197 
CDR20291_3468 2586.596 2496.415 2554.083 3881.039 0.315473 0.793494 0.80625 0.000415 
CDR20291_3498 4548.442 2225.877 2958.996 3973.919 0.723494 0.351677 0.192918 1.55 e-08 



















Alignment of CDR20291_0342 amino acid sequence from C. difficile strains 630 and R20291. Amino 
acid sequence of CDR20291_0342 from R20291 was aligned against CDR20291_0342 from strain 630 
































Repeat glycosylation test of transfer of the E. coli O13-antigen onto AcrAtag. E. coli O13 cells 
harbouring pEC415_AcrAtag and pEXT21_pglB were induced at 37oC overnight with 1 mM IPTG and 
0.2% L-arabinose. Cells were lysed and protein was nickel affinity purified before resolving on an 
SDS-PAGE gel then probing on an anti-His immunoblot. (1) Uninduced, (2) Induced with L-arabinose 
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Antimicrobial Resistance and Immunisation 
 
Antimicrobial resistance (AMR) is an urgent 
global health threat that, if left unchecked, 
could account for an estimated 10 million 
deaths per year by 2050.1 Immunisation is one 
potential way of reducing AMR. This POSTnote 
describes the role for immunisation in tackling 
AMR, both globally and in the UK, the use of 
existing vaccines and how vaccine 
development aligns with public health priorities. 
 
Overview 
 Antimicrobial resistance (AMR) has reached 
a point where some infections may become 
untreatable.  
 Immunisation is one strategy to tackle AMR, 
by decreasing rates of infection and thereby 
antibiotic use and preventing the 
development of resistant infections.  
 The World Health Organization has 
developed a list of pathogens where AMR is 
of most concern and new antibiotics are 
needed; there is no equivalent for vaccines.  
 Quantifying the impact of immunisation on 
AMR and incorporating this into calculating 
the cost-effectiveness of vaccines is still an 
area of ongoing research.   
 Using immunisation to tackle AMR depends 
on wider use and increased uptake of 
existing vaccines, and increasing the 
development of new ones. 
 
Background 
Antimicrobial drugs kill or inhibit the growth of microbes (for 
example, bacteria, viruses and fungi). Microbes adapt by 
developing or acquiring traits that make them resistant to 
these drugs. This process is accelerated by widespread 
(including inappropriate) use of antimicrobials in humans 
and animals.2,3 When resistance occurs in microbes capable 
of causing disease (pathogens), treatment options become 
limited. There are ~700,000 deaths globally every year from 
drug-resistant infections.4 AMR poses a significant health 
and economic burden, and is a priority for the UN General 
Assembly.5 Plans to tackle AMR recognise the need for 
multiple approaches, including immunisation and improved 
sanitation, but the focus has tended to be on more careful 
use of existing drugs and the development of new ones.4-8 
In 2014, the UK Government commissioned the (O’Neill) 
Review on AMR, to assess the global burden of resistance 
and make recommendations. It concluded that vaccines 
have been overlooked as a tool to reduce AMR and should 
be an investment focus.9 
Immunisation as an AMR intervention  
Immunisation confers protection from infection by 
introducing a non-harmful form or component of the 
pathogen in a vaccine. The body develops an immune 
response (such as antibodies) without disease. For many 
vaccines, high uptake in a population generates herd 
immunity. Non-immunised people are indirectly protected by 
being surrounded by immunised people who do not transmit 
the infection.10 Some bacteria are naturally carried in or on 
the body, and often beneficially, but can be transmitted to 
and lead to disease in susceptible people.11 Immunisation 
can prevent carriage, thereby reducing transmission to non-
immunised people.12 Mass immunisation programmes save 
~2.5 million lives a year, globally.13  
Immunisation can reduce the AMR burden through two main 
mechanisms. Firstly, it prevents infections (including 
resistant ones), disease and deaths, and negates the need 
for expensive, more complex drugs to treat resistant 
infections.14,15 Secondly, preventing infection avoids the 
need for treatment, so antimicrobial use is reduced, in 
humans and animals.16-18 One study estimated increasing 
uptake of the pneumococcal conjugate vaccine (PCV) could 
reduce antibiotic (antimicrobials for bacteria) use for 
pneumococcal pneumonia in children aged under 5 years by 
47%.19 Antibiotic use is linked to the development of AMR; 
as use decreases, so too the pressure for resistance to 
develop in the pathogen.2,20,21 
Vaccines offer long-term protection from infection in contrast 
to antibiotics, and many vaccines still effective today were 





introduced decades ago.22 However, if a pathogen 
undergoes high rates of mutation, the vaccine will need to 
be changed, such as for influenza.23 Furthermore, if a 
vaccine only covers some strains of a pathogen, infections 
caused by other strains can occur or increase.24,25  
Priority Infections  
The World Health Organization (WHO) and the US Centers 
for Disease Control and Prevention (CDC) have priority lists 
of bacterial pathogens of most concern, due to risk of 
resistance (Box 1).26,27 The O’Neill Review identified key 
contexts where immunisation could reduce AMR. This 
includes vaccinating against: infections acquired in hospital 
or the community; viral infections, for which antibiotics are 
ineffective but may be prescribed for symptoms of, or to 
prevent (secondary) bacterial infections.9   
Box 1. Antibiotic Resistant Priority Pathogens  
There is no specific list of the most important resistant pathogens for 
the UK but lists have been developed by CDC and WHO, focusing on 
bacteria. Many pathogens are on both lists and categorised by threat 
level; the most urgent/critical threats are described here. In 2013, 
CDC identified the most urgent threats for the US as Clostridium 
difficile, carbapenem-resistant Enterobacteriaceae and Neisseria 
gonorrhoeae.27 In 2017, WHO identified pathogens for which research 
and development of new antibiotics was most needed (Mycobacterium 
tuberculosis has a dedicated programme). Critical threats include:26 
 Acinetobacter baumannii that are resistant to carbapenem drugs 
 Pseudomonas aeruginosa that are carbapenem-resistant 
 Enterobacteriaceae that are carbapenem-resistant and/or resistant 
to 3rd generation cephalosporin drugs.  
 Carbapenem resistance is an issue as this is a “last resort” class of 
antibiotic, used for treatment when other options have failed.28 
There are no licensed vaccines for any of the pathogens listed 
above, although some are currently in development.29 
The Global Context  
The burden of disease and AMR varies considerably across 
the world. Many serious infections disproportionally affect 
low- and middle-income countries (LMICs).30-32 HIV, 
tuberculosis and malaria are the “big three” infections, so-
called because of the health burden they pose. Resistance 
is an issue for treatment of all three.33-36 Vaccine 
development for each is ongoing; there is no HIV vaccine 
and the major vaccine in development for malaria and the 
only available vaccine for tuberculosis provide a sub-optimal 
level of protection.29,37,38  
There are a number of infections where new vaccines or 
increased uptake of existing ones could reduce mortality 
and/or antibiotic use, such as those caused by group A 
streptococci, pneumococci, influenza and respiratory 
syncytial virus (RSV).19,39-43 In 2016, there was an outbreak 
of typhoid fever in Pakistan, resistant to multiple 
antibiotics.44 A new typhoid vaccine has been 
recommended, with higher efficacy than previous 
vaccines.45-47 
The UK Context 
Many infections that present a global problem are also an 
issue in the UK. Vaccines could be a useful tool in 
managing infections where antibiotic treatment is 
undermined by resistance, such as gonorrhoea (Box 2). 
Cases of gonorrhoea have increased since 2008 and many 
antibiotics are no longer recommended for routine use due 
to the emergence of resistance. A recent case of 
gonorrhoea in the UK was resistant to both current primary 
recommended treatments.51,48-50  
Box 2. Gonorrhoea 
Gonorrhoea is a common bacterial sexually transmitted infection and 
can result in infertility if left untreated. Antibiotic treatment options are 
limited by high levels of AMR.51,52 There is no vaccine currently 
available.29 Data from New Zealand show that a vaccine against 
meningitis B had an estimated 31% efficacy against gonorrhoea. The 
bacteria causing meningitis B and gonorrhoea are related. This has 
led to suggestions of optimising the next generation of this vaccine to 
prevent gonorrhoea.53 In 2015, the UK became the first country to 
offer routine meningitis B immunisation, using a vaccine which shares 
a component with the vaccine used in New Zealand.54   
 
Healthcare-associated infections (HCAIs) 
HCAIs incur significant costs to the NHS and can result in 
severe outcomes, such as blood-stream infections (BSIs).55-
57 Clostridium difficile and methicillin-resistant 
Staphylococcus aureus (MRSA) infections remain a burden 
in healthcare settings, but have decreased substantially in 
recent years (due to better infection prevention and control, 
and reduced prescribing). Between 2007/08 and 2017/18, 
there was a 76.1% decrease in C. difficile infections and 
81% decrease in MRSA BSIs.58 Another cause of HCAIs are 
the “Gram-negative” class of bacteria, where resistance is 
significant.55,59 Most Gram-negative BSIs are caused by 
Escherichia coli, Klebsiella and Pseudomonas aeruginosa.55 
Almost half of E. coli-BSIs are resistant to co-amoxiclav, a 
routinely used antibiotic, and resistance to carbapenem 
antibiotics (Box 1) is low but increasing annually.55 The 
Government has a target to reduce the incidence of Gram-
negative BSIs by 50% by 2021, through improved infection 
prevention and control.55  
There are no licensed vaccines for any of these infections.29 
It is suggested that these vaccines could be targeted to 
people with an increased risk of infection, such as those 
with planned surgical procedures.9,60,61 Vaccines are in 
development for MRSA and C. difficile and three E. coli 
vaccines are in early trials, but there are no candidates in 
trials for P. aeruginosa or Klebsiella.29 Although Gram-
negative bacteria can cause serious infections at certain 
sites in the body, many normally live in the gut of healthy 
people.62-64 It is unclear how immunisation would impact gut 
bacteria and consequently overall health.11,65 
Viral infections  
Lack of rapid diagnostics for use at the time of consultation 
means many antibiotics are prescribed on the basis of 
symptoms alone, which can be caused by multiple 
pathogens, for example for respiratory tract infections 
(RTIs).66-68 This can lead to unnecessary antibiotic use for 
RTIs caused by viruses that can resolve without antibiotic 
treatment, but which are prescribed due to the risk of 
bacterial infection, particularly in children and the elderly.69-
73 Vaccinating against common viral causes of RTIs, such 
as influenza virus, can reduce antibiotic use and acquisition 
of secondary bacterial infections.17,74,75 RSV is the most 




common cause of acute lower respiratory tract infections in 
children under 5 years of age globally and is an issue for 
adults with other conditions and/or lowered immune 
systems.76,77 There is no licensed vaccine but there are 
many vaccine candidates in different stages of clinical 
trials.78-80   
The influenza vaccine is offered to all over 65s, at-risk 
groups (including pregnant women), and more recently to 
children, to provide protection from infection and to 
decrease transmission from children to vulnerable older 
individuals.81 Vaccine uptake in the UK varies between 
groups but is high (>70%) for over 65s.82 Variations in the 
circulating strains causing infections each season can lead 
to mismatches, where the available vaccine does not fully 
target the current strain. There is ongoing research in 
developing a vaccine that covers all strains, to reduce 
influenza infections83-86 and with further benefits of reduced 
antibiotic use and secondary ear infections.87-89 Population-
wide influenza vaccination in Ontario was associated with a 
64% decrease in influenza-associated respiratory antibiotic 
prescriptions.17 Research by Public Health England (PHE) is 
assessing any changes in antibiotic prescribing and 
secondary lower respiratory tract infections in the context of 
the influenza immunisation programme in England.90 
 
Decisions about Vaccine Use  
There are two main approaches to reducing AMR using 
immunisation: maximising the utility of existing vaccines by 
ensuring good uptake and offering them more widely as  
appropriate, and making decisions about which vaccines 
should be developed and introduced and when and where 
to use them most efficiently.9 Decisions about choices for 
national immunisation programmes vary between countries 
due to vaccine availability and affordability, disease risk, 
vaccine efficacy and different frameworks for advice.91,92  
 
Measuring the Impact of Vaccines on AMR  
Vaccines may have several direct and indirect effects on 
AMR:93 
 preventing disease and deaths   
 reducing the progression to and severity of disease 
 reducing transmission of infection between people 
 reducing antibiotic use and pressure for resistance 
 reducing GP visits and hospital stays. 
Monitoring and quantifying the effects of immunisation on 
AMR and assigning economic benefit to these outcomes is 
challenging and requires surveillance data and complex 
analysis (Box 3).7,93,94 The committee that advises the UK 
Government on vaccination considers AMR in its decision-
making process insofar as it is able, based on the evidence 
(Box 4).95 
Surveillance and Data Collection 
Understanding disease burden and the proportion that is 
resistant is important in informing design and use of AMR 
interventions, including vaccines.4,96-98 The UK has 
Box 3. Mathematical Modelling and Cost-Effectiveness Analysis  
Mathematical modelling of the impact of a vaccine on a target 
population and cost-effectiveness evaluations are an important part of 
decision-making about vaccines in the UK. This is a statutory 
requirement before a vaccine can be recommended to Ministers.92 
Modelling of immunisation and AMR is a useful tool to increase 
understanding and predict impact but its utility in informing public 
health strategies is restricted by the complexity in modelling this 
relationship.93 For example, although antibiotic use has accelerated 
development of AMR, this can vary depending on the drug, pathogen 
and host setting.94 Furthermore, antibiotic use can also pressure the 
bacteria carried in the body of healthy people to develop resistance.99 
Existing studies aiming to model AMR in the context of immunisation 
are restricted to pneumococcal and S. aureus infections.93 
 
separate surveillance systems to monitor disease and 
AMR.55,100 Some lower income countries, in which AMR has 
a disproportionate impact, do not have the capacity for 
detailed surveillance, which limits understanding.101,102 
Programmes to increase surveillance in these regions 
include The Fleming Fund and the WHO Global AMR 
Surveillance System.103,104 Monitoring antibiotic use is one 
way to quantify the impact of immunisation on AMR but this 
is complex.105-108 The Wellcome Trust has commissioned a 
review of studies on immunisation and antibiotic use. It is 
also encouraging data collection about antibiotic use during 
clinical trials and post-vaccine roll out studies.109 
Box 4. Scientific Advice to the UK Government on Immunisation 
The Government amends the national immunisation schedule on the 
advice of the Joint Committee on Vaccination and Immunisation 
(JCVI). Decision making is informed by a range of evidence including 
disease burden, vaccine availability, safety and efficacy and cost-
effectiveness. The AMR burden for an infection is considered where 
possible. This is limited by the complex challenges in quantifying the 
impact of vaccination on the AMR burden and assigning economic 
benefit to this impact. Researchers are developing models to predict 
these complex effects. The JCVI has identified two infections for which 
vaccines are unavailable but could be beneficial and cost-effective, 
RSV and Group B Streptococcus (GBS).95,110 These could also be 
beneficial from an AMR standpoint as both infections lead to 
potentially avoidable antibiotic use. Antibiotics are ineffective against 
RSV but may still be prescribed, including for secondary bacterial 
infections.41 For GBS, there are global differences in screening 
practices and antibiotic use.111-113 
 
Utility of Existing Vaccines 
The O’Neill Review recommended wider use of existing 
vaccines, such as those for pneumococcal infections.9 After 
the pneumococcal conjugate vaccine (PCV) was introduced 
in the UK in 2006, the incidence of disease across all age 
groups caused by types (“serotypes”) contained in the 
vaccine fell by 97% by 2016, and infections resistant to a 
certain class of antibiotics (macrolides) also decreased (Box 
5).25,114 Reduced prevalence of drug-resistant infections and 
antibiotic use through immunisation depends on achieving 
good vaccine uptake. There are major global disparities in 
uptake, as a consequence of supply and affordability, 
weaknesses in health systems and public attitudes.115,116  





Box 5. Pneumococcal Conjugate Vaccine (PCV) 
Streptococcus pneumoniae can cause severe disease, including 
meningitis, septicaemia and pneumonia, with under 5 year-olds and 
the elderly most at risk.117 There are >100 identified serotypes that 
vary in their prevalence, drug-resistance and ability to cause disease 
118,119 PCV7, a vaccine covering 7 serotypes, has been linked to 
reduced antibiotic use and resistant infections in some regions.120-122 
A reduction in vaccine-targeted serotypes was followed by an increase 
in disease caused by other serotypes, known as serotype 
replacement.25 New vaccines are required to cover serotypes arising 
through this process, for example PCV13 is now used in many 
countries, including the UK.25,117 
 
The Global Context 
The effectiveness of national immunisation programmes 
relies on high vaccine uptake in the target populations.10,123 
However, many countries do not have the infrastructure or 
means to achieve this. For example, the WHO estimates 
that global coverage of PCV for children under 5 is 42%.124  
Gavi is a public-private partnership that aims to increase 
vaccine coverage in the world’s poorest countries.125 Gavi’s 
portfolio contains 11 vaccines,126 and they estimate that 
their provision of Haemophilus influenzae type b, 
pneumococcal and meningococcal vaccines between 2001 
and 2030, could mean that 500 million doses of antibiotics 
would not be used. AMR is a recent addition to Gavi’s 
vaccine investment decision criteria.127 
The UK Context 
The UK has one of the most comprehensive immunisation 
schedules and high uptake.128 There are still inequalities in 
uptake in certain socioeconomic and ethnic groups, but PHE 
and NHS England are working to reduce them.129,130 Public 
perceptions of vaccination also influence uptake and can 
lead to increases in vaccine-preventable infections.131,132 
Survey data from 2016 showed that 94% of parents in 
England had confidence in the immunisation programme.133 
This high level of confidence is not reflected worldwide, 
including some high income European countries.134  
Developing New Vaccines   
Vaccine development requires advanced technologies, is 
expensive, time-consuming and subject to high attrition, so 
companies require markets to make research and 
development (R&D) commercially viable.9,135-136 There are a 
number of vaccines in development for pathogens on the 
WHO and CDC lists (Box 1), but some vaccines may be 
less attractive as they offer lower returns, such as those 
targeting diseases that mainly affect LMICs.29,137,138 A key 
question is how to stimulate and prioritise the development 
of new vaccines in the context of AMR. The O’Neill review 
highlighted the need to support early research and maintain 
a viable market.9 However, the majority of funding for new 
AMR products (excluding direct industry investment) targets 
development of new antibiotics.139 Several government 
AMR initiatives are ongoing, including vaccine development 
(Box 6). Other proposed methods to encourage 
development include product development partnerships, 
market entry rewards and tax credits. 4,40,140 
Vaccine Development and Public Health Priorities  
Where collections of symptoms could be caused by several 
different pathogens (such as RTIs), vaccinating against 
many of these (such as influenza and RSV) could have a 
greater impact on antibiotic use, by preventing infection and 
reducing the need for medical intervention.77,40,141 It has 
been suggested that future research could focus on 
developing vaccines that preferentially target resistant 
pathogens or are against HCAIs.7,40,61,142 As HCAIs are 
more likely to affect certain groups, vaccinating the whole 
population may not be appropriate.9,143 However: 
 unwell or elderly people may not be able to develop a 
protective immune response after vaccination9,143  
 identifying the target population risks missing people61  
 for those entering hospitals in an emergency, there may 
not be time to be vaccinated and generate immunity, 
although treatments (monoclonal antibodies) that confer 
immediate, short-term immunity are being developed.145  
Public Health Priorities  
Guidance on public health priorities can inform research and 
help manufacturers understand potential markets.146 For 
example, target product profiles that outline what is 
expected from a vaccine can bring stakeholders together 
and coordinate development.147,148 The Wellcome Trust has 
commissioned work to assess vaccine development for all 
pathogens on the WHO priority pathogen list, including:109   
 R&D pipeline - past failures, existing efforts and need  
 market analysis - sizing calculations and target population  
 payers - who would pay or support access to vaccines 
 barriers - commercial, clinical trials and delivery   
 benefits for each pathogen and any cross-protection.  
Vaccine Development 
Various initiatives can support the pre-clinical development 
of promising vaccine candidates; CARB-X is a public-private 
partnership funding development of antimicrobial products 
for priority pathogens (Box 1).149 The UK government 
funded BactiVac Network aims to accelerate development of 
anti-bacterial vaccines for LMICs and covers UK needs 
following investment from the Industry Strategy Challenge 
Fund.150 The planned UK National Vaccine Development 
and Manufacturing Centre aims to support later stages of 
development.151 Medicines regulators such as the European 
Medicines Agency are co-operating with other bodies to 
discuss vaccine regulation in the context of AMR.152  
Box 6. Government AMR Strategies and Immunisation 
The Department of Health and Social Care (DHSC) leads the 5-Year 
AMR Strategy which includes increasing uptake of immunisation and 
investment in new vaccines.153 The £50 million Global AMR Innovation 
Fund - set up in response to the O’Neill review - funds R&D in 
underinvested areas.154 This focuses on LMICs and includes the 
development of alternatives to antibiotics, such as vaccines, with 
investment in CARB-X.155 Innovate UK works with GAMRIF and 
conducts other AMR and vaccine work.151 The Department for 
International Development contributes to the UK AMR Strategy and is 
the biggest contributor to Gavi.156 The AMR Funders Forum includes 
research councils, government and charities and coordinates UK AMR 
research. This includes vaccine development and work to identify 
which interventions will have the most impact in different settings.157 
 
POST is an office of both Houses of Parliament, charged with providing independent and balanced analysis of policy issues that have a basis in science and technology. 
POST is grateful to Catherine Hall for researching this briefing, to the Medical Research Council for funding her parliamentary fellowship, and to all contributors and 
reviewers. For further information on this subject, please contact the co-author, Dr Sarah Bunn. Parliamentary Copyright 2018. Image copyright iStockphoto 





Endnotes (fully referenced version available online) 
1 Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of 
Nations, The Review on Antimicrobial Resistance, Chaired by Jim O’Neill and 
published by the Wellcome Trust and HM Government, 2014  
2 Goossens H et al, Lancet, 365, 579-587, 2005 
3 Verweij PE et al, Lancet Infect Dis, 9, 789-795, 2009 
4 Tackling Drug-Resistant Infections Globally, The Review on Antimicrobial 
Resistance, Chaired by Jim O’Neill and published by the Wellcome Trust and 
HM Government, 2016 
5 Political Declaration of the high-level meeting of the General Assembly on 
antimicrobial resistance, United Nations General Assembly, 2016 
6 Global Action Plan on Antimicrobial Resistance, World Health Organisation, 
2015 
7 Lipsitch M & Siber GR, MBio, 7, 2016 
8 https://www.nature.com/news/vaccines-promoted-as-key-to-stamping-out-
drug-resistant-microbes-1.22324 
9 Vaccines and alternative approaches: reducing our dependence on 
antimicrobials, The Review on Antimicrobial Resistance, Chaired by Jim 
O’Neill and published by the Wellcome Trust and HM Government, 2016 
10 Heymann DL & Aylward RB, Curr Top Microbiol Immunol, 304, 2006 
11 The Microbiome and Human Health, POSTnote 574, Parliamentary Office of 
Science and Technology, 2018 
12 Trotter CL et al, Vaccine, 26, 4434-4445, 2008 
13 Global Vaccine Action Plan 2011-2010, World Health Organisation 
14 Antimicrobial Resistance, World Health Organisation, 2018  
15 Marks SM et al, Emerg Infect Dis, 20, 812-821, 2014 
16 Grijalva CG, Lancet Infect Dis, 14, 175-177, 2014 
17 Kwong JC et al, Clin Infect Dis, 49, 750-756, 2009 
18 Markestad A & Grave K, Fish Vaccinol, 90, 365-369, 1997  
19 Laxminarayan R et al, Lancet, 387, 168-175, 2016 
20 Costelloe C et al, BMJ, 340, 2010 
21 Livermore DM et al, J Antimicrob Chemother, 68, 2667-2674, 2013  
22 Kennedy DA & Read AF, Proc Biol Sci, 284, 2017 
23 https://www.cdc.gov/flu/about/viruses/change.htm 
24 Martcheva M et al, J R Soc Interface, 5, 3-13, 2008 
25 Ladhani SN et al, Lancet Infect Dis, 18, 441-451, 2018 
26 Global Priority List of Antibiotic-resistant bacteria to guide research, discovery 
and development of new antibiotics. World Health Organisation, 2017 
27 https://www.cdc.gov/drugresistance/biggest_threats.html 
28 Meletis MD, Ther Adv Infect Dis, 3, 15-21, 2016 
29 Antimicrobial Resistance Benchmark, Access to Medicine Foundation, 2018 
30 Vitoria M et al, Am J Clin Pathol, 131, 844-848, 2009 
31 Preventing disease through healthy environments: a global assessment of the 
burden of disease from environmental risks, World Health Organisation, 2016 
32 Lozano R et al, Lancet, 380, 2095-2128, 2012 
33 Goldberg DE et al, Cell, 148, 1271-1283, 2012 
34 HIV Drug Resistance Report 2017, World Health Organisation, 2017 
35 Global Tuberculosis Report 2017, World Health Organisation, 2017 
36 Global report on antimalarial efficacy and drug resistance: 2000-2010, World 
Health Organisation, 2010 
37 Mangtani P et al, Clin Infect Dis, 58, 470-480, 2014 
38 Agnandji ST et al, N Engl J Med, 367, 2284-2295, 2012 
39 Zühlke LJ et al, Curr Treat Options Cardiovasc Med, 19, 15, 2017 
40 The Value of Vaccines in the Avoidance of Antimicrobial Resistance, Centre 
on Global Health Security, Chatham House, 2017 
41 van Houten CB et al, Pediatr Infect Dis, 2018 
42 Global Action Plan for Influenza Vaccine Global Progress Report, World Health 
Organisation, 2014 
43 Shi T et al, Lancet, 390, 946-958, 2018 
44 Klemm EJ et al, MBio, 9, 2018 
45 Summary of the October 2017 meeting of the Strategic Advisory Group on 
Experts on Immunisation, World Health Orgnaization, 2017 
46 Jin C et al, Lancet, 390, 2472-2480, 2017 
47 Typhoid vaccines: WHO position paper, March 2018 – Recommendations, 
World Health Organisation, 2018 
48 MacFadden DR et al, Lancet Infect Dis, 18, 599, 2018 
49 UK case of Neisseria gonorrhoeae with high-level resistance to azithromycin 
and resistance to ceftriaxone acquired abroad, Public Health England, 2018 
50 Unemo M & Shafer WM, Clin Microbiol Rev, 27, 587-613, 2014 
51 Surveillance of antimicrobial resistance in Neisseria gonorrhoeae in England 
and Wales. Key findings from the Gonococcal Resistance to Antimicrobials 
Surveillance Programme (GRASP), Public Health England, 2017 
52 Unemo M & Shafer WM, Clin Microbiol Rev, 27, 587-613, 2014 
53 Petousis-Harris H et al, Lancet, 390, 1603-1610, 2017 
54 https://www.nhs.uk/conditions/vaccinations/meningitis-b-vaccine/ 
 
                                                                                                 
55 English Surveillance Programme for Antimicrobial Utilisation and Resistance, 
Public Health England, 2017 
56 Preventing healthcare associated Gram-negative bloodstream infections: an 
improvement resource, Public Health England, 2017 
57 Plowman R et al, J Hosp Infect, 47, 198-209, 2001 
58 Annual epidemiological commentary: Gram-negative bacteraemia, MRSA 
 bacteraemia, MSSA bacteraemia and C.difficile infections, up to and including 
 financial year April 2017 to March 2018, Public Health England, 12 July 2018 
59 Blair JMA et al, Nat Rev Microbiol, 13, 42-51, 2015  
60 Van Kleef et al, Vaccine, 34, 5562-5570, 2016 
61 McIntosh EDG, Ther Adv Vaccines, 6, 19-27, 2018 
62 Jansen KU & Anderson AS, Hum Vaccin Immunother, 22, 1-17, 2018 
63 Moradigaravand D et al, MBio, 8, 2017 
64 Marcel JP et al, Clin Microbiol Infect, 14, 895-907, 2008 
65 Hays MP et al, BMC Res Notes, 11, 401, 2016  
66 Pouwels KB et al, J Antimicrob Chemother, 73, 19-26, 2018 
67 Dolk FCK et al, J Antimicrob Chemother, 73, 19-26, 2018 
68 Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics, The Review on 
Antimicrobial Resistance, Chaired by Jim O’Neill and published by the 
Wellcome Trust and HM Government, 2015 
69 Respiratory tract infections (self-limiting): prescribing antibiotics, National 
Institute for health and Care Excellence, 2008 
70 Jain S et al, N Engl J Med, 372, 835-845, 2015 
71 Pavia AT, Clin Infect Dis, 52, 284-289, 2011 
72 Bruning AHL et al, Clin Infect Dis, 65, 1026-1032, 2017 
73 Infection Control Precautions to Minimise Transmission of Acute Respiratory 
Infections in Healthcare Settings, Public Health England, 2016 
74 Norhayati MN et al, Cochrane Database Syst Rev, 2017 
75 Ampofo K et al, Pediatrics, 122, 229-237, 2008 
76 Nair H et al, Lancet, 375, 1545-1555, 2010 
77 Lee N et al, Clin Infect Dis, 57, 1069-1077, 2013 
78 Simoes EAF et al, Infect Dis Ther, 7, 87-120, 2018  
79 Regulating Clinical Trials, POSTnote 561, Parliamentary Office of Science and 
Technology, 2017 
80 https://www.path.org/publications/files/CVIA_RSV_snapshot_fs.pdf 
81 The national flu immunisation programme 2018/19 letter, Public Health 
England, 2018 
82 Seasonal influenza vaccine uptake in GP patients: winter season 2017 to 
2018, Public Health England, 2018 
83 Zimmerman RK et al, Clin Infect Dis, 63, 1564-1573, 2016 
84 Zhou F et al, Curr Opin Immunol, 29, 88-95, 2018  
85 Erbleding EJ et al, J Infect Dis, 2018 
86 The Lancet Infectious Diseases, Lancet Infect Dis, 18, 475, 2018 
87 Kash JC & Taubenberger JK, Am J Pathol, 185, 1528-1536, 2015 
88 Ozgur SK et al, Pediatr Infect Dis J, 25, 401-404, 2006 
89 Marchisio P et al, Pediatr Infect Dis J, 28, 855-859, 2009 
90 Personal Communication: Dr Richard Pebody, Public Health England  
91 Burchett HE et al, Health Policy Plan, 27, 2012 
92 Joint Committee on Vaccination and Immunisation Code of Practice, 2013 
93 Atkins KE et al, Lancet Infect Dis, 2017 
94 Holmes AH et al, Lancet, 387, 176-187, 2016 
95 Personal Communication: Professor Andrew Pollard, Chair Joint Committee on 
Vaccination and Immunisation 
96 Hyde TB et al, Vaccine, 31, 94-98, 2013 
97 Global Framework for Immunisation Monitoring and Surveillance, World Health 
Organization, 2007  
98 The Role of Vaccination in Reducing Antimicrobial Resistance, Vaccines 
Europe, 2013 
99 Tedijanto C et al, bioRxiv, 288704, 2018 
100 Surveillance of Infectious Diseases, POSTnote 462, Parliamentary Office of 
Science and Technology, 2014 
101 Laxminarayan R & Heymann DL, BMJ, 344, 2012 
102 Seale AC, Wellcome Open Res, 2, 2017 
103 http://www.flemingfund.org/ 
104 http://www.who.int/glass/en/ 
105 Personal Communication, Professor Marc Lipsitch 
106 Fireman B et al, Pediatr Infect Dis J, 22, 10-16, 2003 
107 Lau WCY et al, Vaccine, 33, 5072-5079, 2015 
108 Ben-Shimol S et al, Clin Infect Dis, 63, 611-618, 2016 
109 Personal Communication: Dr Elizabeth Klemm and Dr Zoe Seager, The 
Wellcome Trust  
110 Cromer D et al, Lancet Public Health, 2, 367-374, 2017 
111 Hughes RG, Brocklehurst P, Steer PJ, Heath P, Stenson BM on behalf of the 
Royal College of Obstetricians and Gynaecologists, BJOG, 124, e280-e305, 
2017 
112 Martinez de Tejada B, Int J Environ Res Public Health, 11, 7993-8009, 2014 
 





                                                                                                 
113 Le Doare K et al, Clin Infect Dis, 65, 143-151, 2017 
114 Henderson KL et al, J Antimicrob Chemother, 65, 369-70, 2010 
115 Access to Vaccines Index 2017, Access to Medicine Foundation, 2017 
116 Larson HJ et al, Vaccine, 32, 2150-2159, 2014 
117 Pneumococcal: the green book, chapter 25, Public Health England, 2018 
118 Weiser JN et al, Nat Rev Microbiol, 16, 355-367, 2018 
119 Song JH et al, vaccine, 30, 2728-2737, 2012  
120 Palmu AA et al, Lancet Infect Dis, 14, 205-212, 2014 
121 Kyaw MH, N Engl J Med, 354, 1455-1463, 2006 
122 Von Gottberg A et al, N Engl J Med, 371, 1889-1899, 2014 
123 NHS Public Health Functions Agreement 2015-2016 Core Service 
Specification National immunisation programme, Department of Health, 2014 




128 Childhood Vaccination Coverage Statistics, National Statistics, 2017 
129 UK Trends in Infectious Diseases, POSTnote 545, Parliamentary Office of 
Science and Technology, 2017 
130 Immunisations: reducing differences in uptake in under 19s, National Institute 
of health and Care Excellence, 2009 (updated 2017) 
131 Dubé E et al, Humm Vaccin Immunother, 9, 1763-1773, 2013 
132 Omer SB et al, N Engl J Med, 360, 1984-1988, 2015 
133 Parental attitudes to childhood immunisation, Public Health England, 2016 
134 Larson HJ et al, EBioMedicine, 12, 295-301, 2016 
135 Rappuoli R et al, Lancet, 378, 360-368, 2011 
136 Pronker ES et al, PLoS One, 8, 2013 
137 Oyston P & Robinson K, J Med Microbiol, 61, 889-894, 2012 
138 Making Markets for Vaccines: Ideas to Action, Center for Global Development, 
2005 
139 Tackling Antimicrobial Resistance, Ensuring Sustainable R&D, The 
Organisation for Economic Co-operation and Development (OECD), 2017 




142 Joice R & Lipsitch M, PLoS One, 8, 2013 
143 Knisely JM et al, Clin Infect Dis, 63, 657-662, 2016 
144 Dorrington MG & Bowdish DM, Front Immunol, 28, 171, 2013 
145 Sparrow E et al, Bull World Health Organisation, 95, 235-237, 2017 
146 Report of an expert panel discussion on: The future of vaccines: The next 
decade, Association of the British Pharmaceutical Industry, 2018 
147 Lee BY & Burke DS, Vaccine, 28, 2806-2809, 2010  
148 Follow-up Report for the German GUARD Initiative, Breaking through the Wall, 




151 Personal Communication: Phil Packer, Innovate UK 
152 Personal Communication, Dr Marco Cavaleri. European Medicines Agency 
153 UK Five Year Antimicrobial Resistance Strategy 2013 to 2018, Department of 
Health and Department for Environment, Food and Rural Affairs, 2013 
154 https://www.gov.uk/government/news/expert-advisory-board-to-support-the-
global-amr-innovation-fund 
155 https://www.gov.uk/government/news/30-million-of-funding-to-tackle-
antimicrobial-resistance 
156 https://www.gavi.org/funding/donor-contributions-pledges/ 
157 https://mrc.ukri.org/research/initiatives/antimicrobial-resistance/antimicrobial-
resistance-funders-forum/ 
